Document:

Collaboration and License Agreement

 Exhibit 10.57 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 Execution Copy 
 Confidential 

COLLABORATION AND LICENSE AGREEMENT 
 This Collaboration and License Agreement (this “Agreement”), effective as of January 31, 2012 (the “Effective Date”), is entered into by and between Sangamo
BioSciences, Inc., a company organized under the laws of Delaware and having a place of business at 501 Canal Blvd. Suite A100, Richmond, CA 94804 (“Sangamo”), and Shire AG, a company limited by shares organized under the laws of
Switzerland, with its registered office at Business Park Terre-Bonne, Batiment A1, Ch. De Terre-Bonne 1, 1262 Eysins, Switzerland (“Shire”, and each of Shire and Sangamo, a “Party” or collectively the “Parties”),
with respect to the following facts: 
 RECITALS 
 WHEREAS, Shire is a leading specialty biopharmaceutical company that has technology and expertise in developing and commercializing therapies for human genetic diseases. 

WHEREAS, Sangamo has technology and expertise in the development of zinc finger DNA-binding protein/nuclease technology used for
diagnostic and therapeutic purposes. 
 WHEREAS, Sangamo and Shire desire to engage in a collaborative research program to
identify products and processes employing Sangamo’s zinc finger DNA-binding technology for treating certain diseases caused by particular monogenic defects, which can be advanced into human clinical trials and following regulatory approval,
commercialized. 
 WHEREAS, Sangamo is willing to grant a license of certain of its technology to Shire to clinically develop
and commercialize such products and processes, and Shire wishes to obtain such a license on the terms of this Agreement. 
 NOW
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties agree as follows: 
  

	 	1	DEFINITIONS 

 For purposes
of this Agreement, the terms set forth in this Article 1 shall have the respective meanings set forth below: 
 1.1
“Additional Targets” shall have the meaning set forth in Section 2.2. 
 1.2
“Affiliate” means, with respect to any person or entity, any other person or entity which controls, is controlled by, or is under common control with, such person or entity. For purposes of this Agreement, a person or entity
shall be deemed to control an entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is
not a corporation, for the election of the corresponding managing authority), or otherwise has the power to direct the management and policies of such other entity. 

 1.3 “Change of Control” means, with respect to a Party, (a) a
merger or consolidation of such Party with a Third Party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving
entity immediately after such merger or consolidation, or (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined
voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party’s business to which the subject matter of this Agreement relates. 

1.4 “Clinical Development Plan” means the description and time-line covering the specific activities to be
performed by Shire to develop, after the first IND or CTA filing and up to Market Approval, a particular Shire ZF Product. 

1.5 “CTA” means a clinical trial application filed with a competent European regulatory authority to support the
authorization of a clinical trial on a medicinal product for human use. 
 1.6 “Commercially Reasonable
Efforts” means: 
 (i) in the case of Sangamo, the efforts and resources typically used by biotechnology companies
similar in size and scope to Sangamo to perform the obligation at issue; 
 (ii) in the case of Shire, the efforts and
resources typically used by Shire and its Affiliates to perform the obligation at issue; 
 in each case, which efforts shall not be less than
those efforts made with respect to other products at a similar stage of development or in a similar stage of product life, with similar developmental risk profiles, of similar market and commercial potential, taking into account the competitiveness
of the market place, the proprietary position of the products, the regulatory structure involved, the profitability of the applicable products (taking into account payments to Sangamo under this Agreement) and other relevant factors. Commercially
Reasonable Efforts requires that the Party: (a) promptly assign responsibility for such obligation to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis, (b) set and seek to achieve
specific and meaningful objectives for carrying out such obligation, and (c) make and implement decisions and allocate resources designed to advance progress with respect to such objectives. 

1.7 “CDA” shall have the meaning set forth in Section 1.8. 

1.8 “Confidential Information” means all Know-How and other proprietary information (including information about
any element of a Party’s technology or business) that is disclosed by a Party or its Affiliates or by any of the Party’s or its Affiliates’ employees or consultants (“the Disclosing Party”) to the other Party or its
Affiliates or to any of the other Party’s or its Affiliates’ employees or consultants (“the Receiving Party”) except to the extent that the information: (a) as of the date of disclosure is demonstrably known to the Receiving
Party, as shown by written documentation, other than by virtue of a prior confidential disclosure by the Disclosing Party, (b) as of the date of disclosure is in, or subsequently enters, the public

  
 2 

 
domain, through no fault or omission of the Receiving Party or (c) as of the date of disclosure or thereafter is obtained by the Receiving Party from a Third Party free from any obligation
of confidentiality to the Disclosing Party. Unless otherwise provided herein, all work product by either Party under this Agreement, including any Joint Technology, is deemed to be Confidential Information of each Party. The terms and conditions of
this Agreement shall be considered Confidential Information of each Party. In addition, all confidential Know-How disclosed by either Party pursuant to that certain Confidential Disclosure Agreement between Shire Pharmaceuticals Inc. (an Affiliate
of Shire) and its Affiliates and Sangamo dated [***] (the “CDA”) shall be deemed to be the disclosing Party’s Confidential Information hereunder (with the mutual understanding and agreement that any use or disclosure thereof
that is authorized under Article 11 shall not be restricted by, or be deemed a violation of, the CDA). 
 1.9
“Control” or “Controlled” means the possession of the ability to grant a license, sublicense or [***] of Patent Rights, Know-How, or other tangible or intangible rights as provided for herein without violating
the terms of any agreement or arrangement with any Third Party. 
 1.10 “Donor Nucleic Acid” means, with
respect to a ZF Product, a nucleic acid that has been designed to be inserted, or is capable (in the form in existence in such ZF Product) of being inserted, in the location in the genome that is cleaved by the ZF Compound-associated nucleases in
such ZF Product. 
 1.11 “Earned Royalties” shall have the meaning set forth in
Section 9.4. 
 1.12 “Excluded Compound” shall have the meaning set forth in
Subsection 5.2(c). 
 1.13 “Excluded Target” means a Target that: (a) during
the [***] period after the Effective Date, is an Initial Excluded Target, or (b) commencing [***], (i) is subject to rights granted or intended to be granted to a Third Party pursuant [***] or (ii) is subject to a current and active
[***] which Sangamo already has invested in direct expenses for such program at least [***], of which at least [***] is documented expenses for products or services provided by Third Parties. A direct expense pursuant to this
Section 1.13 means an expense that (A) arises only after a [***], (B) is related to work undertaken [***], and (C) is a documented expense for products or services provided by [***] based upon the amount [***] program
(which shall be calculated at the [***]. 
 1.14 “Existing Third Party Licenses” means the agreements,
entered into by Sangamo prior to the Effective Date, including any amendments thereto as of the Effective Date, pursuant to which Sangamo Controls Sangamo Licensed Technology. Such agreements existing as of the Effective Date are listed on
Schedule 1.14. Notwithstanding the foregoing, Shire understands and acknowledges that the [***] Licenses (and hence are not listed in Schedule 1.14), and the licenses granted to Shire under Subsection 7.1(a) do not include
sublicenses of any licenses received by Sangamo under such agreements. 
 1.15 “Existing Third Party
Patent Rights” means Patent Rights licensed to Sangamo under Existing Third Party Licenses. 

  
 3 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 1.16 “Extended Research Term” means any additional period of time
added to the Initial Research Term pursuant to Section 3.9. 
 1.17 “FDA” means the Food
and Drug Administration of the United States, or the successor thereto. 
 1.18 “Field” means:
(a) with respect to a Shire ZF Product described in Subsection 1.73(a)(i) or (ii) or Subsection 1.73(b)(i) or (ii), [***] (b) with respect to a Shire ZF Product described in [***] that are [***] in connection with any
[***] for which [***]. 
 1.19 “First Commercial Sale” means, with respect to a particular Shire ZF
Product, the first Net Sales in any country of such Shire ZF Product for any indication. 
 1.20 “First GLP Tox
Studies” means, with respect to a Shire ZF Product or Shire Target, (1) GLP toxicology studies or (2) animal toxicology study the results of which are intended to be included in an IND or CTA, as designated in the Research Plan by
the JSC, in each case (1) and (2) with respect to such Shire ZF Product or of any Shire ZF Product for such Shire Target, respectively. 
 1.21 “FTE” means a full time equivalent scientific person (with B.S., M.S. or Ph.D. level or equivalent degrees), working for a minimum of a total of [***] hours per year of
scientific or other work and who is an employee of Sangamo working on the Research Program, or performing work directly related to and in support of, the Research Program, including recording and writing up results, reviewing literature and
references, holding scientific discussions, and managing and leading scientific staff to the extent that such management and leading is directed to any work on, directly related to or in support of the Research Program. 

1.22 “FTE Rate” shall have the meaning set forth in Subsection 3.6(d). 

1.23 “Generic Product” means, with respect to a particular therapeutic Shire ZF Product in a particular country,
a product on the market in such country commercialized by any Third Party that is not a Sublicensee of Shire or its Affiliates and that did not purchase such product in a chain of distribution that included any of Shire or its Affiliates or
Sublicensees, that: (i) is approved, under any then-existing laws and regulations in the applicable country pertaining to approval of [***]; (ii) is otherwise recognized as a [***] interchangeable product [***]; (iii) is a [***]
approved in such country for, or prescribed by [***], an indication that is [***] (iv) in the case where the [***] is in effect solely on the basis of [***] is any [***] for an indication that is the [***]. 

1.24 “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA as
defined in 21 C.F.R. Part 58 or the successor thereto, or comparable regulatory standards in jurisdictions outside the U.S. 

1.25 “Infringement” shall have the meaning set forth in Subsection 10.3(a). 

1.26 “IND” means an investigational new drug application filed with the FDA for approval to commence Phase
I Clinical Trials or any successor to the FDA for equivalent purposes. 

  
 4 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 1.27 “Initial Excluded Target” means the up to [***] provided by
Sangamo to Marya Postner prior to the Effective Date and held in escrow by Marya Postner on behalf of Sangamo’s outside counsel Cooley LLP (or by another individual designated by Cooley LLP if Marya Postner becomes unavailable or is no longer
affiliated with Cooley LLP), which list contains (i) [***] identified by [***] are subject to [***], existing prior [***], provided that the Initial Excluded Targets do not include the following [***], each as defined by Gene ID in the [***].
Shire acknowledges and agrees that in the event of a dispute, including litigation, between Sangamo and Shire with respect to the Initial Excluded Targets or the list held by Cooley LLP, [***] in connection with [***], and Shire shall [***] in
connection with such a [***]. 
 1.28 “Initial Research Term” means the six (6) year period
following the Effective Date. 
 1.29 “Initial Targets” means the four (4) Targets identified on
Schedule 1.29. 
 1.30 “JAMS Rules” shall have the meaning set forth in
Subsection 3.10(c)(v). 
 1.31 “Joint Know-How” means Know-How that is conceived,
discovered, invented, created, made or reduced to practice or tangible medium jointly by at least one employee of each of the Parties, their Affiliates, or their Subcontractors during the course of performing activities under this Agreement. For the
avoidance of doubt, “Joint Know-How” does not include Patent Rights in the Joint Know-How. 
 1.32
“Joint Patent Rights” means any Patent Rights (i) claiming Joint Know-How and (ii) naming at least one inventor with [***] such Patent Rights to Shire (or a Shire Affiliate) and at least one inventor with [***] such
Patent Rights to Sangamo (or a Sangamo Affiliate), with inventorship determined according to U.S. patent laws. 
 1.33
“Joint Steering Committee” or “JSC” means the scientific oversight committee comprised of representatives of Shire and Sangamo described in Article 4. 

1.34 “Joint Technology” means the Joint Know-How and the Joint Patent Rights. 

1.35 “Know-How” means intellectual property, data, results, pre-clinical and clinical protocols and study data,
information, materials, compounds, inventions, know-how, formulas, trade secrets, techniques, methods, processes, procedures, and developments; except that “Know-How” does not include Patent Rights in the foregoing. 

1.36 “Major European Country” means France, Germany, Italy, Spain or the United Kingdom. 

1.37 “Marketing Approval” means, with respect to a particular country or territory, the approval of a new drug
application, biologic license application (“BLA”), marketing authorization application (“MAA”) or similar approval required to sell a ZF Product in such country or territory, including, where required by applicable
law, pricing and reimbursement approval and schedule classifications. 
 1.38 “Milestone
Event” shall have the meaning set forth in Section 9.3. 

  
 5 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 1.39 “Milestone Payment” shall have the meaning set forth in
Section 9.3. 
 1.40 “Necessary to Obtain a License” shall have the meaning
set forth in Subsection 10.4(b). 
 1.41 “Net Sales” means the gross amount
invoiced for sales of Shire ZF Product(s), in arm’s length sales by Shire or its Affiliates or Sublicensees to Third Parties (“Gross Sales”), less: 
 (a) Normal and customary trade, cash and quantity discounts actually given, coupons actually taken, credits, price adjustments or allowances for damaged Shire ZF Products, returns or rejections of Shire
ZF Products; 
 (b) Adjustments, allowances, credits, fees, reimbursements, chargeback payments and rebates (or the equivalent
thereof) for the Shire ZF Products granted to group purchasing organisations or other buying groups, managed health care organisations, pharmacy benefit management companies, health maintenance organisations and any other providers of health
insurance coverage, health care institutions (including hospitals) or other health care organisations, Third Party health care administrators or patient assistance or other similar programs, or to federal, state/provincial, local and other
governments, including their agencies, or to wholesalers, distributors or other trade customers; 
 (c) Reasonable and customary
freight, shipping insurance and other transportation expenses, each directly related to the sale of the Shire ZF Products (if actually borne by Shire, its Affiliates or Sublicensees without reimbursement from any Third Party); 

(d) Distribution commissions/fees paid or payable to any Third Party providing distribution services to Shire, its Affiliates, or
Sublicensees; 
 (e) Sales or excise taxes, tariffs and duties, including, without limitation, VAT and U.S. sales tax, and all
other taxes and government charges related to the sale of Shire ZF Product, in each case to the extent that each such item is actually borne by Shire, its Affiliates, Sublicensees or distributors without reimbursement from any Third Party (but
excluding taxes properly assessed or assessable against the income derived by Shire or its Affiliates from such sale); 
 (f)
Actual bad debt expense (but not exceeding [***] of Net Sales); and 
 (g) Any item substantially similar in character or
substance to any of the foregoing, which is permitted by US GAAP prevailing at the time and customary in the pharmaceutical industry at the time. 
 The transfer of Shire ZF Products by Shire or one of its Affiliates or Sublicensees to another Affiliate or Sublicensee shall not be considered Net Sales. 

For the avoidance of doubt, disposal or use of Shire ZF Products in clinical trials, as free samples, or under compassionate use, patient
assistance, named patient or test marketing programs or non-registrational studies or other similar programs or studies where the Shire ZF Product is supplied without charge, shall not be considered Net Sales or result in any Net Sales

  
 6 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
under this Section 1.41. Nor shall any Shire ZF Products donated by a Party, its Affiliates or Sublicensees, to non-profit institutions or government agencies for a
non-commercial purpose, result in any Net Sales. Similarly, any free Shire ZF Products which are supplied to a Third Party in conjunction with the offer for sale, or sale of any Shire ZF Product (in an amount customary in the industry), will not
result in any Net Sales of such free goods. The use of a Shire ZF Product by a Party, its Affiliates or Sublicensees for research and development purposes shall not result in any Net Sales. For clarity, there shall be no limit on the quantity of
Shire ZF Products which may be used in clinical trials. Such amounts shall be determined from the books and records of Shire maintained in accordance with US GAAP, consistently applied. 

In the event any Shire ZF Product is sold as part of a combination product (being a product containing both a Shire ZF Product and one or
more other active ingredients, or a product in which both a Shire ZF Product and one or more other active ingredients are packaged, in each case where such other active ingredients are not part of or used to implement any zinc finger technology
(e.g., vectors for delivering ZF Compounds or Donor Nucleic Acids whose insertion is accomplished in part using ZF Compounds are not considered other active ingredients)), the Net Sales from the combination product, for the purposes of determining
royalty payments, shall be determined by multiplying the Net Sales of the combination product (as defined in the standard Net Sales definition), during the applicable royalty reporting period, by the fraction, A/(A+B), where A is the average per
unit sale price of Shire ZF Product when sold separately as a stand-alone ZF Product in finished form in the country in which the combination product is sold and B is the average per unit sale price of the other active ingredients contained in the
combination product when sold separately as stand-alone products in finished form in the country in which the combination product is sold, in each case during the applicable royalty reporting period or, if sales of stand-alone Shire ZF Product did
not occur in such period, then in the most recent royalty reporting period in which arms-length fair market sales of such Shire ZF Product, as applicable, occurred. In the event that such average sale price cannot be determined for the stand alone
Shire ZF Products or the other products, Net Sales for the purposes of determining royalty payments shall be mutually agreed upon by the Parties based on the relative value contributed by each component, such agreement not to be unreasonably
withheld, conditioned or delayed. 
 1.42 “New Third Party Patent Rights” means Patent Rights licensed
to Sangamo under Third Party Licenses entered into by Sangamo pursuant to Subsection 10.4(c) or Subsection 10.4(e). 
 1.43 “Party” and “Parties” shall have the meaning set forth in the first paragraph of this Agreement. 

1.44 “Patent Rights” means issued patents and pending patent applications in any country or region, including all
provisional, non-provisionals, substitutions, continuations, continuations-in-part, divisionals, renewals and all patents granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations and patents of
addition thereof, including supplementary protection certificates. 

  
 7 

 1.45 “Phase I Clinical Trial” means a human clinical trial of a
Shire ZF Product in human subjects according to 21 C.F.R. §312.21(a), as amended, or its equivalent, as appropriate, in foreign jurisdictions. 
 1.46 “Phase II Clinical Trial” means a human clinical trial of a Shire ZF Product according to 21 C.F.R. §312.21(b), as amended, or its equivalent, as appropriate, in foreign
jurisdictions. 
 1.47 “Phase III Clinical Trial” means a human clinical trial of a Shire ZF Product
intended to be a pivotal trial for obtaining Marketing Approval, or according to 21 C.F.R. §312.21(c), as amended, or its equivalent, as appropriate, in foreign jurisdictions. 

1.48 “Replacement Target” shall have the meaning set forth in Section 2.3. 

1.49 “Research Plan” means, with respect to each Shire Target, the description, time-line and budget covering the
specific activities to be performed by Sangamo during the Research Term to identify ZF Compound(s) that Specifically Bind such Shire Target or a [***] and to develop pre-clinically Shire ZF Product(s) for such Shire Target. For the avoidance of
doubt, pre-clinical development respecting a particular Shire ZF Product may extend beyond IND/CTA filing. 
 1.50
“Research Program” means the research collaboration between the Parties, under the direction and oversight of the JSC, aimed at identifying ZF Compounds that Specifically Bind a Shire Target or a [***] and developing through
IND/CTA filings Shire ZF Products for Shire Targets and shall include all activities of the Parties in the performance of any and all Research Plans during the Research Term. 
 1.51 “Research Term” means the Initial Research Term plus any Extended Research Term. 
 1.52 “Royalty Payment” shall have the meaning set forth in Subsection 10.4(c). 
 1.53 “Royalty Period” means, with respect to each different Shire ZF Product, the period commencing on the First Commercial Sale of such Shire ZF Product in any country and
continuing until the longer of: (i) [***] such First Commercial Sale of such Shire ZF Product; (ii) on a country by country basis, the [***]; and (iii) on a country by country basis, the expiration of all [***] which, but for the
licenses granted or assignments made herein, would be [***] by, in each case, the [***]. Only for the purposes of this Section 1.53, a [***] when the [***]. For the avoidance of doubt, changes to [***]. Only for the purposes of making
the determination under Subsection 1.53(iii), [***] as though they are [***] that are pending and that have an [***]. 

1.54 “[***]” means a [***]. 
 1.55 “Sangamo Know-How” means any Know-How Controlled by Sangamo as of the Effective Date or that comes into the Control of Sangamo after the Effective Date and during the term of
this Agreement (other than through the grant of a license by Shire or its Affiliates or Sublicensees hereunder) that is (a) necessary to practice the licenses granted herein, (b) utilized by Sangamo pursuant to the Research Program or
pursuant to activities conducted pursuant to 

  
 8 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
Subsection 5.2(c) in making a Shire ZF Compound, [***] or Shire ZF Product, or (c) part of, used to implement, or directly related to zinc finger technology and useful to practice the
licenses granted herein. For the avoidance of doubt, the Sangamo Know-How does not include any Patent Rights. Notwithstanding anything in this Agreement to the contrary, in the event of a Change of Control of Sangamo, the Sangamo Know-How shall not
include any Know-How that is (i) owned or controlled by a Third Party described in the definition of “Change of Control” prior to the closing of such Change of Control, (ii) developed after such Change of Control without the use
of the Sangamo Know-How in existence prior to the closing of such Change of Control, or (iii) developed after such Change of Control and not directly related to zinc finger technology. Notwithstanding the foregoing, Sangamo Know-How shall not
include any Know-How licensed to Sangamo or its Affiliates by a Third Party unless (A) such Know-How can be sublicensed by Sangamo to Shire free of any financial or other material obligation owing to the Third Party as a result of such
sublicense to Shire or (B) such Know-How is licensed pursuant to a Third Party License. 
 1.56 “Sangamo
Licensed Technology” means all Sangamo Know-How, Sangamo Patent Rights and Sangamo’s interest in the Joint Technology, and any Third Party intellectual property that is included as Sangamo Licensed Technology pursuant to
Section 10.4. For the avoidance of doubt, Sangamo Licensed Technology shall not include [***]. 
 1.57
“Sangamo Patent Rights” means Patent Rights Controlled by Sangamo as of the Effective Date or that come into the Control of Sangamo after the Effective Date and during the term of this Agreement (other than through the grant of
a license by Shire hereunder) that are (a) necessary to practice the licenses granted herein or (b) part of, used to implement, or directly related to zinc finger technology and useful to practice the licenses granted herein. The Sangamo
Patent Rights existing as of the Effective Date are set forth on Schedule 1.57 (it being understood that any Sangamo Patent Right existing as of the Effective Date that is not set forth on such schedule shall, notwithstanding such omission,
still be a Sangamo Patent Right to the extent otherwise provided in this Section 1.57). Notwithstanding anything in this Agreement to the contrary, in the event of a Change of Control of Sangamo, the Sangamo Patent Rights shall not
include any Patent Rights owned or controlled by a Third Party described in the definition of “Change of Control” and (1) existing prior to the closing of such Change of Control, (2) existing after the closing of such Change of
Control and claiming inventions made prior to the closing of such Change of Control, (3) claiming only inventions made after such Change of Control without the use of the Sangamo Know-How in existence prior to the closing of such Change of
Control, or (4) claiming only inventions made after such Change of Control and not directly related to zinc finger technology. Notwithstanding the foregoing, Sangamo Patent Rights shall include Existing Third Party Patent Rights and New Third
Party Patent Rights but shall not include (i) any other Patent Rights licensed to Sangamo or its Affiliates by a Third Party unless such Patent Rights can be licensed by Sangamo to Shire free of any financial or other material obligation owing
to the Third Party as a result of such sublicense to Shire and (ii) the [***] that have been [***] to Shire pursuant to Subsection 10.1(b). 
 1.58 “[***]” shall have the meaning provided in Subsection 3.4(c). 
 1.59 “[***]” means the Shire Target Specific [***] Patent Rights and the [***]. 

  
 9 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 1.60 “Shire Exclusive Target Pool” means the group of Shire Targets
that constitutes the exclusive target pool for the Research Program. The Shire Exclusive Target Pool existing as of the Effective Date consists of the Initial Targets, as set forth on Schedule 1.29. For the avoidance of doubt, the
Shire Targets in the Shire Exclusive Target Pool are licensed exclusively to Shire as set forth in Subsection 7.1(a), unless a Shire Target becomes a Terminated Target. 

1.61 “Shire Patent Rights” means Patent Rights Controlled by Shire or its Affiliates as of the Effective Date or
that come into the Control of Shire or its Affiliates after the Effective Date and during the term of this Agreement (other than through the [***] or grant of a license by Sangamo hereunder) that are necessary or useful to practice under the
licenses granted herein. 
 1.62 “[***]” means any [***] that: 

i) contains [***], 
 ii) does not contain any [***] (a) any [***] (b) the manufacture or use of such [***], 
 iii) Sangamo reasonably determines, after consultation with Shire, that such Patent Right will not be subject to [***], 
 iv) Shire agrees in writing to accept such assignment. 
 1.63
“[***]” means [***] (b) [***] Subsection 3.4(c). 
 1.64 “[***] Patent
Rights” means, with respect to a particular [***] that includes limitations to (a) a [***] (b) [***]. 

1.65 “[***]” means any [***] Subsection 1.73(b). 

1.66 “[***]” means any [***]. 
 1.67 “Shire Target” means an Initial Target or any other Target made part of the Shire Exclusive Target Pool pursuant to Section 2.2 or 2.3; provided,
however, that a Target shall cease to be a Shire Target when it becomes a Terminated Target. 
 1.68 “Shire
Target Specific Assigned Patent Rights” means the Shire Target Specific ZF Compound Patent Rights and the Shire Target Specific ZF Product Patent Rights. 
 1.69 “Shire Target Specific ZF Compound Patent Rights” means any Patent Right that contains only claims limited to Shire ZF Compounds. For the purposes of this
Section 1.69, a “claim limited to Shire ZF Compounds” means a claim that (i) includes language that specifically describes one or more ZF Compounds that Specifically Bind a particular Shire Target, (ii) if presumed to
be issued, would not be infringed by a ZF Compound (or the manufacture or use of a ZF Compound) that Specifically Binds a locus other than such Shire Target, if such ZF Compound were combined with the non-ZF Compound elements in such claim,
(iii) does not include language that specifically describes a product (or the manufacture or use of such product) that is not a Shire Target Specific Product, and (iv) does not include

  
 10 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
language describing any product (other than a Shire ZF Compound) or process that is Know-How, whether patentable or not, conceived, discovered, invented, created, made or reduced to practice or
tangible medium, whether solely or jointly, by one or more employees, agents or contractors of Sangamo, if such Know-How is being protected as a trade secret by Sangamo, is the subject of a claim in a Patent Right controlled by Sangamo, or is
sufficiently disclosed in a Patent Right controlled by Sangamo to support a claim to such Know-How in such Patent Right under 35 U.S.C § 112 (first paragraph), unless Sangamo consents in writing to the inclusion of such Know-How. 

1.70 “Shire Target Specific ZF Product Patent Rights” means any Patent Right that contains only claims limited to
Shire Target Specific Products. For the purposes of this Section 1.70, a “claim limited to Shire Target Specific Products” means a claim that (i) includes language that specifically describes one or more
Shire Target Specific Products, (ii) if presumed to be issued, would not be infringed by a product (or the manufacture or use of such product) that is not a Shire Target Specific Product, (iii) does not include language that specifically
describes a product (or the manufacture or use of such product) that is not a Shire Target Specific Product, and (iv) does not include language describing any product (other than a Shire ZF Compound) or process that is Know-How, whether
patentable or not, conceived, discovered, invented, created, made or reduced to practice or tangible medium, whether solely or jointly, by one or more employees, agents or contractors of Sangamo, if such Know-How is being protected as a trade secret
by Sangamo, is the subject of a claim in a Patent Right controlled by Sangamo, or is sufficiently disclosed in a Patent Right controlled by Sangamo to support a claim to such Know-How in such Patent Right under 35 U.S.C § 112 (first paragraph),
unless Sangamo consents in writing to the inclusion of such Know-How. 
 1.71 “Shire Unilateral Target
Termination” shall have the meaning provided in Subsection 3.10(a). 
 1.72 “Shire ZF
Compound” means any ZF Compound that Specifically Binds a particular Shire Target, as shown pursuant to the Research Program or pursuant to activities conducted pursuant to Subsection 5.2(c). For the avoidance of doubt,
any ZF Compound that was formerly a Shire ZF Compound and that Specifically Binds a Terminated Target shall no longer be a Shire ZF Compound. 
 1.73 “Shire ZF Product” means, with respect to a Shire Target: 
 (a) a “Shire Target Specific Product”, meaning: 
 (i) a pharmaceutical
product or medical therapy for deleting, inactivating, repairing, modulating the expression of, or inserting a functional version of, such Shire Target but not any other Target or locus, which product or therapy (1) contains or employs at least
one Shire ZF Compound which Specifically Binds such Shire Target and (2) does not contain or employ (A) any ZF Compound that Specifically Binds a Target or other chromosomal location that is not such Shire Target or within such Shire
Target, or (B) any Donor Nucleic Acid that encodes a protein (including a functional portion of a larger protein) that is neither a protein encoded by such Shire Target nor a functional version of the protein encoded by such Shire Target;

  
 11 

 (ii) a pharmaceutical product or medical therapy that contains or employs a human cell or
tissue made using a product or therapy described in (a)(i); or 
 (iii) a diagnostic product or service for detecting the
sequence or allele of such Shire Target, which product or service (1) contains or employs one or more Shire ZF Compounds each of which Specifically Binds such Shire Target and (2) does not contain or employ (A) any ZF Compound that
Specifically Binds a Target or other chromosomal location that is not such Shire Target or within such Shire Target, or (B) any Donor Nucleic Acid that encodes a protein (including a functional portion of a larger protein) that is neither a
protein encoded by such Shire Target nor a functional version of the protein encoded by such Shire Target; or 
 (b) a
“[***]”, meaning: 
 (i) a pharmaceutical product or medical therapy for [***] contains or employs (A) at least
[***] is included in the [***] is developed and shown to [***], and (B) a [***] that encodes a [***] and (2) does not contain or employ (A) any [***] or (B) any [***] that is not a protein encoded [***]; or 

(ii) a pharmaceutical product or medical therapy that contains or employs [***]. 

1.74 “Specifically Bind” means, with respect to a ZF Compound and Target or locus, that such ZF Compound
preferentially binds such Target or locus without known off-Target or off-locus binding that is preclinically or clinically significant. 
 1.75 “Subcontractor” shall have the meaning set forth in Subsection 3.4(b). 
 1.76 “Sublicensee” means an Affiliate or Third Party to whom Shire (or a Sublicensee or Affiliate) has granted a right to make, use, develop, sell, offer for sale or import a Shire
ZF Product. 
 1.77 “Target” means a human gene, including all naturally occurring mutants or allelic
variants of such gene, which contributes to a human disease or medical condition when the gene or the protein encoded by such gene is defective, including regions within such gene [***] regions [***] provided that such [***] are not in [***] and
that the [***] does not affect the expression of [***]. 
 1.78 “Term” shall have the meaning provided
in Section 14.1. 
 1.79 “Terminated Products” shall have the meaning set forth in
Subsection 14.5(a)(v). 
 1.80 “Terminated Target” means a former Shire Target that was
terminated by the JSC, terminated by Shire under Section 3.10, or terminated under Article 14. 
 1.81
“Territory” means the entire world. 

  
 12 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 1.82 “Third Party” means any person or entity other than Sangamo and
Shire (and their respective Affiliates). 
 1.83 “Third Party IP Rights” shall have the meaning set
forth in Subsection 10.4(b). 
 1.84 “Third Party Licenses” means the Existing Third Party
Licenses and any Third Party agreement that is deemed to be a Third Party License pursuant to Subsection 10.4(c) or Subsection 10.4(e). 
 1.85 “Triggering Event” has the meaning set forth in the letter agreement between the Parties of even date herewith. 

1.86 “Valid Claim” means a claim of any issued, unexpired patent within the Sangamo Patent Rights, [***] or Joint
Patent Rights that has not been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction in an unappealed or unappealable decision and a claim of any patent application within
the Sangamo Patent Rights, [***] or Joint Patent Rights to the extent that the effective priority date for such claim is less than five years. 
 1.87 “Value Added Tax (VAT)” means tax applicable under Council Directive 2006/112/EC or any similar or equivalent indirect tax system operated outside of the European Union and
any sales, purchase or turnover tax in any applicable jurisdiction. 
 1.88 “Vector Rights” means Third
Party IP Rights that cover a delivery vector used to introduce a Shire ZF Product into a cell. Potential delivery vectors include, but are not limited to, viral vectors [***] and non-viral vectors [***]. 

1.89 “ZF Compound” means any zinc finger nucleic acid binding protein and any nucleic acid that encodes such
protein. 
 1.90 “ZF Product” means any therapeutic or diagnostic product containing a ZF Compound.

  

	 	2	OVERVIEW 

 2.1
Collaboration. Shire and Sangamo shall collaborate for the purpose of identifying and developing pre-clinically Shire ZF Products for Shire to advance through human clinical trials and bring to patients as commercial therapeutics and
diagnostics in the applicable Fields, by performing the activities of the Research Program, which activities are outlined in Article 3. The Research Program will focus on Shire Targets, unless any such Shire Target is terminated as provided
in Section 3.10 or Article 14. This Agreement shall be understood to be a joint research agreement under 35 U.S.C. § 103(c)(3) entered into for the purpose of researching, identifying and developing Shire ZF Products. For the
avoidance of doubt, the Research Program will continue during the Research Term until the completion of all activities under the Research Plans, unless the Agreement is terminated in its entirety as provided in Article 14. 

  
 13 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 2.2 Shire Target Selection. The Initial Targets are included in the Shire
Exclusive Target Pool as of the Effective Date. Shire shall have the right to designate three additional Targets (“Additional Targets”) for inclusion as Shire Targets in the Shire Exclusive Target Pool as provided below in this
Section 2.2, provided that each of the Additional Targets is not ineligible as a Section 2.2 Rejected Target and is not a gene that is related to the cause or treatment of any of the following: [***]. Unless otherwise agreed to by
the Parties in writing, Shire shall be entitled to have up to seven active Shire Targets in the Research Program and the Shire Exclusive Target Pool at any one time during the Research Term. The Additional Targets are included as Shire Targets in
the Shire Exclusive Target Pool according to the following procedure: 
 (a) Within the [***] period immediately following the
Effective Date (the “Additional Target Period”), Shire shall identify in writing to Sangamo at least four (4) and up to twelve (12) proposed Additional Targets and shall include in such notice, for each such proposed
Additional Target, (i) the nucleic acid sequence and locus identification number of the wild-type allele (as obtained from a mutually agreed publicly available database), (ii) the cell(s) in which the protein encoded by such proposed
Additional Target is normally expressed, (iii) whether the product or therapy of interest to Shire for such proposed Additional Target would be designed to delete, inactivate, repair, modulate the expression of or insert a functional version of
such proposed Additional Target, and (iv) the particular mutation(s) of interest. Shire may identify such proposed Additional Targets at any time during the Additional Target Period and shall not be required to identify all such proposed
Additional Targets at one time. 
 (b) Within [***] (or sooner if practical) of receipt by Sangamo of the identity of, and the
required information described in (a) for, each such proposed Additional Target, Sangamo shall notify Shire whether the Target is an Excluded Target. (Prior to [***], if such proposed Additional Target is an Initial Excluded Target, and during
the six (6)-month period after the Effective Date, if such proposed Additional Target is a Target in clause (i) of the definition of Initial Excluded Target but is not an Excluded Target in clause (b) of the definition of Excluded Target,
such notification shall include a confirmation in writing by Marya Postner (or other Cooley LLP designee) that the Target is on the list of Initial Excluded Targets held in escrow by Cooley LLP.) Following such notification, Sangamo shall conduct
initial in silico feasibility studies for each such proposed Additional Target that is not an Excluded Target, during which conduct the Parties shall discuss the results of such studies and potential approaches to address any issues or
concerns arising from such studies. Within thirty (30) days of receipt by Sangamo of the information described in (a) for each proposed Additional Target, Sangamo shall notify Shire in writing whether or not each such proposed Additional
Target: (i) is not a technically viable candidate for developing ZF Compounds that Specifically Bind such proposed Additional Target for the type of product or therapy identified pursuant to Subsection 2.2(a)(iii) or for developing [***]
for such proposed Additional Target, or (ii) is subject to any other substantial, bona fide concern known to Sangamo with respect to developing a Shire ZF Product for such proposed Target. Such notification under Subsection 2.2(b)(i) or
(ii) shall include an explanation of the reasons why the Target is not a technically viable candidate and/or Sangamo’s other substantial bona fide concern. 
 (c) If Sangamo notifies Shire that a proposed Additional Target is rejected because (i) under Subsection 2.2(b) the proposed Additional Target is an Excluded Target or
(ii)

  
 14 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
under Subsection 2.2(b)(i) the proposed Additional Target is subject to any such conditions (a “Section 2.2 Rejected Target”), then such
Section 2.2 Rejected Target shall not be included as a Shire Target in the Shire Exclusive Target Pool. 
 (d) If
any such proposed Additional Target is not a Section 2.2 Rejected Target, then Shire shall have [***] from receipt of notice from Sangamo under the penultimate sentence of Subsection 2.2(b) to conduct a review and evaluation of
all relevant intellectual property and any concerns raised under Subsection 2.2(b)(ii) relating to each such proposed Additional Target and the Parties shall discuss the same; provided, that Shire shall be solely responsible for all
intellectual property assessments concerning each such Target. During such [***] review period, the Parties, each at its own expense, shall collaborate to develop, and shall develop, a Research Plan for each such proposed Additional Target.

 (e) Prior to the end of the review period set forth in Subsection 2.2(d), Shire shall, in its sole discretion,
determine whether to designate each such Target as a Shire Target, provided that Shire shall designate no more than (3) proposed Additional Targets as Shire Targets in the Shire Exclusive Target Pool, which Shire Exclusive Target Pool shall not
exceed a total of seven (7) Shire Targets, and shall notify Sangamo of such determination. 
 (f) If Shire does not elect
in Subsection 2.2(e) to designate a proposed Target as a Shire Target in the Shire Exclusive Target Pool by the end of the applicable [***] period, such proposed Target shall not be included in the Shire Exclusive Target Pool and neither
Party shall have any rights or obligations to the other Party hereunder in respect of such Target, except as required pursuant to Article 11. 
 (g) If Shire elects under Subsection 2.2(e) to include a proposed Additional Target as a Shire Target in the Shire Exclusive Target Pool, then such Additional Target shall be included in the Shire
Exclusive Target Pool. 
 (h) If at the end of the review period set forth in Subsection 2.2(d), fewer than three
(3) proposed Additional Targets are added to the Shire Exclusive Target Pool for any reason, then during the [***] following the Effective Date, Shire may propose Additional Targets for inclusion in the Shire Exclusive Target Pool. Upon
identifying to Sangamo such proposed Additional Target(s) and providing the information described in Subsection 2.2(a) for each such proposed Additional Target, the procedures outlined in Subsections 2.2(b)-(g) shall be followed.

 (i) If the Triggering Event occurs and Shire provides notice of [***] with respect to the [***], then Shire shall be entitled
to [***], provided that (i) the total number of Shire Targets [***] and (ii) [***] shall be included in the [***] identifying to Sangamo up to four (4) proposed Additional Targets and providing Sangamo with the information described
in subsection (a) above and the Parties following the procedures set forth in subsections (b) through (g) above. 

2.3 Replacement Targets. If the JSC determines during the Research Term that any Shire Target in the Shire Exclusive Target Pool
fails to meet the criteria established in the applicable Research Plan for continuing work on such Shire Target under such Research Plan, 

  
 15 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
such Target shall be deemed a Terminated Target to which Sections 3.10 and 14.5 apply, and Shire shall be entitled to replace only one such Terminated Shire Target with a single
replacement Target (“Replacement Target”) for inclusion in the Shire Exclusive Target Pool. The Replacement Target is included in the Shire Exclusive Target Pool subject to the following procedure: 

(a) If the JSC determines during the Research Term that one (1) or more Shire Targets failed to meet the criteria established in the
Research Plans for such Shire Target(s), Shire shall have the right to notify Sangamo in writing during the Research Term that Shire proposes to designate a Target as a Replacement Target. Such notice shall identify up to four (4) proposed
Replacement Targets from which a single Replacement Target will be selected and shall include, for each such proposed Replacement Target, (i) the nucleic acid sequence and locus identification number of the wild-type allele (as obtained from a
mutually agreed publicly available database), (ii) the cell(s) in which the protein encoded by such proposed Replacement Target is normally expressed, (iii) whether the product or therapy of interest to Shire for such proposed Replacement
Target would be designed to delete, inactivate, repair, modulate the expression of or insert a functional version of such proposed Replacement Target, and (iv) the particular mutation(s) of interest. 

(b) Within [***] (or sooner if practical) of receipt by Sangamo of the identity of, and the required information described in
(a) for, each such proposed Replacement Target, Sangamo shall notify Shire whether the proposed Replacement Target is an Excluded Target. Following such notification, Sangamo shall conduct initial in silico feasibility studies for each
such proposed Replacement Target that is not an Excluded Target, during which conduct the Parties shall discuss the results of such studies and potential approaches to address any issues or concerns arising from such studies. Within thirty
(30) days of receipt by Sangamo of the information described in (a) for each proposed Replacement Target, Sangamo shall notify Shire in writing whether or not each such proposed Replacement Target: (i) is not a technically viable
candidate for developing ZF Compounds that Specifically Bind such proposed Replacement Target for the type of product or therapy identified pursuant to Subsection 2.3(a)(iii) or for developing [***] for such proposed Replacement Target; or
(ii) is subject to any other substantial, bona fide concern known to Sangamo with respect to the technical feasibility of developing a Shire ZF Product for such proposed Replacement Target. Such notification under Subsection 2.3(b)(i) or
(ii) shall include an explanation of the reasons why the Target is not a technically viable candidate and/or Sangamo’s other substantial bona fide concern. 
 (c) If Sangamo notifies Shire that a proposed Replacement Target [***] such [***] Rejected Target shall not be [***]. Shire shall have the right [***]. 

(d) If any such proposed Target is not a Section 2.3 Rejected Target, then Shire shall have an [***] from delivery of the notice by
Sangamo under the penultimate sentence of Section 2.3(b) to conduct a review and evaluation of all relevant intellectual property and any concerns raised under Subsection 2.3(b)(ii) relating to each such proposed Replacement
Target and the Parties shall [***] provided, that Shire shall be [***]. During such [***] review period, the Parties [***]. 

  
 16 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (e) Prior to the end of the review period set forth in Subsection 2.3(d), Shire
shall, [***] and shall [***]. 
 (f) If Shire does not elect [***], such proposed [***] shall not [***], except as required
pursuant [***]. 
 (g) If Shire elects under Subsection 2.3(e) to include a proposed Replacement Target in the Shire
Exclusive Target Pool, such Replacement Target shall be included in the Shire Exclusive Target Pool, and within 60 days of such election, (i) Shire shall pay Sangamo [***], which payment shall be non-refundable and non-creditable, and
(ii) the JSC shall direct the Parties to initiate work under the Research Plan for such Replacement Target. 
 (h) If the
Triggering Event occurs and Shire provides notice of a Shire Unilateral Target Termination pursuant to Subsection 2.2(i) and Section 3.10 with respect to the [***] (i) [***] and (ii) if the JSC determines during the
Research Term that a [***], then Shire shall have the right to [***]. Such [***] shall be [***] by following the procedures set forth in subsections (a) through (g) above, and the payment set forth in Subsection 2.3(g) shall be due
[***]. 
  

	 	3	RESEARCH PROGRAM; RESEARCH TERM 

 3.1 Sangamo Responsibilities. During the Research Term and subject to the oversight of the JSC, Sangamo shall be solely responsible for carrying out the tasks allocated to Sangamo in each
Research Plan, which shall be developed and approved by the JSC. Subject to Section 3.6, Sangamo shall use Commercially Reasonable Efforts in the performance of its obligations under the Research Program and the applicable Research Plans
during the Research Term. 
 3.2 Shire Responsibilities. During the Research Term, Shire shall be solely
responsible for the costs set forth in the budgets for the Research Plans, which budgets shall be developed and approved by the JSC. Upon request by Sangamo, Shire shall provide reasonable consulting and technical support in order to assist Sangamo
in carrying out its Research Program obligations. For the avoidance of doubt, the JSC shall have the right to prioritize Shire Targets within the Research Program and make final decisions as to whether and when to proceed with particular activities
under the Research Program, provided that, during the Research Term, for so long as there are [***] in the Shire Exclusive Target Pool, Shire shall be required to fund the budget for a [***] Research Plans, each of which will attempt, where
commercially and scientifically reasonable, to achieve an IND or CTA filing for a Shire ZF Product within [***] after the initiation of activities under such Research Plan. 
 3.3 Research Plans. Research Plans shall be developed and approved by the JSC. Each Shire Target shall be the subject of a separate Research Plan, which shall be reviewed and updated as
necessary, but at least quarterly, by the JSC. Each Research Plan will define events leading to and including submission of either an IND or a CTA for at least one Shire ZF Product for the applicable Shire Target and will include (a) a
description of the process for identifying and the criteria for selecting ZF Compounds to be used with Shire ZF Products (which description shall not include any Know-How Controlled by Sangamo with respect to the design

  
 17 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
of ZF Compounds), (b) a description of the Shire ZF Product to be researched and preclinically developed under such Research Plan, including lead and back-up ZF Compounds and Shire ZF
Products, (c) the proposed indication for the applicable Shire Target, (d) a description of the companion diagnostic Shire ZF Product, if any, that will be developed under such Research Plan for use with the therapeutic Shire ZF Product
developed under such Research Plan, (e) a listing of the specific components that each potential Shire ZF Product will contain, (f) a description of the specific activities to be performed by Sangamo, including the pre-clinical work
necessary to file an IND/CTA and to support the related clinical trials through BLA/MAA submission, and for each animal toxicology study, a designation of whether such study will be GLP compliant and whether the results of such study are intended to
be included in an IND/CTA, (g) projected timelines for completion of such activities, (h) a budget, (i) particular decision points and associated criteria, including decisions as to whether to terminate the applicable Shire Target,
whereby expenditures will not be undertaken for subsequent activities unless and until such criteria have been met as determined by the JSC, and (j) a plan for technology transfer from Sangamo to Shire with respect to Shire ZF Products. At the
appropriate time, as determined by the JSC, each Research Plan also will provide the details of and budget for the manufacture and supply of Shire ZF Products. In addition, each Research Plan shall identify a Sangamo project leader, reasonably
acceptable to Shire, which project leader shall devote no less than [***] of his/her time to carrying out the Research Plan during the active conduct of such Research Plan. Each Research Plan shall be consistent with the terms of this Agreement and
shall be appended to and form a part of this Agreement. In the event of an inconsistency between the Research Plan and this Agreement, the terms of this Agreement will prevail. The Research Plans as of the Effective Date, which may be subsequently
modified by the JSC in accordance with this Section 3.3, for [***] of the Initial Targets are set forth in Schedule 3.3. 
 3.4 Conduct. 
 (a) The Parties will form a working team for each
Research Plan comprising at least the project leader for the Research Plan (who will be a Sangamo employee) and one or more representative(s) from each of Shire and Sangamo, which team will stay in active communication about activities taking place
and information arising under the respective Research Plan. This team shall be subordinate to the JSC and shall confer regularly, and at such specific times as the JSC shall reasonably request, to ensure close cooperation and exchange of information
between the Parties as Sangamo fulfills its responsibilities under the Research Program. The working teams will have decision-making authority, by unanimous agreement, solely in order to carry out the day to day implementation of a Research Plan but
will not have the authority to alter a Research Plan. 
 (b) In performing its activities under the Research Plan and this
Agreement, Sangamo shall, and shall require its Affiliates and any consultant, subcontractor, or other vendor conducting Sangamo’s obligations under a Research Plan (each, a “Subcontractor”) to, comply with all applicable laws,
regulations and guidelines concerning such manufacturing and development activities, including where appropriate in accordance with current Good Manufacturing Practices and GLP (or similar standards) for the performance of laboratory activities as
are required by applicable law. For the avoidance of doubt, during the period prior to Sangamo’s transfer of information and materials to Shire pursuant to Subsection 5.2(b)(ii)(B) or 4.6(w)(A) with respect to a Research Plan,
Sangamo shall, and shall require its Affiliates and any Subcontractor to, maintain such information and materials as required by law in connection with any IND or CTA anticipated to be filed under such Research Plan. 

  
 18 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (c) As of the Effective Date, the only [***]. In the course of developing and updating a
Research Plan or conducting the Research Program, either Party may propose [***] Sangamo shall reasonably consider [***]. Upon the Parties’ written agreement that [***] and the relevant Research Plan(s) will be [***], if Sangamo is developing a
[***], or if the JSC is developing a Research Plan that [***], Sangamo shall [***]. As used in this Subsection 3.4(c), “[***]” means a locus (A) that is not [***], (B) to which [***], and (c) to which Sangamo has the
right [***]. 
 (d) Sangamo will provide to Shire a copy of all substantive written correspondence from any regulatory authority
involving an IND/CTA regulatory submission for a Shire ZF Product, notify Shire of all oral substantive communications from any regulatory authority involving a regulatory submission for a Shire ZF Product and provide Shire with an advance draft of
each proposed regulatory submission for a Shire ZF Product sufficiently in advance of providing the submission to the regulatory authority (and no less than ten (10) days in advance, where possible) to enable Shire to have a meaningful
opportunity to provide input on the content of such submission. To the extent permitted by applicable laws and regulations, Sangamo shall permit Shire to[***]. For the avoidance of doubt, IND/CTA regulatory submissions by Sangamo respecting Shire ZF
Products are subject to the oversight and approval of the JSC. 
 (e) Sangamo shall [***] be the owner of any IND/CTA filing for
a Shire ZF Product. Following acceptance of the IND/CTA by a regulatory authority, Sangamo shall [***]. 
 (f) To facilitate the
conduct of the Research Program, or otherwise pursuant to Section 5.2(c), either Party may provide to the other Party certain biological materials or chemical compounds owned by or licensed to the supplying Party for use by the other
Party (such materials or compounds and any progeny and derivatives thereof, collectively, “Materials”). All such Materials shall remain the sole property of the supplying Party, shall be used only in the fulfillment of obligations
or exercise of rights under this Agreement and solely under the control of the receiving Party, shall not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party, and shall not be used
in research or testing involving human subjects, unless expressly agreed. The Materials supplied under this Subsection 3.4(f) are supplied “as is” and must be used with prudence and appropriate caution in any experimental work,
since not all of their characteristics may be known. 
 3.5 Subcontractors. Sangamo may engage any Subcontractor to
perform any work under the Research Program; provided that all such engagements and any contracts related to such engagements are subject to prior approval by the JSC. Such contracts shall include provisions, including intellectual property
provisions, adequate for Shire to enjoy the licenses granted hereunder as though Sangamo had performed the contracted work. To facilitate approval by the JSC, Sangamo shall identify each Subcontractor, the activities proposed to be performed by such
Subcontractor and the budget for such activities. The JSC in its discretion may request a copy of the proposed contract with the Subcontractor prior to approving such contract. Sangamo shall be responsible for the management of its permitted
Subcontractors. The engagement of any 

  
 19 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
Subcontractor in compliance with this Section 3.5 shall not relieve Sangamo of its obligations under this Agreement or any applicable Research Plan. Any agreement with a permitted
Subcontractor pertaining to the Research Program shall be consistent with the provisions of this Agreement. 
 3.6 Funding of
the Research Program. 
 (a) Budgeted costs. Shire shall pay all FTE costs and external costs incurred by Sangamo and
its Affiliates in the conduct of the Research Program, in accordance with the budget set forth in each of the Research Plans. For the avoidance of doubt, external costs will be passed through to Shire with no mark-up by Sangamo. The JSC shall in
good faith establish [***] budgets for each of the Research Plans. The JSC in its sole discretion shall approve such [***] budgets. Sangamo shall be deemed to agree to a budget unless within ten (10) days of Sangamo receiving notification that
the JSC has approved a budget, Sangamo notifies Shire in writing that Sangamo disagrees with such budget. Such notification shall include a Sangamo proposed budget, which Sangamo proposed budget shall identify the activity and cost differences from
the JSC approved budget. If Sangamo is deemed to agree with a budget, then except as provided by Subsection 3.6(e), variances from the budget shall be paid by Sangamo, unless otherwise agreed to by the JSC. 

(b) Budget changes. A change to a budget can be made only by the JSC. If Sangamo reasonably anticipates that the costs of
conducting, or having a Subcontractor conduct, any activity set forth in a Research Plan will exceed the budgeted amount therefor, Sangamo shall notify the JSC and request a change to the budget. The JSC shall in good faith consider all such
reasonable requests by Sangamo to change a budget for a Research Plan. The JSC in its sole discretion shall approve such reasonable requests to change the budget within thirty (30) days of Sangamo’s request. Sangamo shall be deemed to
agree to such a change to the budget or such JSC decision not to approve Sangamo’s request to change a budget unless within ten (10) days of Sangamo receiving notification that the JSC has approved such change to the budget or decided not
to approve Sangamo’s request to change a budget, Sangamo notifies Shire in writing that Sangamo disagrees with the budget change or decision. Such notification shall include a Sangamo proposed budget change, which Sangamo proposed budget change
shall identify the activity and cost differences from the JSC approved budget change or existing budget, if the JSC decided not to approve Sangamo’s request to change the existing budget. If Sangamo is deemed to agree [***], then except as
provided by [***]. 
 (c) Failure to agree. In the event Sangamo does not agree to a JSC approved Research Plan budget, a
JSC approved change to such budget or a JSC decision not to approve Sangamo’s request to change a budget, then (i) Sangamo shall not be obligated to conduct, or cause any Subcontractor to conduct, any activity under a Research Plan that
will not be fully reimbursed by Shire; and (ii) Shire shall have the right to subcontract such activity to a Third Party; provided, that the cost charged by such Third Party subcontractor for such activity does not exceed [***] of the cost
proposed by Sangamo for such activity and that Shire shall not have any right, in connection with any such subcontract, to access Sangamo Know-How relating to ZF Compound design (including optimization). 

  
 20 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (d) FTE rate. Shire shall pay Sangamo the rate for each FTE of [***] per year (the
“FTE Rate”) for the first [***] months of this Agreement. Beginning at month [***], the FTE rate shall increase [***] annually. 
 (e) Invoices. Sangamo shall accrue and report its actual costs quarterly. Sangamo shall provide an invoice within five (5) business days of the end of each quarter, with sufficient detail
reasonably acceptable to Shire, for the activities performed during such quarter and external costs invoiced to Sangamo during such quarter. The actual number of FTEs or external costs reported in the invoice may vary by not more than [***] from the
expected number based on each budget for each Research Plan, provided that the actual number is consistent with, and not more than [***] above, the overall budget for a particular Research Plan. Subject to Section 3.6(b), Shire shall
have no obligation to pay Sangamo any amount that (i) is more than [***] above the budget for any Research Plan in any quarter, and (ii) exceeds by [***] the overall budget under a Research Plan. 

(f) Annual budgets. No later than September 30 of each calendar year during the Research Term (except for the last calendar
year during the Research Term), the JSC will prepare and approve a budget for each Research Plan under which activities are anticipated to be conducted in the following calendar year. 

3.7 Records. 
 (a) Research Records. Sangamo shall maintain, and cause its employees and Subcontractors to maintain, records and laboratory notebooks in sufficient detail and in a good scientific manner
appropriate for (i) inclusion in filings with regulatory authorities, and (ii) obtaining and maintaining intellectual property rights and protections, including Patent Rights. Such records and laboratory notebooks shall be complete and
accurate in all material respects and shall fully and properly reflect all work done, data and developments made, and results achieved. Laboratory notebooks shall be signed, dated and witnessed on a regular basis. During the Research Term Sangamo
shall periodically, but not less than [***], allow Shire to inspect and, to the extent necessary or useful for such regulatory or intellectual property protection purposes, copy such records. 

(b) JSC Reports. Sangamo shall keep the JSC informed of the progress of its activities under each Research Plan, including a
detailed written quarterly report of its progress under each Research Plan. 
 (c) Expense Records. Sangamo shall
maintain complete and accurate books, records and accounts used for the determination of FTEs and external expenses incurred in connection with the performance of its obligations under the Research Program, in sufficient detail to confirm the
accuracy of any payments required under this Agreement, which books, records and accounts will be retained by Sangamo for three (3) years after creation of the individual records, or longer as is required by applicable law. Such books, records
and accounts shall be kept in accordance with U.S. GAAP and Sangamo’s then-current accounting procedures. For the avoidance of doubt, if Sangamo’s then-current accounting procedures are not US GAAP compliant, then Sangamo shall alter
its accounting procedures such that they are US GAAP compliant. 

  
 21 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 3.8 Shire Audit Rights. 

(a) Upon fourteen (14) days advance written notice by Shire and not more than once in each calendar year, Sangamo and its Affiliates
shall permit an independent certified public accounting firm of internationally recognized standing, selected by Shire and reasonably acceptable to Sangamo, at Shire’s expense, to have access during normal business hours to such of the records
of Sangamo and its respective Affiliates as may be reasonably necessary to verify the accuracy of the invoices provided by Sangamo to Shire pursuant to Subsection 3.6(e) for any year ending not more than eighteen (18) months prior to the
date of such request. No year may be audited more than once, except for cause. The accounting firm will enter a confidentiality agreement reasonably acceptable to Sangamo governing the use and disclosure of Sangamo’s information disclosed to
such firm, and such firm shall disclose to Shire only whether the invoices are correct or not and the specific details concerning any discrepancies, which information shall be Confidential Information of Sangamo. 

(b) Unless disputed by Shire or Sangamo in good faith, if such accounting firm concludes that the amounts paid during the audited period
were more or less than the amounts actually due to Sangamo, Shire shall pay any additional amounts due, and Sangamo will refund any amounts overpaid, in each case plus interest as set forth in Section 9.13, within thirty (30) days
after the date the written report of the accounting firm so concluding is delivered to Sangamo and Shire. The fees charged by such accounting firm shall be paid by Shire; provided, that if the audit discloses that the amounts payable by Shire
for such period have been overpaid by more than [***], then, subject to Subsection 3.8(c), Sangamo shall pay the reasonable fees and expenses charged by such accounting firm. 

(c) In the event of a good faith dispute by Shire or Sangamo regarding the result of an audit made pursuant to this
Section 3.8, the Parties shall agree in good faith on an alternative independent certified public accounting firm of internationally recognized standing to perform a second audit. If such audit is requested by Shire because Shire was
found by the initial audit to have underpaid and the second audit confirms that Shire underpaid, then Shire shall bear all costs associated with the second audit. If such audit is requested by Sangamo because Shire was found by the initial audit to
have overpaid and the second audit confirms that Shire overpaid, then Sangamo shall bear all costs associated with the second audit. Notwithstanding the above, in the event that the second audit confirms the findings of the first audit, the
requesting Party shall pay. No over or under payment indicated by the initial audit shall be payable in the event of a dispute until the second audit is complete and such second audit shall be binding on the Parties, with any under or over payment
determined thereby, plus interest as set forth in Section 9.13, being payable within thirty (30) days after the date the written report of the accounting firm so concluding is delivered to Sangamo and Shire. 

(d) Shire shall treat all financial information disclosed by its accounting firm pursuant to this Section 3.8 as Confidential
Information of Sangamo for purposes of Article 11 of this Agreement, and shall cause its accounting firm to do the same. 

3.9 Research Term. 
 (a) Extension of the Initial Research Term. 

  
 22 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 The Initial Research Term may be extended as follows: 

(i) If the Parties agree, the Initial Research Term may be extended by two (2) years, one or more times; and 

(ii) If activity under a specific Research Plan for a Shire Target has been initiated within four (4) years of the Effective Date,
then Shire shall have the right, at its option and in its sole discretion, to extend the Research Term for a period of time sufficient to complete the pre-clinical activities contemplated by the Research Plan. 

(b) Re-establishment of the Research Term. If the Research Term has expired and if Shire is pursuing clinical development or
maintenance of Marketing Approval of a first Shire ZF Product for a Shire Target, then, at Shire’s request and expense, the Research Term may be re-established for a term as necessary for Sangamo to provide such assistance to Shire as necessary
for Shire to obtain or maintain Marketing Approval (i) for such first Shire ZF Product for such Shire Target or (ii) a second Shire ZF Product for such Shire Target if Shire fails to gain Marketing Approval for such first Shire ZF Product,
provided that Sangamo has sufficient expertise and then available capacity to provide such assistance or is capable of acquiring sufficient capacity through the use of Commercially Reasonable Efforts. If Sangamo declines to provide such assistance
on account of such insufficient expertise or such incapability of acquiring sufficient capacity, then at Shire’s option, Shire shall be allowed to obtain such assistance from a Third Party subcontractor, in which case Sangamo shall grant to
such Third Party licenses under the Sangamo Licensed Technology to the extent necessary to conduct the specific requested activities. By way of example and not limitation, such assistance may involve conducting further pre-clinical studies on the
Shire ZF Product in clinical development or as a post-marketing commitment, conducting studies on new formulations of the Shire ZF Product in clinical development, or conducting full pre-clinical studies on a back-up Shire ZF Product for the
respective Shire Target. 
 3.10 Termination of a Shire Target. 

(a) Right to Terminate-Shire Unilateral Termination. In addition to each Party’s rights to terminate this Agreement under
Article 14 and subject to Section 3.2, at any time during the Research Term, any particular Shire Target may be terminated and its respective Research Plan halted in its entirety upon ninety (90) days prior written notice
from Shire to Sangamo (a “Shire Unilateral Target Termination”), provided that, for the first 24 months of this Agreement, Shire may not terminate all Shire Targets. Such termination shall take effect at the expiration of such
ninety (90) day period. For the avoidance of doubt, Shire may not terminate this Agreement in its entirety during the 24 month period after the Effective Date. 
 (b) JSC Termination. During the Research Term, the JSC may unanimously agree at any time to terminate a particular Shire Target and halt its respective Research Plan in its entirety. Such
termination shall take effect no later than ninety (90) days from such unanimous decision. Any unanimous decision by the Parties to discontinue a Research Plan prior to IND or CTA filing shall be deemed a termination by the JSC subject to this
Section 3.10. 

  
 23 

 (c) Effects of Target Termination. Upon notice of a Shire Unilateral Target
Termination, or upon a unanimous JSC decision to terminate all activities under a Research Plan for a Shire Target: 
 (i)
Wind down costs. During such ninety (90) day notice period (in the case of a Shire Unilateral Target Termination), or such ninety (90) day period following a JSC unanimous decision to terminate a Shire Target, Sangamo shall wind
down the Research Plan for the Terminated Target, and Shire shall pay all FTE costs of Sangamo for direct work [***] necessary for Sangamo to wind down such Research Plan. Upon expiration of such ninety (90) day notice period (in the case of a
Shire Unilateral Target Termination), or such ninety (90) day period following a JSC unanimous decision to terminate a Shire Target, [***], except as provided in Subsection 3.10(c)(ii) below. Such reasonably necessary costs shall be
invoiced as provided in Subsection 3.6(e). Sangamo shall use [***] efforts to minimize any costs incurred following receipt of the notice of termination by Shire or decision to terminate by the JSC. 

(ii) Non-cancelable costs. Shire shall pay any non-cancelable costs relating to such Terminated Target to which Sangamo has
committed after the Effective Date prior to receiving such notice under Subsection 3.10(a) or such unanimous decision under Subsection 3.10(b). Such non-cancelable costs shall be invoiced as provided in Subsection 3.6(e).
Sangamo shall use [***] efforts to minimize any non-cancelable costs incurred upon receiving such notice under Subsection 3.10(a) or such unanimous decision under Subsection 3.10(b). 

(iii) Target Removal from Pool. Such Terminated Target shall be removed from the Shire Exclusive Target Pool and shall no longer
be a Shire Target. 
 (iv) [***]. Within sixty (60) days of such notice or decision, to the extent Sangamo elects, Shire
shall [***] to Sangamo all [***] and [***] that (1) relate to the Terminated Target and (2) were [***] to Shire from Sangamo. 
 (v) Other Shire Intellectual Property. Within [***] days of such notice or decision, if Sangamo elects, the Parties shall negotiate in good faith and on commercially reasonable terms with respect
[***] (i) any or all [***] and (ii) [***] that both (a) relate to the [***] (b) for which [***] have been initiated under the Research Program, provided that such agreement shall include, if the [***] Such negotiation shall take
into consideration[***] and if Sangamo has requested [***] to the extent applicable to the [***] In addition, if Sangamo’s [***] Notwithstanding anything to the contrary in this Agreement, if Shire or its Affiliates is [***] then Shire shall
not be required to [***] provided that Shire agrees[***] By way of example, if Shire [***] In addition, for the avoidance of doubt, Sangamo shall not have the right to[***] under clause (ii) above will include [***] in clause (ii) above
that exists as of the [***] In the event that the Parties are unable to agree upon commercially reasonable terms within [***] then the Parties shall submit the determination of commercially reasonable terms to an independent arbitrator agreed upon
by Parties who has significant relevant experience in the licensing of pharmaceutical products. If the Parties do not agree on an arbitrator within [***] then either Party may request that JAMS appoint an arbitrator with such experience on behalf of
the Parties in accordance with JAMS’ Comprehensive Arbitration Rules & Procedures then in effect, except that the Parties expressly agree that [***] The date on which such arbitrator is

  
 24 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
selected or appointed will be the “Section 3.10 Arbitration Commencement Date”. The arbitration shall be conducted under the JAMS Rules, to the extent consistent with this
Subsection 3.10(c)(v). Within [***] after the Section 3.10 Arbitration Commencement Date, each Party will [***] provided that unless the Parties agree otherwise in writing in advance[***] Within[***] after receipt of the other
Party’s [***] each Party may submit to the arbitrator (with a copy to the other Party)[***] Within [***] after the Section 3.10 Arbitration Commencement Date, the arbitrator will[***] provided that, for the avoidance of doubt, in no
circumstance will Shire be obligated to[***] except for those [***] The decision of the arbitrator shall be final and unappealable. Within thirty (30) days of receiving the arbitrator’s decision, Sangamo shall notify Shire of its
acceptance or rejection of the selected Section 3.10 Proposal, which election shall be in Sangamo’s sole discretion. [***] The arbitrator’s fees and expenses will be [***] The effects of termination set forth in Subsections
14.5(a)(i), (iv), (vi), (vii) and (viii) shall apply to such Terminated Target, to the extent applicable. 
  

	 	4	JOINT STEERING COMMITTEE 

4.1 Composition. The JSC shall be formed as soon as practicable, but no later than 30 days following the Effective Date of this
Agreement. The JSC shall be comprised of an equal number of representatives from each Party, initially four (4). A representative from each Party who is a specialist with respect to intellectual property matters shall attend JSC meetings when
appropriate as an ad hoc, non-voting member in addition to the regular voting membership of the JSC. If mutually agreed by all JSC members on a case-by-case basis, the JSC may invite other non-members to participate in the discussions and meetings
of the JSC, provided that such participants shall have no voting authority at the JSC. Each Party shall notify the other Party in writing of its initial representatives to the JSC within ten business days after the Effective Date, and may substitute
one or more representatives from time-to-time effective upon written notice to the other Party. [***], and in such capacity, he/she shall be responsible for setting the agenda for meetings of the JSC, with input from the other members, and for
conducting the meetings of the JSC. 
 4.2 Responsibilities. 

(i) Oversight. The JSC shall be responsible for oversight of the Research Program during the Research Term, including the Research
Plans, pre-clinical work, and IND/CTA submissions for each Shire Target. Any amendments or modifications to the Research Plans shall require the approval of the JSC and shall be subject to the applicable terms of this Agreement, and the JSC shall be
required to formally document updates to the Research Plans on a quarterly basis as part of the agreed upon and accepted minutes of the quarterly meetings of the JSC. The JSC shall manage the technology transfer of Know-How from Sangamo to Shire
that is set forth in a Research Plan or that otherwise is necessary for Shire to practice the licenses granted under this Agreement, except that Sangamo shall have no obligation to transfer Know-How concerning the design of ZF Compounds. In addition
to the foregoing general responsibilities, the JSC shall in particular: (a) establish and approve budgets and timelines in the Research Plans, (b) manage the overall strategy for the research and development of potential Shire ZF Products
under the Research Plans, (c) determine the development and staging of lead and back-up Shire ZF Compounds and Shire ZF Products, (d) determine whether criteria set forth in a Research Plan with respect to a Shire Target and/or

  
 25 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
potential Shire ZF Products have been met, (e) make decisions on whether and how to continue activities under a particular Research Plan at each decision point set forth in such Research
Plan based on the then-available data and results and consistent with the criteria set forth in such Research Plan, including with respect to whether to terminate the Research Plan for a particular Shire Target, (f) approve any Subcontractors
(and, if requested by Shire, contracts with Subcontractors) proposed by Sangamo and the budgets therefor, (g) oversee the preparation of the [***], subject to decision-making authority as set forth in Subsection 10.2(a) (which authority
shall not be subject to Shire’s final decision-making authority under Section 4.4), and (h) review and approve the draft IND or CTA for each Shire ZF Product. The JSC will have solely the powers assigned to it in this
Article 4 and elsewhere in this Agreement, and will not have any power to amend, modify, or waive compliance with this Agreement. For clarity, Sangamo, and not the JSC, will be responsible for decisions with respect to the day-to-day
implementation of each Research Plan, unless [***] to Shire. The JSC, in its discretion, may establish subcommittees to assist the JSC in carrying out the responsibilities of the JSC. 

(ii) Manufacture. The JSC shall oversee the manufacture of Shire ZF Products and components thereof according to the Research
Plans during the Research Term; if Sangamo is responsible for performing such manufacture or engaging a Subcontractor to do so, then such manufacture shall be performed pursuant to the Research Plan and Shire shall reimburse Sangamo with respect
thereto in accordance with Section 3.6. For each Research Plan, the JSC shall at a minimum: establish the amount to be manufactured and maintained by Sangamo; review the manufacture of (and supply chain for) each Shire ZF Product to
identify potential risks and where necessary, implement through the Research Plan risk management strategies; analyze and review technical and quality control issues for each Shire ZF Product; review and approve any manufacturing agreements with
Third Parties pursuant to which Shire ZF Products are manufactured; review and approve all manufacturing specifications for Shire ZF Products including release specifications; and manage the transfer of manufacturing capability for Shire ZF Products
from Sangamo to Shire pursuant to the Research Plan in a manner to permit Shire to undertake its clinical development activity without delay. For the avoidance of doubt, Shire has the sole authority respecting the manufacture of clinical supplies of
Shire ZF Products for which Sangamo files an IND/CTA. 
 (iii) General. Sangamo shall update Schedule 1.57 as
necessary, but in no event less than[***] Sangamo shall[***] The JSC shall conduct its responsibilities hereunder in good faith and with reasonable care and diligence. 
 4.3 Meetings. 
 (a) The JSC shall meet in person or by teleconference not
less than once per calendar quarter during the Research Term. Subject to the preceding sentence, the JSC shall meet on such dates and at such times and places as agreed to by the members of the JSC. Meetings of the JSC shall be alternately hosted by
the Parties, with the host determining whether the meeting will be in person or by teleconference; provided, that at least one meeting hosted by each Party in each calendar year shall be in person. Shire shall host the first meeting of the
JSC at a mutually agreeable time and place no later than 60 days from the Effective Date of this Agreement. Each Party shall be responsible for all its own expenses relating to attendance at or participation in JSC meetings. 

  
 26 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (b) Within 10 days following each JSC meeting, the Party hosting the meeting shall cause to
be prepared and will provide to the other Party a draft of reasonably detailed written minutes describing all matters reviewed or considered by the JSC and all determinations made and actions taken by the JSC and a summary of the reasons therefor
stated by the members at the meeting. Discussions relating to amendments to the Research Program shall be included in the minutes. The minutes of any meeting of the JSC must be finalized by approval of the members of the JSC within 15 days of the
meeting. The final minutes shall include the relevant executed amendments to the Research Plans reflecting the discussed and approved changes. The minutes and the drafts of any minutes shall be the Confidential Information of both Parties.

 4.4 Actions. Each Party shall be entitled to cast one vote on matters before the JSC. For the transaction of business,
a quorum consisting of not less than one representative of each Party must be present at a meeting. Decisions of the JSC shall be made by unanimous approval, provided that a quorum is present. If the JSC is unable to reach agreement with
respect to any decision within the scope of its authority, the Chief Executive Officer of Sangamo (or his/her nominee) and a Senior Vice President of Shire (or his/her nominee) will meet promptly to attempt to resolve the dispute by good faith
negotiations. If these individuals are unable to resolve the dispute within [***] of the request for such meeting, then Shire shall[***] provided that such [***] For the avoidance of doubt, Shire shall not [***]. The Parties expressly understand and
agree that the[***] will not authorize Shire to [***]. 
 4.5 Term. The term of the JSC shall commence on the Effective
Date and continue in effect until the expiration or earlier termination of the Research Term. Thereafter, Shire will provide annually to Sangamo a written summary of, or the Parties will meet annually to share information regarding, Shire’s
development and commercialization of Shire ZF Products. For the avoidance of doubt, the term of the JSC shall be re-established for any period during which the Research Term is re-established according to Subsection 3.9(b). 

4.6 Change of Control. In the event of a Change of Control of Sangamo during the Research Term, within thirty (30) days of
such Change of Control, the Parties shall meet to discuss Shire’s concerns, if any, regarding the effect of such Change of Control. If Shire determines, in good faith and in its sole discretion, that [***] then Shire may, [***] do the
following: 
 (i) For any Research Plan where an [***] or, if a potential [***] or, if applicable, such [***] (ii) For any
Research Plan where either an [***] or, if a [***] Shire may (1) maintain the [***] or, if applicable, such [***] In the event Shire assumes all remaining activities of the Research Program with respect to a particular Research Plan according
to this Section 4.6, then (v) Sangamo shall promptly[***] that (1) is necessary for the completion of such Research Plan with respect to [***] and shall [***] that are necessary for such completion of such Research Plan, to the
extent such [***] in each case solely to complete such Research Plan with respect to the applicable products, or (2) is necessary for Shire to practice the licenses granted under Subsection 7.1(a) with respect to the Shire Target which
is the subject of such Research Plan; (w) Sangamo shall (A) [***] (if any) in Sangamo’s possession and control that are required by law or regulation to be maintained [***] (B) for any [***] described in clause (A) but that
are in Sangamo’s control and in the possession of a Third Party service provider, [***] provided that Shire 

  
 27 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
[***] and (C) provide [***] that are related to such [***] and used or generated in conducting activities under the applicable Research Plan but are not addressed in clause (A) or (B),
which information and materials Sangamo shall maintain for [***] years following Shire’s assumption of such Research Plan and shall not thereafter destroy without providing Shire notice and the opportunity to access such information and
materials, and (x) Sangamo shall promptly [***] solely relating to the Research Plans being assumed by Shire, such that Shire may continue, to the extent possible without interruption, the activities under such Research Plans and Shire’s
clinical development activities; provided that [***] but is otherwise necessary for Shire to [***] then Sangamo shall use [***] so long as Shire [***] prior to the applicable due date [***] (y) Sangamo shall provide, [***] to the extent that
Sangamo has the [***] and then available [***] and (z) Shire shall provide [***] to Sangamo a report of its progress under the Research Program. Solely in the event Shire assumes remaining activities under a Research Plan under which Sangamo is
[***]. 
  

	 	5	CLINICAL DEVELOPMENT AND COMMERCIALIZATION 

 5.1 Shire Responsibilities. 
 During the Term: 

(a) Subject to Subsections 5.1(b) and 5.4(a), Shire shall be solely responsible for and have sole discretion over (i) the
planning and conduct of, and expenses associated with, clinical trials of Shire ZF Products; (ii) all regulatory filings and interactions with regulatory agencies with respect to such Shire ZF Products, except those filings and interactions in
connection with any IND/CTA under a Research Plan; (iii) the selection of the countries in which Shire will pursue and maintain Marketing Approvals for such Shire ZF Products and expenses related to obtaining and maintaining such Marketing
Approvals; and (iv) commercialization of such Shire ZF Products in the Territory and expenses associated with the commercialization of such Shire ZF Products. 
 (b) For each Shire Target for which Sangamo has filed an IND or CTA for a Shire ZF Product directed to such Shire Target, or for which Shire has assumed the applicable Research Plan pursuant to
Section 4.6, Shire shall use Commercially Reasonable Efforts to obtain Marketing Approval for at least one therapeutic Shire ZF Product directed to such Shire Target in each of the United States and at least one Major European Country.
For the avoidance of doubt, if [***] Shire may [***]. 
 (c) In the event that a Shire Target for which Sangamo has filed or
intends to file an IND, CTA, or other foreign equivalent qualifies for an orphan drug designation, that designation will be in the name of Shire or one of its Affiliates. 
 5.2 Sangamo Responsibilities. 
 During the Term: 

(a) In order to permit Shire to conduct clinical trials without substantial delay, at the direction of the JSC and at least 60 days prior
to filing an IND/CTA for a Shire ZF Product 

  
 28 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
(or in the event Shire assumes all remaining activities of a Research Plan in accordance with Section 4.6), Sangamo will complete the transfer to Shire, in accordance with the
Research Plan but subject to Subsection 3.6(c), or otherwise as determined by the JSC and subject to Shire’s reimbursement of Sangamo’s [***] FTE costs and [***] external costs to conduct such transfer, of all Sangamo Know-How
(including synthesis protocols and documentation) necessary for Shire to manufacture clinical supplies of such Shire ZF Product according to the specifications and manufacturing techniques then in use by Sangamo for such Shire ZF Product. Sangamo
will provide such technical assistance to Shire as necessary to complete the transfer of such Sangamo Know-How in accordance with the Research Plan, subject to Subsection 3.6(c), or otherwise as determined by the JSC and subject to
Shire’s reimbursement of Sangamo’s [***] FTE costs and [***] external costs of such technical assistance. In addition, no later than the date on which Sangamo files an IND/CTA for a Shire ZF Product (or in the event Shire assumes all
remaining activities of a Research Plan in accordance with Section 4.6), (i) Sangamo will supply to Shire any then-existing supplies of such Shire ZF Product manufactured by or on behalf of Sangamo (except to the extent that any
such supplies need to be retained by Sangamo or its manufacturer, consistent with the requirements of regulatory authorities or otherwise as required by law), and (ii) to the extent any manufacturing contracts between Sangamo and a Third Party
contract manufacturer are specific to such Shire ZF Product, Sangamo will, if permitted under the terms of the contract, assign such contract to Shire. 
 (b) After filing and acceptance of an IND/CTA for a Shire ZF Product and upon payment of the development milestone under Section 9.3 for “First acceptance of either an IND or a CTA
submission by the applicable regulatory agency”, (i) Shire shall assume sole control, subject to Subsections 5.1(b) and 5.4(a), for all development, regulatory, manufacturing and commercialization activities for such Shire ZF
Product, and JSC oversight shall cease for that Shire ZF Product and, in Shire’s discretion, its related Shire Target, and (ii) Sangamo shall (A) promptly assign to Shire such IND/CTA, (B) promptly transfer to Shire all
information and materials in Sangamo’s possession and control that are required by law or regulation to be maintained by the holder of such IND/CTA, (C) for any information and materials of the type otherwise described in clause
(B) but that are in Sangamo’s control and in the possession of a Third Party service provider, either assign to Shire such contract (which contract Shire shall assume), to the extent assignable, and if not assignable (either by its terms
or because it does not relate solely to such Shire ZF Product), provide access to such information and materials to Shire, provided that Shire bears all costs for maintenance of and access to such information and materials, (D) provide Shire
access, to the extent reasonably requested by Shire and necessary or useful for Shire to pursue the clinical development and Marketing Approval of (or the maintenance of Marketing Approval of) such Shire ZF Product, to any information and materials
in Sangamo’s control that are related to such Shire ZF Product and used or generated in conducting activities under the applicable Research Plan but are not addressed in clause (B) or (C), which information and materials Sangamo shall
maintain for two (2) years following assignment of the IND/CTA to Shire and shall not thereafter destroy without providing Shire notice and the opportunity to access such information and materials, and (E) provide, at Shire’s expense,
such technical assistance as Shire may reasonably request to assist Shire in the clinical development, Marketing Approval and commercialization of such Shire ZF Product during the Royalty Period for such Shire ZF Product, to the extent that Sangamo
has the relevant expertise and then available capacity by functional group or is capable of acquiring sufficient capacity through the use of Commercially Reasonable Efforts. 

  
 29 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (c) If, after completion of activities under a Research Plan for a Shire Target, Shire
desires to (i) change one or more Shire ZF Compounds in the Shire Target Specific Product directed to such Shire Target or (ii) change one or more [***] in the [***] directed to such Shire Target, as applicable, Shire shall notify Sangamo
in writing, identifying the proposed change; provided that (A) any such change to a Shire ZF Compound shall not change the Shire Target to which such Shire ZF Compound Specifically Binds and shall not cause such Shire ZF Compound to
Specifically Bind any other Target or chromosomal location other than the Shire Target, (B) any such change to a [***] shall not result in a ZF Compound that is identical in amino acid sequence to a ZF Compound that Sangamo or its Affiliates or
Third Party licensees or collaborators is pursuing or to which Sangamo or its Affiliate has granted or intends to grant, pursuant to a then-existing bona fide written document (including a term sheet or letter of intent), exclusive or non-exclusive
rights to a Third Party (each such ZF Compound, an “Excluded Compound”), and (C) any such change to a [***], if it changes the [***] to which such [***] Specifically Binds, shall cause such ZF Compound to Specifically Bind to a
different locus that is also a [***]. If such notice includes a proposed change to a [***], then Sangamo shall notify Shire, within fifteen (15) days after receipt of such notice from Shire, if such modified ZF Compound is identical in amino
acid sequence to an Excluded Compound, in which case, Shire shall not research, develop or commercialize such modified ZF Compound. If, in the case of a [***], the modified ZF Compound is not identical in amino acid sequence to an Excluded Compound,
and for all Shire ZF Compounds and [***], in each case if such change complies with the rules set forth above, Sangamo shall notify Shire, within such fifteen (15)-day period, whether (i) Sangamo would conduct the necessary development
activities, in which case Sangamo shall use commercially reasonable efforts to develop the modified ZF Compound, at Shire’s expense, pursuant to a Research Plan or (ii) Sangamo declines to conduct the necessary development activities, in
which case Shire has the right to conduct such activities; provided that in no event shall Sangamo be obligated to disclose to Shire any Know-How related to the design of ZF Compounds. Upon successful development of the modified ZF Compound by
Sangamo or Shire, the modified ZF Compound shall be deemed a Shire ZF Compound or [***], as applicable. 
 5.3 Clinical
Development. 
 (a) Upon the filing and acceptance of an IND/CTA for a particular Shire ZF Product, Shire shall, itself or
through its Sublicensees hereunder, or any Affiliates of any of the foregoing, or Third Parties, complete clinical development activities and seek Marketing Approval for such Shire ZF Product in accordance with a Clinical Development Plan for such
Shire ZF Product, subject to Subsection 5.1(b). Each Clinical Development Plan will be developed, and amended from time to time, by Shire. Each Clinical Development Plan, including each such amendment, will be presented in the form of a
written summary provided to Sangamo that includes sufficient detail for Sangamo to understand the activities planned by Shire and Shire’s anticipated timelines for performing such activities. 

(b)Shire shall provide Sangamo with prompt written notice of Shire’s decision to change the Donor Nucleic Acid in any Shire ZF
Product, such notice to include the nucleic acid sequence of the new Donor Nucleic Acid. 

  
 30 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (c) Shire shall keep Sangamo informed about the status of Shire’s clinical development
activity by providing, in a timely manner, a copy of the clinical study report synopsis for each clinical trial arising out of such activity. Shire will use reasonable efforts to keep Sangamo informed as to material developments in clinical trials,
prior to issuing press releases about such developments. 
 (d) [***] prior to the first IND filing respecting [***] the Parties
agree to meet to negotiate and draft a [***] as it stands at the time of such [***]. 
 5.4 Commercialization.

 (a) Shire and its Affiliates, as appropriate, shall use Commercially Reasonable Efforts to commercialize each Shire ZF
Product in each country for which Marketing Approval of such Shire ZF Product is obtained. 
 (b) In performing its marketing
and promotion activities in respect of Shire ZF Products, Shire and its Affiliates shall comply with all applicable laws, regulations and guidelines concerning such promotional activities. 

 

	 	6	SUPPLY AND MANUFACTURE 

6.1 Shire’s Exclusive Right to Manufacture. Except as permitted under this Agreement for Sangamo to meet its obligations under
this Agreement, Shire shall have the exclusive right in the Territory to manufacture Shire ZF Compounds and Shire ZF Products for use in the applicable Field, either directly or through one or more Affiliates or Third Parties selected by Shire in
its sole discretion. 
 6.2 Requirements regarding Supply and Manufacture. Each of the Parties agrees that all supply and
manufacture of Shire ZF Compound and Shire ZF Product, as the case may be, pursuant to this Agreement, whether by a Party or a Third Party, shall comply with all applicable legal and regulatory requirements, including applicable good manufacturing
practices. 
  

	 	7	GRANT OF LICENSES 

 7.1
Grants by Sangamo 
 (a) License Grant. Subject to the terms and conditions of this Agreement, Sangamo hereby grants
to Shire an exclusive, royalty-bearing license, with the right to sublicense as provided in Subsection 7.1(b), under the Sangamo Licensed Technology, (i) to make, have made, use, and import Shire ZF Compounds and [***] in the Territory
solely for the purpose of developing and commercializing Shire ZF Products pursuant to the license granted in Subsection 7.1(a)(ii), and (ii) to make, have made, use, develop, sell, offer for sale, and import Shire ZF Products in the
applicable Field in the Territory. 
 (b) Sublicenses. 

(i) Affiliates. Subject to the terms and conditions of this Agreement, Shire may grant to one or more of its Affiliates a
sublicense under the rights granted to Shire 

  
 31 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
under Subsection 7.1(a). Such sublicense may be in whole or in part of the rights granted to Shire under Subsection 7.1(a) and may be on a country by country basis. Shire shall
remain responsible for the performance of such Affiliates under such rights to the same extent as if such activities were conducted by Shire, and shall remain responsible for any payments due hereunder with respect to activities of such Affiliates.

 (ii) Third Parties. Subject to the terms and conditions of this Agreement, Shire may also grant, through one or more
tiers, to Third Parties a sublicense under the rights granted to Shire under Subsection 7.1(a). Such sublicense may be in whole or in part of the rights granted to Shire under Subsection 7.1(a) and may be on a country by country basis.
Shire shall remain responsible for any payments due hereunder with respect to activities of the Sublicensee. In the event of termination of this Agreement by Sangamo pursuant to Section 14.2 or 14.3, any permitted sublicense under
this Subsection 7.1(b)(ii) shall, at the Sublicensee’s option, survive such termination, provided that the Sublicensee is not in material breach of any of its obligations under such sublicense. In the event of termination of this
Agreement by Shire pursuant to Section 14.4, any permitted sublicense under this Subsection 7.1(b)(ii) shall, at the Sublicensee’s option and with Sangamo’s prior written consent, not to be unreasonably withheld,
conditioned, or delayed, survive such termination, provided that the Sublicensee is not in material breach of any of its obligations under such sublicense. In order to effect this provision, at the request of the Sublicensee and, if applicable, with
consent of Sangamo pursuant to the preceding sentence, Sangamo shall enter into a direct license with the Sublicensee on substantially the same terms as the sublicense, provided that Sangamo shall not be required to undertake obligations in addition
to those required by this Agreement, and that Sangamo’s rights under such direct license shall be consistent with its rights under this Agreement, taking into account the scope of the license granted under such direct license. 

(iii) Notice. With respect to any sublicense agreement that includes a sublicense under a Third Party License that requires
Sangamo to provide the applicable Third Party licensor a copy of any sublicense agreement or a summary of the terms of such sublicense agreement, Shire shall provide Sangamo with such copy or summary within fifteen (15) days of the execution of
such sublicense agreement. Any such copy or summary shall be treated by Sangamo as Shire’s Confidential Information. 

(iv) Requirements. Each agreement in which Shire grants a sublicense under the license granted in Subsection 7.1(a) shall
be subject to (i) the applicable terms and conditions of this Agreement and (ii) the applicable terms and conditions set forth in Schedule 7.6B of any Third Party Licenses sublicensed to the Sublicensee, and shall expressly include
the terms set forth in Schedule 7.1(b)(iv) respecting each Third Party License sublicensed to the Sublicensee. 
 (v)
Direct Sublicense from Sangamo. If Shire cannot grant further sublicenses under a particular Third Party License, then at Shire’s request in conjunction with Shire’s granting of a sublicense to a Sublicensee under this Subsection
7.1(b), subject to Subsection 7.1(b)(vi), Sangamo shall grant a sublicense under such Third Party License to such Sublicensee on terms that are consistent with the Third Party License, the sublicense granted by Shire to such Sublicensee
and the terms of this Agreement. 

  
 32 

 (vi) Payments under Third Party Licenses. Notwithstanding anything in
Section 10.4 to the contrary, Shire shall be solely responsible for paying any sublicense issuance and sublicense maintenance fees owed to Third Parties pursuant to Third Party Licenses on account of the grant of a sublicense by Shire or
its Sublicensees or by Sangamo pursuant to Subsection 7.1(b)(v), which fees are set forth in Schedule 7.1(b)(vi). 

7.2 Grant by Shire. Subject to the terms and conditions of this Agreement, Shire hereby grants to Sangamo a royalty-free,
non-exclusive license, with the right to grant sublicenses only to permitted Subcontractors under Section 3.5, under all Shire Patent Rights and other intellectual property rights Controlled by Shire and its Affiliates as of the
Effective Date or that come into the Control of Shire and its Affiliates during the Research Term solely as necessary to perform the activities to be performed by or on behalf of Sangamo under the Research Program during the Research Term.

 7.3 Exclusivity. During the Term, Sangamo shall not work independently of this Agreement for itself or any Affiliate
or Third Party (including the grant of any license to any Third Party) with respect to the discovery or research of any product that is intended to be used clinically or diagnostically to (1) [***] or (2) [***]other than through the [***].
During the Term, Sangamo shall not work independently of this Agreement for itself or any Affiliate or Third Party (including the grant of any license to any Third Party) with respect to the development or commercialization, for therapeutic or
diagnostic purposes, of (a) any product that can be used clinically or diagnostically to (1) [***], or (2) [***] other than through the [***], (b) any Shire ZF Product, (c) any ZF Compound that Specifically Binds a Shire
Target, or (d) any [***]. [***] in each case (i), (ii) and (iii) unless and until such [***]. For the avoidance of doubt and not by way of limitation, during the Term, Sangamo shall not work independently of this Agreement for itself
or any Affiliate or Third Party (including the grant of any license to any Third Party) on any therapeutic product containing a ZF Compound or process employing a ZF Compound that (i) with respect to either the Factor VII gene and Factor X
gene, for so long as each such gene is a Shire Target and not a Terminated Target, provides a functional copy of such gene, or (ii) with respect to any other Shire Target, corrects expression of such defective Shire Target or provides a
functional copy of the protein encoded by the non-defective version of such Shire Target. Sangamo’s obligations under this Section 7.3 shall terminate with respect to a Target when it ceases to be a Shire Target and becomes a
Terminated Target. Shire acknowledges that Sangamo, prior to the Effective Date, entered into agreements pursuant to which it granted licenses to Third Parties with respect to research and agricultural uses of ZF Compounds and that such licenses are
not prohibited by this Section 7.3. If Sangamo acquires a Third Party that is, prior to such acquisition, researching, developing or commercializing a product or service described in the first two sentences of this
Section 7.3, Sangamo (i) [***] (ii) shall not [***] (iii) shall not [***] and (iv) shall [***] the obligations of Sangamo under this Section 7.3 shall not apply to any product or service that (1)[***].

 Sangamo shall notify Shire promptly if it decides to [***] or if it is contacted by a Third Party to[***] in each case with respect to a
[***] provided, however, that Sangamo shall not [***] Upon Shire’s request within [***] days after such notice, the Parties will negotiate in good faith for up to sixty (60) days (the “Negotiation Period”) regarding the
terms under which Sangamo [***] Sangamo may engage in [***]. 

  
 33 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 7.4 No Implied Rights. Except as expressly provided in this Agreement, neither Party
shall be deemed by estoppel, implication or otherwise to have granted the other Party any license or other right with respect to any intellectual property of such Party. 
 7.5 Negative Covenant. Each Party covenants that it will not knowingly use or practice any of the other Party’s intellectual property rights licensed to it under this Article 7 except
for the purposes expressly permitted in the applicable license grant. 
 7.6 Third Party Licenses. The licenses granted
to Shire in Subsection 7.1(a) include sublicenses under Sangamo Licensed Technology licensed to Sangamo pursuant to Third Party Licenses, which sublicenses are subject to the terms set forth on Schedule 7.6A, which terms Shire hereby
acknowledges. Schedule 7.6B sets forth those obligations under the Third Party License that are obligations of Shire under this Agreement. Shire hereby agrees to be bound by the terms set forth in Schedule 7.6B. 

 

	 	8	REPRESENTATIONS AND WARRANTIES 

 8.1 Mutual Representations. Each Party represents and warrants to the other Party as follows as of the Effective Date: 

(a) Organization. Such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which
it is organized. 
 (b) Authorization and Enforcement of Obligations. Such Party: (i) has the requisite power and
authority and the legal right to enter into this Agreement and to perform its obligations hereunder, (ii) has the requisite resources and expertise to perform its obligations hereunder, and (iii) has taken all requisite action on its part
to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable
against such Party in accordance with its terms. 
 (c) Consents. All necessary consents, approvals and authorizations of
all governmental authorities and other persons or entities required to be obtained by such Party in connection with the execution and delivery of this Agreement have been obtained. 

(d) No Conflict. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder:
(i) do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies, (ii) do not conflict with, or constitute a breach or default under, any contractual obligation of such Party, and
(iii) do not conflict with or result in a breach of any provision of the organizational documents of such Party. 
 8.2
Additional Sangamo Representations. Sangamo further represents and warrants to Shire as of the Effective Date as follows: 

(a) No Conflicts. Sangamo has not granted, and will not grant during the Term, any rights that are inconsistent with the rights
granted to Shire herein. Neither Sangamo nor its Affiliates has entered into any agreement, arrangement or understanding with any Third Party that is inconsistent with the provisions of this Agreement. Sangamo has the right to grant the licenses
granted in Subsection 7.1(a). 

  
 34 

 (b) Litigation. Except as set forth in Schedule 8.2(b), there are no actions,
suits, proceedings or investigations pending or, to its knowledge, threatened against Sangamo before any court, government or regulatory body, agency, commission, official or any arbitrator that is reasonably expected to have an adverse effect on
Sangamo’s ability to consummate the transactions contemplated hereby. 
 (c) Sangamo Intellectual Property.
Schedule 1.57 is an accurate listing by owner, inventor(s), serial number, filing date, country, and status of all of the Sangamo Patent Rights. Except as set forth in Schedule 8.2(c), Sangamo owns, is the licensee in good standing of,
or Controls all Sangamo Licensed Technology. Except as set forth in Schedule 8.2(c), (i) there is no fact or circumstance known to Sangamo that would cause Sangamo to reasonably conclude that any of the issued patents in the Sangamo
Patent Rights is invalid or unenforceable, (ii) the inventorship of each Sangamo Patent Right owned by Sangamo and, to Sangamo’s knowledge, of each Sangamo Patent Right licensed to Sangamo, is properly identified on each patent,
(iii) all official fees, maintenance fees and annuities for the Sangamo Patent Rights owned by Sangamo and, to Sangamo’s knowledge, for the Sangamo Patent Rights licensed to Sangamo, have been paid and all administrative procedures with
governmental agencies have been completed for the Sangamo Patent Rights owned by Sangamo and, to Sangamo’s knowledge, for the Sangamo Patent Rights licensed to Sangamo, such that the Sangamo Patent Rights owned by Sangamo and, to Sangamo’s
knowledge, the Sangamo Patent Rights licensed to Sangamo are subsisting and in good standing, (iv) Sangamo, including its employees and agents, has complied with its U.S. PTO duty of disclosure respecting the prosecution of all of the Sangamo
Patent Rights, and, to Sangamo’s knowledge, the licensors of the Existing Third Party Licenses, including their employees and agents, have complied with the U.S. PTO duty of disclosure respecting the prosecution of the applicable Sangamo Patent
Rights, (v) none of the Sangamo Patent Rights owned by Sangamo, and to Sangamo’s knowledge none of the Sangamo Patent Rights licensed to Sangamo, is currently involved in any interference, reissue, re-examination, cancellation or
opposition proceeding and neither Sangamo, nor any of its Affiliates, has received any written notice from any person of such actual or threatened proceeding, (vi) Sangamo has not done or omitted to do anything which may cause Sangamo Patent
Rights in existence as of the Effective Date to lapse prematurely, (vii) Sangamo has not received notice that any of the Sangamo Patent Rights is the subject of a compulsory licence, and (viii) Sangamo has disclosed to Shire all
information of which it is aware or which is in its possession or control that is material to the novelty or validity of the Sangamo Patent Rights in existence as of the Effective Date and any challenges thereto. 

(d) Third Party Intellectual Property. Sangamo is not aware of, or, alternatively, has described in Schedule 8.2(d), any
Patent Rights or other intellectual property rights of any Third Party that could materially adversely affect Sangamo’s ability to consummate the transactions contemplated hereby with respect to (1) the experiments contemplated in the
Research Plans set forth in Schedule 3.3, (2) the zinc finger protein technology platform, (3) zinc finger proteins targeted to an Initial Target, [***], or the native locus of [***], (4) Donor Nucleic Acids encoding a protein
encoded by an Initial Target or by the [***] (5) [***] for zinc finger nucleases, and (6) [***] for zinc finger proteins (collectively, the “Initial Subject Matter”). To

  
 35 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
Sangamo’s knowledge, except as identified in Schedule 8.2(d), (i) the exercise of Shire’s rights granted under and contemplated by this Agreement with respect to the Initial
Subject Matter will not infringe or conflict with any Third Party intellectual property rights and will not result in any obligation by Shire to any Third Party, and (ii) there are no pending Third Party patent applications which, if issued
with the currently pending or published claims, would materially adversely affect the right of Shire to practice the Sangamo Licensed Technology as contemplated by this Agreement with respect to the Initial Subject Matter. Sangamo has disclosed to
Shire all information of which it is aware or which is in its possession or control that is material to evaluating any Third Party intellectual property rights which might be an obstacle to Shire’s commercialization of the Sangamo Licensed
Technology to the extent related to the Initial Subject Matter. Sangamo agrees to immediately notify Shire in writing in the event that Sangamo becomes aware of any patent, trade secret or other right of the nature referred to in this Subsection
8.2(d). For the avoidance of doubt, a disclosure of any item or other matter in Schedule 8.2(d) is not an admission or indication that such item or other matter is required to be disclosed, or an admission of any current or
potential obligation or liability to any Third Party or of any actual or potential breach or violation of any law or regulation. 
 (e) Third Party Infringement. So far as Sangamo is aware, except as set forth in Schedule 8.2(e), no Third Party is infringing or has infringed any of the Sangamo Patent Rights or has
misappropriated any of the Sangamo Know-How. 
 (f) Existing Third Party Licenses. The Existing Third Party Licenses are
in full force and effect as modified or amended prior to the Effective Date. Neither Sangamo nor, to Sangamo’s knowledge, any Third Party licensor is in default with respect to a material obligation under, and neither such party has claimed or,
to Sangamo’s knowledge, has grounds upon which to claim that the other party is in default with respect to a material obligation under, any Existing Third Party License. Sangamo will promptly provide Shire with a copy of any amendments to the
Existing Third Party Licenses made after the Effective Date and will not amend the Existing Third Party Licenses in a manner that will materially adversely affect Shire’s rights under this Agreement, without Shire’s prior written consent.
Except as identified in Schedule 8.2(f), Sangamo does not Control any other Third Party intellectual property necessary or useful for Shire to practice the licenses granted under this Agreement. 

(g) Other Encumbrances. No order has been made, no petition has been presented, no board meeting has been convened to consider a
resolution, and no resolution has been passed, for the winding up or dissolution of Sangamo; (b) no agreement or arrangement with creditors for [***] of Sangamo’s intellectual property assets for the benefit of creditors exists or has been
proposed in respect of the Sangamo Patent Rights or Sangamo Know-How; and (c) no event has occurred causing, or which upon instruction or notice by any Third Party may cause, any security interest to be perfected in the Sangamo Patent Rights or
Sangamo Know-How. 
 (h) Confidentiality. Sangamo has entered into all confidentiality agreements necessary to be in
compliance with this Agreement as of the Effective Date. 

  
 36 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (i) Disclosure. Sangamo, to its knowledge, has disclosed to Shire all information
respecting zinc finger technology in Sangamo’s possession or Control material to Shire’s decision to enter into this Agreement. 
 8.3 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND PARTICULARLY THE PARTIES
DISCLAIM ALL IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
  

	 	9	PAYMENTS AND VALUE ADDED TAX 

 9.1 License Fee. Within ten (10) business days after the Effective Date, Shire shall pay to Sangamo a non-creditable, non-refundable license fee of thirteen million U.S. dollars
($13,000,000.00). 
 9.2 Ongoing Research and Development Payments. In respect of the activities conducted by or
on behalf of Sangamo under the Research Plans, Shire shall make non-creditable, non-refundable quarterly payments in U.S. dollars to reimburse Sangamo for actual costs incurred as specified in Section 3.6. Subject to any good
faith disputes promptly brought to Sangamo’s attention and for which Shire is diligently seeking resolution, Shire shall pay such invoices within 30 days of the date of receipt of the invoice. 

9.3 Milestone Payments. Shire will make the following non-refundable, non-creditable payments (“Milestone
Payments”) to Sangamo within thirty (30) business days after the first occurrence of each of the following events by Shire or its Affiliates or Sublicensees (“Milestone Events”) on a Shire Target-by-Shire Target basis:

  

							
	 Milestone Event
	  	Milestone Payment
(in
Millions (“M”) in USD).
Respecting Milestone
Events 1-4, for the first
Shire ZF Product to
achieve the Milestone
Event on a
Shire
Target-by-Shire
Target Basis	 
			
	 1
	 	[***]	  	$	1M	  
			
	 2
	 	First acceptance of either an IND or a CTA submission by the applicable regulatory agency	  	$	7.5M	  
			
	 [***]
	 	[***]	  	 	[***	] 
			
	 [***]
	 	[***]	  	 	[***	] 
			
	 [***]
	 	[***]	  	 	[***	] 
			
	 [***]
	 	[***]	  	 	[***	] 
			
	 [***]
	 	[***]	  	 	[***	] 
			
	 [***]
	 	[***]	  	 	[***	] 
			
	 [***]
	 	[***]	  	 	[***	] 
			
	 [***]
	 	[***]	  	 	[***	] 

  
 37 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (i) Milestone Payments shall be made [***] 

(ii) Following the First Commercial Sale of a Shire ZF Product for any indication, Shire may seek [***] as used herein, means any [***]
that is related to the[***] are (i) treating substantially [***] (ii) achieving one or more of the [***] (iii) expanding the [***] (iv) expanding the [***] For the avoidance of doubt, Milestone Payments [***] shall not be due in
the event [***] Less likely is that Shire will [***] as used herein, means any [***] An example of an [***] would be [***]. 

(iii) If a Shire ZF Product for a specific Shire Target is discontinued in development after Shire has paid one or more Milestone
Payments for Milestone Events achieved by such Shire ZF Product and [***] then [***]. 
 (iv) If more than one Milestone Event
is achieved in the same year, all applicable Milestone Payments shall be payable for such year. 
 (v) No Milestone Payments
shall accrue and be due for a terminated Shire Target (or all Shire Targets if this Agreement is terminated in its entirety), for a Milestone Event that occurs after notice has been given by Shire or the JSC for termination pursuant to [***].

 (vi) In the event that a Milestone Payment is based on a [***] Event for an indication that is an indication with less than
[***] For the avoidance of doubt, this Subsection 9.3(vi) shall not apply to [***]. 
 9.4 Earned
Royalties. Shire shall pay Sangamo a royalty calculated as the following percentages of the annual Net Sales of all Shire ZF Products on a Shire Target-by-Shire Target basis (the “Earned Royalties”). 

 

					
	 Annual Net Sales for all Shire ZF Products for a Shire Target
	  	Royalty
Rate	 
		
	 Amount of annual Net Sales up to or equal to [***]
	  	 	[***	]% 
		
	 Amount of annual Net Sales over [***]
	  	 	[***	]% 

  
 38 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 For example, for annual Net Sales of [***] of all Shire ZF Products for a particular Shire
Target, the total Earned Royalty would be calculated as follows: 
 [***] 

(i) Only one Earned Royalty shall be payable on a single Shire ZF Product regardless of the number of Sangamo Patent Rights, Joint
Patent Rights and [***] covering such Shire ZF Product. For the avoidance of doubt, only one Earned Royalty shall be payable on a single Shire ZF Product regardless of the number of ZF Compounds in the Shire ZF Product and regardless of whether the
Shire ZF Product contains both diagnostic and therapeutic components. 
 (ii) [***]. In the event Shire, or the JSC as
appropriate, reasonably believes it Necessary to Obtain a License (as defined in Subsection 10.4(b)) from a Third Party pursuant to Section 10.4 under the Third Party’s intellectual property rights to research, develop,
manufacture or commercialize particular Shire ZF Products (but not including any part of a combination product that is not a Shire ZF Product), and a license is obtained in accordance with Sections 10.4(c), 10.4(d), or 10.4(e), then Shire
shall be entitled to the [***]. 
 (iii) [***] 
 (A) The Earned Royalties due to Sangamo for Net Sales of a Shire ZF Product in a country shall be[***] if following the [***] the [***] in such country of such Shire ZF Product in any [***] are [***] by
more than [***] of such Shire ZF Product in such country [***] immediately prior to the [***] in such country. If such [***] takes effect, it will apply for each [***] thereafter in which the [***] of such Shire ZF Product in such country remain
[***] by at [***]%[***] of such Shire ZF Product in such country [***] immediately prior to the [***] in such country. 
 (B)
The Earned Royalties due to Sangamo for Net Sales of a Shire ZF Product in a country shall be [***]%[***] if following [***] respecting such Shire ZF Product in such country[***] in such country of such Shire ZF Product in [***]% [***] of such Shire
ZF Product in such country [***] immediately prior to the first sale of such Generic Product in such country. If such reduction takes effect, it will apply for [***] thereafter in which the [***] of such Shire ZF Product in such country remain
[***]%[***] of such Shire ZF Product in such country [***] immediately prior to [***] in such country. 
 (C) For clarity,
subsections (A) and (B) shall not apply simultaneously. Notwithstanding anything to the contrary, if any [***] in a country in which (A) or (B) applies, the [***]. 

9.5 Following expiration of the Royalty Period for any Shire ZF Product in any country, no further Earned Royalties shall
be payable to Sangamo in respect of Net Sales of such Shire ZF Product in such country and thereafter the licenses granted to Shire hereunder with respect to such Shire ZF Product in such country shall be fully paid-up, exclusive, irrevocable and
royalty-free; provided, however, that if after the expiration of the Royalty Period for a Shire ZF Product in a country any payments are due by Sangamo to Third Parties under the Third Party Licenses on account of Shire’s or its
Affiliates’ or Sublicensees’ development or sale of a 

  
 39 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
Shire ZF Product in a country after the expiration of the Royalty Period for such Shire ZF Product in such country, Shire shall pay to Sangamo such amounts due to such Third Parties under any
such Third Party License, and the sublicense with respect to the applicable Sangamo Licensed Technology shall be fully-paid up, exclusive, irrevocable and royalty-free only after all such payment obligations expire. Schedule 9.5 identifies
those Existing Third Party Licenses in which Sangamo’s payment obligations may extend beyond the Royalty Period. 
 9.6
Payment of Earned Royalties. Earned Royalties shall become due and payable forty-five (45) days following the end of the calendar quarter during which such First Commercial Sales occur, and within forty-five (45) days of the end
of each calendar quarter thereafter during the Royalty Period, for sales made during each such calendar quarter. 
 9.7
Payments for Third Party IP Rights. To the extent that Sangamo obtains a license to any Third Party intellectual property rights and grants Shire a sublicense under such Third Party intellectual property rights pursuant to Subsection
10.4(c) or 10.4(e) (thus causing the applicable license agreement to be a Third Party License), Shire shall pay to Sangamo all payments due by Shire to Sangamo under such sublicense within thirty (30) days after the applicable due date in
such Third Party License and provide to Sangamo, at least ten (10) days before the applicable due date in such Third Party License, all reports required under the applicable license agreement between Sangamo and such Third Party on account of
Shire’s and its Affiliates’ and Sublicensees’ development, manufacture and commercialization of Shire ZF Products, such that Sangamo may comply with all payment and reporting obligations under such license agreements. Provided it
receives such items in a timely manner, Sangamo shall pay such amounts to, and file such reports with, the applicable Third Party on or before the applicable due date. 
 9.8 Royalty Reports. 
 (a) Within 45 days after the end of each
calendar quarter during the Royalty Period, Shire shall furnish to Sangamo a written report showing in reasonably specific detail, on a Shire ZF Product-by-Shire ZF Product and country-by-country basis: (i) the Gross Sales of all Shire ZF
Product sold by Shire, its Sublicensees hereunder and their respective Affiliates during such calendar quarter, (ii) the calculation of Net Sales from Gross Sales of Shire ZF Product, (iii) the withholding taxes, if any, required by law to
be deducted with respect to royalties due on such sales and (iv) the exchange rates, if any, used in determining the amount payable to Sangamo in United States dollars. 
 (b) With respect to sales of Shire ZF Product invoiced in United States dollars, all such amounts shall be expressed in United States dollars. With respect to sales of Shire ZF Product invoiced in a
currency other than United States dollars, all such amounts shall be expressed both in the currency in which the amount is invoiced and in the United States dollar equivalent. Whenever for the purpose of calculating Net Sales, conversion from any
foreign currency shall be required, the amount of such sales in foreign currencies shall be converted into US dollars using the exchange rate for the relevant month as determined by Shire’s accounting policies (the “Monthly
Rate”), such Monthly Rate being determined as the last price rate of exchange for such currencies on the last business day of the immediately preceding calendar month as published on Bloomberg page FXC (or such other publication as may be
agreed between the Parties from time to time). 

  
 40 

 (c) Shire shall keep complete and accurate records in sufficient detail to enable the
royalties and Milestone Payments based on Net Sales payable under this Article 9 to be determined. 
 9.9
Audits. 
 (a) Upon fourteen days advance written request by Sangamo and not more than once in each calendar year,
Shire, its Sublicensees and their Affiliates shall permit an independent certified public accounting firm of internationally recognized standing, selected by Sangamo and reasonably acceptable to Shire, at Sangamo’s expense, to have access
during normal business hours to such of the records of Shire, its Sublicensees hereunder and their respective Affiliates as may be reasonably necessary to verify the accuracy of the royalty reports and Milestone Payments based on Net Sales hereunder
for any year ending not more than eighteen (18) months prior to the date of such request. No year may be audited more than once, except for cause. The accounting firm will enter a confidentiality agreement reasonably acceptable to Shire
governing the use and disclosure of Shire’s information disclosed to such firm, and such firm shall disclose to Sangamo only whether the reports are correct or not and the specific details concerning any discrepancies, which information shall
be Confidential Information of Shire. 
 (b) Unless disputed by Shire or Sangamo in good faith, if such accounting firm
concludes that the royalties or Milestone Payments based on Net Sales paid during the audited period were more or less than the royalties and Milestone Payments based on Net Sales due, Shire shall pay any additional amounts due, and Sangamo will
refund any amounts overpaid, in each case plus interest as set forth in Section 9.13, within thirty (30) days after the date the written report of the accounting firm so concluding is delivered to Sangamo and Shire. The fees
charged by such accounting firm shall be paid by Sangamo; provided, that if the audit discloses that the royalties and Milestone Payments payable by Shire for such period have been underpaid by [***] then, subject to Subsection
9.9(c), Shire shall pay the reasonable fees and expenses charged by such accounting firm. 
 (c) In the event of a
good faith dispute by Shire or Sangamo regarding the result of an audit made pursuant to this Section 9.9, the Parties shall agree in good faith on an alternative independent certified public accounting firm of internationally
recognized standing to perform a second audit. If such audit is requested by Shire because Shire was found by the initial audit to have underpaid and the second audit confirms that Shire underpaid, then Shire shall bear all costs associated with the
second audit. If such audit is requested by Sangamo because Shire was found by the initial audit to have overpaid and the second audit confirms that Shire overpaid, then Sangamo shall bear all costs associated with the second audit. Notwithstanding
the above, in the event that the second audit confirms the findings of the first audit, the requesting Party shall pay. No over or under payment indicated by the initial audit shall be payable in the event of a dispute until the second audit is
complete and such second audit shall be binding on the Parties, with any under or over payment determined thereby, plus interest as set forth in Section 9.13, being payable within thirty (30) days after the date the written
report of the accounting firm so concluding is delivered to Sangamo and Shire. 

  
 41 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (d) Sangamo shall treat all financial information disclosed by its accounting firm pursuant
to this Section 9.9 as Confidential Information of Shire for purposes of Article 11 of this Agreement, and shall cause its accounting firm to do the same. 
 9.10 Withholding Taxes 
 (a) As of the Effective Date, the Parties agree
that the payments set forth in Sections 9.1 – 9.4 above are not subject to any withholding taxes. If after the Effective Date any laws, rules or regulations change such that withholding of income taxes or other taxes is imposed upon
payments set forth in Sections 9.1 – 9.4 above, Shire shall make such withholding payments as required and subtract such withholding payments from the payments due to Sangamo. Shire shall submit appropriate proof of payment of the
withholding taxes to Sangamo within a reasonable period of time. At the request of Sangamo, Shire shall give Sangamo such reasonable assistance, which shall include the provision of appropriate certificates of such deductions made together with
other supporting documentation as may be required by the relevant tax authority, to enable Sangamo to claim exemption from such withholding or other tax imposed or obtain a repayment thereof or reduction thereof and shall upon request provide such
additional documentation from time to time as is reasonably required to confirm the payment of tax. 
 (b) Notwithstanding
Subsection 9.10(a), if Shire is required to make a payment to Sangamo that is subject to a deduction or withholding of tax, then if such withholding or deduction obligation arises as a result of any action by Shire, including any
assignment or sublicense, or any failure on the part of Shire to comply with applicable laws or filing or record retention requirements, that has the effect of modifying the tax treatment of the Parties hereto (a “Shire Withholding Tax
Action”), then the sum payable by Shire (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Sangamo receives a sum equal to the sum which it would have
received had no such Shire Withholding Tax Action occurred. 
 (c) Notwithstanding Subsection 9.10(a), if Shire is
required to make a payment to Sangamo that is subject to a deduction or withholding of tax, then if such withholding or deduction obligation arises as a result of any action by Sangamo, including any assignment or any failure on the part of Sangamo
to comply with applicable laws or filing or record retention requirements, that has the effect of modifying the tax treatment of the Parties hereto, then the sum payable by Shire (in respect of which such deduction or withholding is required to be
made) shall be made to Sangamo after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted to the proper governmental authority in accordance with applicable laws. 

  
 42 

 9.11 Value Added Tax. 

(a) All payments stated in Sections 3.2, 3.6 and 9.2 of this Agreement are for the purposes of VAT considered to be both -
exclusive of VAT & consideration for the supply of services. 
 (b) For the purposes of this
Section 9.11, Sangamo refers not only to Sangamo but also to any business that this Agreement or part interest in this Agreement may be transferred to. 
 (c) For the purposes of VAT, the services performed by Sangamo under this agreement shall be considered to be covered by Art 44 of Council Directive 2006/112/EC (or any equivalent provision in the country
of performance if performed outside the European Union) and as such will be considered to be liable for VAT in the country where the recipient is established. For the purposes of this agreement, it is understood that Sangamo is established in the
USA and Shire AG is established in Switzerland. 
 (d) If at any stage, the local Tax Authorities assert that they consider the
services performed by Sangamo to be subject to local VAT, Sangamo shall in the first instance undertake all reasonable steps to refute any such assertions by the local Tax Authority. Only once this process is completed should Sangamo raise valid tax
invoices for the additional VAT liability. 
 (e) Shire shall take all reasonable steps to recover any additional VAT liability
from the same local Tax Authorities by submitting regular claims. Sangamo shall provide all reasonably necessary assistance to facilitate the recovery of this tax. However, if in the event that the tax cannot be recovered then Shire shall be
entitled to offset this tax against future payments to Sangamo 
 (f) Any penalties or interest accruing to incorrect VAT
treatment of the supplies made by Sangamo will rest with Sangamo. 
 (g) Should these services be considered to be subject to
Art 44 of Council Directive 2006/112, both Sangamo & Shire warrants that they will fulfill all their necessary VAT reporting requirements in respect of these services. 

(h) In the event that an invoice is raised that is subject to VAT but is raised in a currency other than the local currency of the
territory from where the tax is being charged, the invoice must additionally display this tax in the local currency of the territory having been converted using the relevant monthly exchange rate published on Bloomberg. 

(i) Sangamo hereby represents and warrants that it is not, has never been and has no obligation for whatever reason to be established for
VAT purposes in any jurisdiction outside the United States of America. Solely on this basis Shire acknowledges and agrees that: (1) as of the Effective Date, it is a fully taxable entity for VAT purposes in Switzerland; and (2) as of the
Effective Date, Shire expects to recover any self-assessed Swiss VAT that Shire will need to report to the Swiss VAT authorities in relation to payments to made by Shire to Sangamo under this Agreement. 

  
 43 

 (j) Termination: In the event that this agreement is terminated, Shire will be entitled to
withhold from any remaining sums payable to Sangamo any outstanding VAT claims from the local Tax Authority. These sums will be paid to Sangamo upon successful refunding of the claims from the local Tax Authority. 

9.12 Payment Method. All payments by Shire to Sangamo hereunder shall be in United States dollars in immediately available
funds and shall be made by wire transfer to a bank account designated in writing by Sangamo to Shire. 
 9.13 Late
Payments. If a Party does not receive payment of any sum due to it on or before the due date therefor, simple interest shall thereafter accrue on the sum due to the Party from the due date until the date of payment at a per-annum rate of
two percent (2%) over the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable by applicable laws, whichever is lower. 
  

	 	10	INTELLECTUAL PROPERTY 

10.1 Ownership 
 (a) Inventions. Except as provided in Subsection 10.1(b) below, (i) each Party, as between such Party and the other Party, shall own all Know-How conceived, discovered, invented,
created, made or reduced to practice or tangible medium solely by employees, agents or contractors of such Party (and all Patent Rights claiming such Know-How), and (ii) the Parties shall jointly own and have an undivided one-half interest in
and to all Joint Know-How and Joint Patent Rights. All determinations of inventorship under this Agreement shall be made in accordance with the patent law of the United States. Each Party may exploit any Joint Technology without accounting to or
obtaining consent from the other Party, subject to the exclusive license of Sangamo’s interest thereunder granted, as part of the Sangamo Licensed Technology, under Subsection 7.1(a), provided, however, that nothing in this
Subsection 10.1(a) shall be construed as a grant to any other intellectual property held by the other Party. 
 (b)
Shire [***] Patent Rights. Sangamo agrees to [***] and does hereby [***] to Shire, Sangamo’s entire right, title and interest in and to any [***]. In each case, Sangamo shall execute and deliver to Shire [***] [***], in a mutually
agreeable form, within thirty (30) days after such Patent Right comes into existence. Any such [***] [***] and shall constitute Confidential Information of Shire for the purposes of this Agreement unless it is [***] to Sangamo in accordance
with this Section 10.1(b), in which case it shall constitute the Confidential Information of Sangamo. Notwithstanding the foregoing or anything to the contrary in this Agreement, Shire shall not, directly or indirectly through
Affiliates or Third Parties, practice any of the [***] outside of the scope of the licenses granted to Shire under this Agreement. For any Patent Right that ceases to be a [***] at any time during the Term by virtue of an amendment of the claims,
Shire shall [***], and does hereby [***], effective as of the date of such claim amendment, its entire right, title and interest in and to each such Patent Right to Sangamo. In each case, Shire shall execute and deliver to Sangamo a deed(s) of such
[***], in a mutually agreeable form, within thirty (30) days after the date such Patent Right ceased to be an [***]. 

  
 44 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (c) Personnel Obligations. Each employee, agent or independent contractor of a Party
or its respective Affiliates performing work under this Agreement shall, prior to commencing such work, be bound by invention assignment obligations, including : (i) promptly reporting any invention, discovery, process or other intellectual
property right; (ii) presently assigning to the applicable Party or Affiliate all of his or her right, title and interest in and to any invention, discovery, process or other intellectual property; (iii) cooperating in the preparation,
filing, prosecution, maintenance and enforcement of any patent and patent application; and (iv) performing all acts and signing, executing, acknowledging and delivering any and all documents required for effecting the obligations and purposes
of this Agreement. It is understood and agreed that such invention assignment agreement need not reference or be specific to this Agreement. 
 10.2 Preparation, Filing, Prosecution and Maintenance of Patent Rights. 

(a) [***]. 

(i) Preparation of [***]. Shire [***] will be prepared by Sangamo, as set forth in Subsection 10.2(c). 

(ii) [***]. With respect to the preparation of any patent application that will be a [***], the Parties shall collaborate in
reviewing relevant data, in preparing drafts, and in preparing a final version for filing of such patent application. Shire shall have the final decision making authority, with Sangamo’s prior written consent not to be unreasonably withheld,
respecting the content of any application that will be a [***], provided that Shire shall not include in any such application any information beyond that required to meet the requirements of 35 U.S.C. § 112. Shire shall consider in good faith,
take into account, and implement where possible the reasonable comments made by Sangamo respecting the preparation and content of any [***]. For the avoidance of doubt, Sangamo shall not file a claim limited to Shire ZF Compounds in any patent
application that will not be a [***]. For the purpose of this Subsection 10.2(a)(ii), a “claim limited to Shire ZF Compounds” means a claim that (1) includes language that specifically describes one or more ZF Compounds
that Specifically Bind a particular Shire Target, (2) if presumed to be issued, would not be infringed by a ZF Compound (or the manufacture or use of a ZF Compound) that Specifically Binds a locus other than such Shire Target, if such ZF
Compound were combined with the non-ZF Compound elements in such claim, and (3) does not include language that specifically describes a product (or the manufacture or use of such product) that is not a Shire Target Specific Product. 

(iii) Filing, prosecution and maintenance of [***] [***]. Shire, at its own expense, shall have the sole right
(subject to Subsection 10.2(f)) to file, prosecute and maintain, throughout the world, the [***]. Shire shall not, in its filings, change the specification as prepared under Subsection 10.2(a)(ii) or 10.2(c)(i), without Sangamo’s
prior written consent not to be unreasonably withheld. Shire shall keep Sangamo informed as to material developments with respect to the filing, prosecution and maintenance of the [***], including by providing, copies of all office actions or any
other substantive documents received from any patent office, including notice of all interferences, reissues, re-examinations, oppositions or requests for patent term extensions. Shire shall provide drafts of submissions relating thereto, including
drafts of any material filings or responses to be made to such patent offices, within a 

  
 45 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
reasonable amount of time in advance of submitting such filings or responses to permit Sangamo an opportunity to review and comment thereon. Shire shall consider in good faith, take into account
and implement where possible the reasonable comments made by Sangamo, including comments directed to preventing any detrimental effect of Shire’s patent prosecution actions on the prosecution or enforcement of any Genus [***], Sangamo Patent
Rights or other Patent Rights owned or controlled by Sangamo. 
 (b) Shire Patent Rights. Shire, at its own expense,
shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain, throughout the world, any Shire Patent Rights. 
 (c) [***]. 
 (i) The Parties intend that each [***] and [***] will have the same
or substantially the same specification and priority date as (1) certain related Sangamo Patent Rights (that are not [***] or [***]) that include support for the same [***] and/or [***] as does such [***] or [***] or (2) certain other
Sangamo Patent Rights (that are not [***]), or other Patent Rights owned or controlled by Sangamo that are not included in the Sangamo Patent Rights, that include support for ZF Compounds that Specifically Bind the same [***] but are not [***] ((1)
and (2) collectively, with respect to such [***], the “[***]”). Sangamo shall have the sole right to prepare, and shall be responsible for preparing, at its own expense, the specifications of all [***], which Patent Rights will, if
possible, be filed either on the same day as, or as a divisional application claiming priority from, the applicable [***] and [***]. Shire shall have the right to review and comment on patent application drafts that will be a (i) [***] which
support or could reasonably be drafted to support a claim to a Shire Target and (ii) [***]. Sangamo shall consider in good faith, take into account and implement where possible the reasonable comments made by Shire, provided that Sangamo does
not reasonably determine such comments to be detrimental to the prosecution or enforcement of any [***], Sangamo Patent Rights or other Patent Rights owned or controlled by Sangamo. 

(ii) Subject to Subsections 10.2(g) and the remainder of this Subsection 10.2(c)(ii), Sangamo, at its own expense,
shall have the sole right to prepare the claims of, file, prosecute and maintain, throughout the world, the [***] that are not [***]. Sangamo shall keep Shire informed as to material developments with respect to the filing, prosecution and
maintenance of such [***], including by providing Shire with copies of all material communications (including office actions and notices of interferences, reissues, re-examinations or oppositions) from any patent office regarding such [***] and
shall provide Shire drafts of submissions relating thereto, including drafts of any material filings or responses to be made to such patent offices, within a reasonable amount of time in advance of submitting such filings or responses to permit
Shire an opportunity to review and comment thereon. Sangamo shall consider in good faith, take into account and implement where possible the reasonable comments made by Shire, provided that Sangamo does not reasonably determine such comments to be
detrimental to the prosecution or enforcement of any [***], Sangamo Patent Rights or other Patent Rights owned or controlled by Sangamo. 

  
 46 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (d) Sangamo Patent Rights. 

(i) Except as provided in Subsection 10.2(c), Sangamo, at its own expense, shall have the sole right (subject to
Subsection 10.2(g)) to prepare, file, prosecute and maintain, throughout the world, the Sangamo Patent Rights. 
 (ii)
Sangamo shall keep Shire informed as to material developments with respect to the filing, prosecution and maintenance of such Sangamo Patent Rights, including by providing Shire with copies of all material communications (including office actions
and notices of interferences, reissues, re-examinations or oppositions) from any patent office regarding such Sangamo Patent Rights and shall provide Shire drafts of submissions relating thereto, including drafts of any material filings or responses
to be made to such patent offices, within a reasonable amount of time in advance of submitting such filings or responses to permit Shire an opportunity to review and comment thereon. Sangamo shall consider in good faith, take into account and
implement where possible the reasonable comments made by Shire, provided that Sangamo does not reasonably determine such comments to be detrimental to the prosecution or enforcement of any Sangamo Patent Rights or other Patent Rights owned or
controlled by Sangamo. 
 (e) Joint Patent Rights. If the Parties make any Joint Know-How, the Parties shall promptly
meet to discuss and determine whether to seek Joint Patent Rights thereon. If either Party decides to seek any Joint Patent Rights, then Sangamo shall have the first right, but not the obligation, to prepare, file, prosecute and maintain throughout
the world, at its expense, any Joint Patent Right (other than a [***], the prosecution of which is governed by Subsection 10.2(a)) that claims the composition, manufacture or use of a ZF Compound or of a product or method containing,
employing or made using a ZF Compound, using patent counsel or patent agent selected by Sangamo and reasonably acceptable to Shire. Shire shall have the first right, but not the obligation, to prepare, file, prosecute and maintain throughout the
world, at its expense, any other Joint Patent Right (other than a [***], the prosecution of which is governed by Subsection 10.2(a)), using patent counsel or patent agent selected by Shire and reasonably acceptable to Sangamo. The
prosecuting Party shall keep the non-prosecuting party informed as to material developments with respect to the filing, prosecution and maintenance of the Joint Patent Rights, including by providing copies of all material communications (including
office actions and notices of interferences, reissues, re-examinations or oppositions) from any patent office regarding such Joint Patent Rights and shall provide the non-prosecuting party drafts of submissions relating thereto, including drafts of
any material filings or responses to be made to such patent offices, within a reasonable amount of time in advance of submitting such filings or responses to permit the non-prosecuting party an opportunity to review and comment thereon. The
prosecuting party shall consider in good faith, take into account and implement where possible the reasonable comments made by the non-prosecuting party. 
 (f) Shire Abandonment. If Shire elects not to file a patent application covering any Joint Know-How or Know-How that would be a [***], or elects to cease the prosecution and maintenance of any
Joint Patent Right or [***] in any country or as a PCT application (and does not elect to file one or more new patent applications covering the subject matter claimed in such Patent Right), Shire will promptly provide Sangamo with written notice,
but not less than 30 days if reasonably practical, before any action is required, and will permit Sangamo, at Sangamo’s sole discretion and expense, to file such patent application or continue prosecution or maintenance of such patent
application or patent in such country, as applicable. 

  
 47 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
Upon request from Sangamo, Shire will execute such documents and perform such acts as may be reasonably necessary to permit Sangamo to make such filing or continue such prosecution or
maintenance, as applicable, in Shire’s name. Notwithstanding the foregoing, if such Patent Right is a [***] that (i) would have been solely owned by Sangamo but for the [***] pursuant to Subsection 10.1(b) and is a filing in
Australia, Canada, a Major European Country, Japan or the United States, then Shire shall [***], and does hereby [***], effective upon Sangamo’s written request, to Sangamo all of Shire’s right, title and interest in such [***] in such
jurisdiction or (ii) would have been jointly owned by the Parties but for the [***] pursuant to Subsection 10.1(b) and is a filing in Australia, Canada, a Major European Country, Japan or the United States, then Shire shall [***], and
does hereby [***], effective upon Sangamo’s written request, to Sangamo an undivided one-half interest in such [***] in such jurisdiction. Such [***] shall not, after [***] from Shire to Sangamo pursuant to the preceding sentence, be included
in Sangamo Patent Rights if they pertain to Australia, Canada, a Major European Country, Japan or the United States. 
 (g)
Sangamo Abandonment. If Sangamo elects not to file a patent application covering any Joint Know-How, or elects to cease the prosecution and maintenance of any Sangamo Patent Right or Joint Patent Right in any country or as a PCT application
(and does not elect to file one or more new patent applications covering the subject matter claimed in such Sangamo Patent Right or Joint Patent Right, as applicable), Sangamo will promptly provide Shire with written notice, but not less than 30
days before any action is required, and will permit Shire, at Shire’s sole discretion and expense, to continue prosecution or maintenance of any such Sangamo Patent Right or Joint Patent Right in such country, as applicable, to the extent that
no Third Party has a prior right to assume the prosecution or maintenance of such Sangamo Patent Right. Upon request from Shire, Sangamo will execute such documents and perform such acts as may be reasonably necessary to permit Shire to continue
such prosecution or maintenance, as applicable. 
 (h) Patent Term Extensions. In connection with the Marketing Approval
of a Shire ZF Product, Shire shall consult with Sangamo before determining which Patent Right, if any, is to be extended, by way, for example, of a Patent Term Restoration and a Supplementary Protection Certificate. Shire shall not have the right to
extend in any country (i) a Sangamo Patent Right that is not a [***] or (ii) a Joint Patent Right that is the subject of any such extension for a product other than a Shire ZF Product. Shire shall have the sole discretion to determine
whether a Shire Patent Right, a [***] or a [***] is to be extended. Sangamo shall cooperate with Shire to the extent reasonably requested by Shire to effectuate the intent of this Subsection 10.2(h). 

(i) Orange Book Listing. In connection with the Marketing Approval of a Shire ZF Product, Shire shall have the sole right, in
accordance with applicable laws and regulations, to choose whether a patent(s) is to be listed in the Orange Book or in any similar equivalent thereto in the Territory. Sangamo shall cooperate with Shire to the extent reasonably requested by Shire
to effectuate the intent of this Subsection 10.2(i). 
 (j) Third Party Rights. For the avoidance of doubt,
Shire’s rights under this Section 10.2 to file, prosecute and maintain any Sangamo Patent Right licensed to Sangamo under a Third Party License may be exercised in Sangamo’s name and for the benefit of Sangamo, provided that
this Section 10.2 shall be subject to the terms of such Third Party License. 

  
 48 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 10.3 Enforcement of Patent Rights. 

(a) Notice. If either Shire or Sangamo becomes aware of any infringement, anywhere in the world, of (i) any issued patent
within the Sangamo Patent Rights or Joint Patent Rights on account of a Third Party’s manufacture, use or sale of a Shire ZF Compound or a Shire ZF Product in the Field, or (ii) any issued patent within the [***] or [***] (an
“Infringement”), such Party will promptly notify the other Party in writing to that effect. 
 (b)
Enforcement against a Third Party Infringer. 
 (i) In the case of any Infringement, [***], but not the obligation, to
take action to obtain a discontinuance of the Infringement or bring suit against the applicable Third Party (such Third Party, the “Third Party Infringer”) under the applicable [***] and the [***], within six months from the date of
notice and, if with respect to the [***], to join Sangamo as a party plaintiff. Shire shall bear all the expenses of any suit brought by it claiming Infringement of any such Patent Rights. Sangamo shall cooperate with Shire in any such suit as
reasonably requested by Shire and at Shire’s expense and shall have the right to consult with Shire and to participate in and, if appropriate, be represented by independent counsel in such litigation at its own expense. Shire shall not, without
Sangamo’s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Sangamo or admits the invalidity or unenforceability of any such Patent Rights, which consent
shall not be unreasonably withheld. If Shire has not taken steps to obtain a discontinuance of infringement of such Patent Rights or filed suit against any such Third Party infringer of such Patent Rights within six months from the date of notice of
Infringement, then Sangamo shall have the right, but not the obligation, to bring suit against such Third Party Infringer, provided, that Sangamo shall bear all the expenses of such suit. Shire shall cooperate with Sangamo in any such suit
for infringement of such Patent Rights brought by Sangamo against a Third Party (including joining as a party plaintiff) at Sangamo’s request and expense, and shall have the right to consult with Sangamo and to participate in and be represented
by independent counsel in such litigation at its own expense. Sangamo shall not, without Shire’s prior written consent, which consent shall not be unreasonably withheld, enter into any settlement or consent decree that requires any payment by
or admits or imparts any other liability to Shire or admits the invalidity or unenforceability of any such Patent Rights, or adversely impacts Shire’s ability to maximize Net Sales or impacts market share of Shire ZF Products. The enforcing
Party under this Subsection 10.3(b) shall keep the other Party reasonably informed of all material developments in connection with any such suit. 
 (ii) Any recoveries obtained by either Party as a result of any proceeding against a Third Party Infringer under this Subsection 10.3(b) shall be allocated as follows: 

(A) Such recovery shall first be used to reimburse the enforcing Party for all out-of-pocket litigation costs in connection with such
litigation paid by that Party, and then to reimburse out-of-pocket litigation costs paid by the other Party; 

  
 49 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (B) If Shire is the enforcing Party against an Infringement in the Field, with respect to
any remaining portion of such recovery, Sangamo shall receive an amount equal to [***]% of such amount, but not more than the amounts that would be payable, pursuant to Sections 9.3 and 9.4 if the recovery on infringing sales, after
reimbursing the Parties under Subsection 10.3(b)(ii)(A), were treated as Net Sales of a Shire ZF Product, and Shire shall receive any remaining portion of such recovery; 

(C) If Sangamo is the enforcing Party against an Infringement in the Field, Sangamo shall receive [***]%, and Shire shall receive
[***]%, of the remaining portion of such recovery; 
 (D) For any enforcement against an Infringement outside the Field of an
issued patent in the [***] or [***], Sangamo shall receive [***]%[***]% [***]. 
 (c) Other Infringement of Sangamo Patent
Rights. If the Infringement of any Sangamo Patent Right does not fall within the category of Infringements covered by Subsection 10.3(b), Sangamo shall have the first right, but not the obligation, to take action to obtain a
discontinuance of the Infringement or bring suit against the applicable Third Party Infringer under the applicable Sangamo Patent Rights within six months from the date of notice and to join Shire as a party plaintiff. Sangamo shall bear all the
expenses of any suit brought by it claiming Infringement of any such Patent Rights. Shire shall cooperate with Sangamo in any such suit as reasonably requested by Sangamo and at Sangamo’s expense and shall have the right to consult with Sangamo
and to participate in and, if appropriate, be represented by independent counsel in such litigation at its own expense. Sangamo shall not, without Shire’s prior written consent, enter into any settlement or consent decree that requires any
payment by or admits or imparts any other liability to Shire or admits the invalidity or unenforceability of any such Patent Rights, which consent shall not be unreasonably withheld. If Sangamo has not taken steps to obtain a discontinuance of
infringement of such Patent Rights or filed suit against any such Third Party infringer of such Patent Rights within six months from the date of notice of Infringement, then upon Sangamo’s written consent (not to be unreasonably withheld),
Shire shall have the right, but not the obligation, to bring suit under such Sangamo Patent Rights against such Third Party Infringer, provided, that Shire shall bear all the expenses of such suit. Sangamo shall cooperate with Shire in any such suit
for infringement of such Patent Rights brought by Shire against a Third Party (including joining as a party plaintiff) at Shire’s expense, and shall have the right to consult with Shire and to participate in and be represented by independent
counsel in such litigation at its own expense. Shire shall not, without Sangamo’s prior written consent, which consent shall not be unreasonably withheld, enter into any settlement or consent decree that requires any payment by or admits or
imparts any other liability to Sangamo or admits the invalidity or unenforceability of any such Patent Rights. The enforcing Party under this Subsection 10.3(c) shall keep the other Party reasonably informed of all material developments in
connection with any such suit. 
 (i) Any recoveries obtained by either Party as a result of any proceeding against a Third
Party Infringer under this Subsection 10.3(b) shall be allocated as follows: 
 (A) Such recovery shall first be used to
reimburse the enforcing Party for all out-of-pocket litigation costs in connection with such litigation paid by that Party, and then to reimburse out-of-pocket litigation costs paid by the other Party; 

  
 50 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (B) If Shire is the enforcing Party, with respect to any remaining portion of such
recovery, Sangamo shall receive an amount equal to [***] of such amount, but not more than the amounts that would be payable, pursuant to Sections 9.3 and 9.4 if the recovery on infringing sales, after reimbursing the Parties under
Subsection10.3(c)(i)(A), were treated as Net Sales of a Shire ZF Product, and Shire shall receive any remaining portion of such recovery; 
 (C) If Sangamo is the enforcing Party, Sangamo shall receive [***], and Shire shall receive [***], of the remaining portion of such recovery. 

(ii) Third Party Rights. For the avoidance of doubt, with respect to any Sangamo Patent Right licensed to Sangamo by a Third Party,
Shire’s rights under this Subsection 10.3(c) may be exercised in Sangamo’s name, provided that Shire’s rights under this Subsection 10.3(c) shall be subject to the rights of such Third Party to enforce such Sangamo
Patent Right and to receive a portion of any recoveries obtained as a result of any proceeding against a Third Party Infringer under such Sangamo Patent Right. 
 (d) Other Infringement of Joint Patent Rights. With respect to any Third Party infringement of any Joint Patent Right, other than in the case of a Joint Patent Right subject to Subsection
10.3(b) above, each Party shall promptly notify the other Party of such infringement and the Parties shall meet as soon as reasonably practicable thereafter to discuss such infringement and determine an appropriate course of action. Unless the
Parties agree to jointly address such infringement, if the infringement relates to ZF Compounds or ZF Products or their manufacture, delivery or use, Sangamo shall have the first right but not the obligation, and if the infringement does not relate
to ZF Compounds or ZF Products, Shire shall have the first right but not the obligation, to bring an action against such Third Party infringer or otherwise address such alleged infringement within six months from the date of notice and to control
such litigation or other means of addressing such infringement. If, after the expiration of the six month period (or, if earlier, the date upon which the Party with the first right provides written notice that it does not plan to bring suit), the
Party with the first right has not obtained a discontinuance of infringement of such Joint Patent Right or filed suit against any such Third Party infringer of such Joint Patent Right, then the other Party shall have the right, but not the
obligation, to bring suit against such Third Party infringer of such Joint Patent Right, provided, that such other Party shall bear all the expenses of such suit. In any suit under this Subsection 10.3(d), the non-enforcing Party shall
cooperate with the enforcing Party, at the enforcing Party’s request and expense, in any such suit and shall have the right to consult with the enforcing Party and to participate in and be represented by independent counsel in such litigation
at its own expense. Any recoveries obtained by either Party as a result of any such proceeding against a Third Party infringer shall be allocated as follows: 
 (i) Such recovery shall first be used to reimburse each Party for all litigation costs in connection with such litigation paid by that Party; and 

  
 51 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (ii) With respect to any remaining portion of such recovery, the enforcing Party shall
receive an amount equal to [***] of such amount, and the other Party shall receive the remaining [***] of such amount, and if the Parties brought such proceeding jointly, such remaining portion shall be shared [***] to each Party. 

10.4 Infringement and Third Party Licenses. 
 (a) Existing Third Party Licenses. Notwithstanding anything suggesting the contrary in this Section 10.4, Sangamo shall be solely responsible for all payments respecting Existing Third
Party Licenses, except as provided in Sections 7.1(b)(vi), 9.4 and 9.5. 
 (b) Infringement of Third Party Patents;
Course of Action. If the conduct of the Research Program or the development, manufacture or commercialization in the Field of any Shire ZF Compound or Shire ZF Product is alleged by a Third Party to infringe a Third Party’s patent or
other intellectual property rights, the Party becoming aware of such allegation shall promptly notify the JSC (or, if after the Research Term, the other Party). If either Party believes that, based upon its review of a Third Party’s patent or
patent application or other intellectual property rights (collectively, “Third Party IP Rights”), it is Necessary to Obtain a License under such Third Party IP Rights, such Party shall promptly notify the JSC (or, if after the
Research Term, the other Party) of such determination. The JSC, or if after the Research Term, the Parties, shall promptly schedule and hold a meeting to discuss such Third Party IP Rights. “Necessary to Obtain a License” as used
herein means, with respect to Third Party IP Rights, that [***] that such [***] (1) for which [***] pursuant to a Research Plan or (2) for which [***] The[***] shall make a determination whether it is [***] Such licensing negotiations
shall be handled solely [***] unless, at the time that the JSC decided that it is [***] Shire had [***] 
 (c) Sangamo
Rights. If the [***] that is the subject of a Research Plan that it is [***] and that it is [***] then Sangamo shall have the[***] For the avoidance of doubt, the[***] Such license shall not be [***] Such license, once obtained by Sangamo, shall
be deemed [***] to the extent falling within [***] will be sublicensed to Shire only if: (i) Sangamo [***] (ii) Sangamo and Shire agree [***] and (iii) Shire provides Sangamo with [***] in which (1) Shire consents to [***]
(2) Shire agrees to make [***] and (3) Shire acknowledges in writing that [***] Respecting all Third Party Licenses pursuant to which [***] shall have the right to [***]%[***] except that [***] (A) by more than [***]%[***] or
(B)(i) if such [***] that is less than the [***] and (ii) if such [***] to an amount that is less than [***]%[***] Illustrative examples of the application of this Subsection 10.4(c) are set forth in [***] Such examples are provided
solely for the purposes of clarifying the intended application of this Subsection 10.4(c). The Parties acknowledge that the hypothetical assumptions upon which such examples are based may not ever happen and should not be interpreted as
reflecting any expectations of the Parties regarding such matters. For the avoidance of doubt, for any [***] pursuant to this Subsection 10.4(c), [***]. 
 (d) Shire Rights. 
 (i) (a) If Sangamo fails to [***] within [***]
appropriate time during the Research Term to[***] or (b) [***] Shire shall have the right[***] provided that Shire shall notify Sangamo [***] Shire shall provide Sangamo with a[***] If practical, such agreement shall [***]. 

  
 52 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (ii) [***] shall [***] due under the terms of the [***] except that [***] shall be [***],
provided that [***] under this Section 10.4 [***] (A) if such [***] Subsections 10.4(c) and 10.4(e)) on account of the event giving rise to such Milestone Payment and (B) if such [***]. 

(iii) Respecting all other Third Party IP Rights licensed by Shire pursuant to this Subsection 10.4(d), Shire shall have the
right to[***]%[***] except that such [***] under this Section 10.4 [***] does not reduce [***] (A) by [***]%[***] or (B)(i) if such [***] (excluding those amounts payable by Shire to Sangamo [***] and (ii) if such
payment is a [***] For the avoidance of doubt, for any non-royalty payments that Shire makes with respect to a Shire ZF Product under the terms of any license agreement with a Third Party entered into pursuant to this Subsection 10.4(d),
other than [***] Shire shall have the right to [***]. 
 (e) If Sangamo obtains during the Term a license from a Third Party,
other than [***] that fall within the scope of the [***] then Sangamo shall notify Shire[***] Such license agreement shall be deemed [***] to the extent falling within the [***] only if: (i) Sangamo [***] to the extent applicable to the [***],
(ii) if any [***] as a result of Sangamo’s [***] Sangamo and Shire agree in writing to an [***] with respect to the rights [***] and (iii) [***] in which (1) [***] consents to [***] such license agreement to the definition [***]
(2) [***] agrees to [***] and (3) [***] acknowledges [***] shall have the right to [***]%[***], except that [***] (A) by [***], or (B)(i) if [***] and (ii) if [***] For the avoidance of doubt, for any [***] with respect to
[***]. 
 (f) For the avoidance of doubt, notwithstanding Subsections 10.4 (b), (c), and (d), either Party may [***] In
addition, either Party may [***] which are useful, but which are [***] except that, [***] other than through the [***] In addition, [***] agrees that during the period from the Effective Date until [***] will not [***] other than in accordance with
Subsection 10.4(d). 
 (g) Third Party Infringement Suit. If a Third Party sues a Party or any of such
Party’s Affiliates or any Sublicensees (each Person so sued being referred to herein as a “Sued Party”), alleging that the conduct by either Party of the Research Program or the development, manufacture or commercialization of
any Shire ZF Compound or Shire ZF Product related to a Shire Target in the Shire Exclusive Target Pool pursuant to this Agreement infringes or will infringe such Third Party’s intellectual property, then if the Sued Party is entitled to
indemnification pursuant to Article 12 on account of such suit, then the terms and conditions of Article 12 and not this Subsection 10.4(g) shall apply to such suit. If the Sued Party is not entitled to indemnification pursuant
to Article 12 on account of such suit, then this Subsection 10.4(g) shall apply to suit. Upon the Sued Party’s request and in connection with the Sued Party’s defense of any such Third Party infringement suit, the other Party
shall provide reasonable assistance to the Sued Party for such defense, at the Sued Party’s expense. The Sued Party shall keep the other Party reasonably informed of all material developments in connection with any such suit and shall not,
without the other Party’s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability 

  
 53 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
to the other Party. In the event that Shire is the Sued Party, Shire shall have the right to offset [***] of (i) all costs incurred by Shire in defending the suit, (ii) all damages
awarded in the suit, and (iii) all payments made by Shire for the purposes of resolving the dispute against Milestone Payments and Royalty Payments due under this Agreement for the applicable Shire ZF Product, except that such offset
shall be decreased (or eliminated) so that the combined effect of offsets under this Section 10.4 and royalty reductions under Subsection 9.4(iii) does not reduce any payment due to Sangamo for a particular Shire ZF Product
(A) by more than [***] from the amount that would otherwise be owed to Sangamo without taking into account such offsets and royalty reductions, or (B)(i) if such payment is a Milestone Payment, to an amount that is less than the aggregate
amounts due under all Third Party Licenses (excluding those amounts paid by Shire to Sangamo pursuant to Section 9.7 in accordance with Subsections 10.4(c) or 10.4(e)) on account of the event giving rise to such Milestone
Payment and (ii) if such payment is a Royalty Payment, to an amount that is less than the aggregate amounts due under all Third Party Licenses (excluding those amounts paid by Shire to Sangamo pursuant to Section 9.7 in accordance
with Subsections 10.4(c) or 10.4(e)) on account of the Net Sales giving rise to such Royalty Payment plus [***] of such Net Sales. 
 10.5 Declaratory Judgment Actions by Third Party. 
 (a) Shire’s
Rights. If a Third Party brings a declaratory judgment suit against Shire with respect to [***], [***], Joint Patent Rights or any other Patent Rights owned or controlled by Shire, then Shire shall have the sole right, but not the obligation, to
control the defense of such suit. Sangamo shall cooperate with Shire in any such suit as reasonably requested by Shire and at Shire’s expense. If the suit involves a [***], [***], or Joint Patent Right, then Sangamo also shall have the right to
consult with Shire, and to participate in and be represented by independent counsel in such litigation at its own expense. Shire shall not, without Sangamo’s prior written consent, enter into any settlement or consent decree that requires any
payment by or admits or imparts any other liability to Sangamo or admits the invalidity or unenforceability of any Sangamo Patent Rights, Joint Patent Rights, or [***], which consent shall not be unreasonably withheld. 

(b) Sangamo’s Rights. If a Third Party brings a declaratory judgment suit against Sangamo respecting the Sangamo Patent
Rights or Joint Patent Rights, then Sangamo shall have the sole right, but not the obligation, to control the defense of such suit. Shire shall cooperate with Sangamo in any such suit as reasonably requested by Sangamo and at Sangamo’s expense,
and Shire shall have the right to consult with Sangamo and to participate in and, if appropriate, be represented by independent counsel in such litigation at its own expense in the event the loss of such Patent Rights would adversely impact
Shire’s ability to maximize Net Sales or impact market share of a Shire ZF Product. Sangamo shall not, without Shire’s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any
other liability to Shire or admits the invalidity or unenforceability of any Sangamo Patent Rights, Joint Patent Rights, or [***], which consent shall not be unreasonably withheld. 

(c) Other Rights. If a Third Party brings a declaratory judgment suit against Shire with respect to Sangamo Patent Rights that are
not [***], then Sangamo shall have the first right, but not the obligation, to control the defense of such suit with respect to such Sangamo 

  
 54 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
Patent Rights. If Sangamo exercises such right, then Shire shall cooperate with Sangamo in any such suit as reasonably requested by Sangamo and at Sangamo’s expense. Shire shall have the
right to consult with Sangamo and to participate in and be represented by independent counsel in such litigation at its own expense. Sangamo shall not, without Shire’s prior written consent, enter into any settlement or consent decree that
requires any payment by or admits or imparts any other liability to Shire or admits the invalidity or unenforceability of any Sangamo Patent Rights, which consent shall not be unreasonably withheld. If Sangamo informs Shire that Sangamo does not
intend to exercise its first right to control the defense of such suit, then Shire shall control the defense of such suit and Sangamo shall cooperate with Shire in any such suit as reasonably requested by Shire and at Shire’s expense. With
respect to such Sangamo Patent Rights, Sangamo shall have the right to consult with Shire and to participate in and be represented by independent counsel in such litigation at its own expense. Shire shall not, without Sangamo’s prior written
consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Sangamo or admits the invalidity or unenforceability of any Sangamo Patent Rights, Joint Patent Rights or [***], which
consent shall not be unreasonably withheld. 
 10.6 Interference, Opposition, Revocation and Declaratory Judgment Actions by
Parties. If the Parties mutually determine that, based upon the review of a Third Party’s patent or patent application or other intellectual property rights and subject to applicable laws and regulations, it may be desirable in connection
with a Shire ZF Compound or a Shire ZF Product to provoke or institute an interference, opposition, revocation or declaratory judgment action with respect thereto, then the Parties shall consult with one another and shall reasonably cooperate in
connection with such an action. Unless otherwise agreed to by the Parties, if the Third Party patent or patent application covers a Shire Target or the making, using or selling in the Field of a Shire ZF Compound or Shire ZF Product, then in
connection with an opposition, revocation or declaratory judgment action Shire may, at its discretion, control such action and select counsel for such action. Shire shall be responsible for, and shall bear, all the out-of-pocket expenses of any such
action brought by Shire. If the Third Party patent or patent application is otherwise directed to the Sangamo Licensed Technology, Sangamo may, at its discretion, control such action and select counsel for such action. Sangamo shall be responsible
for, and shall bear, all the out-of-pocket expenses of any such action brought by Sangamo. Unless otherwise agreed to by the Parties, in connection with an interference, the Party responsible for prosecuting the patent application involved in the
interference may, at its discretion, control such action and select counsel for such action, and shall be responsible for and bear all the out-of-pocket expenses of, any such action. The prosecuting party shall consider in good faith, take into
account and implement where possible the reasonable comments made by the non-prosecuting Party. 
  

	 	11	CONFIDENTIALITY 

 11.1
Confidentiality. During the Term and for [***] years thereafter, each Party shall maintain in confidence the Confidential Information of the other Party, shall not use or grant the use of the Confidential Information of the other Party except as
expressly permitted under this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder), and shall not disclose the Confidential Information of the other Party except on a need-to-know basis to such
Party’s directors, officers and employees, and to such Party’s 

  
 55 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
consultants working on such Party’s premises or Subcontractors, to the extent such disclosure is necessary in connection with such Party’s activities as expressly authorized by this
Agreement. To the extent that disclosure to any person is authorized by this Agreement (including Subcontractors as described in Section 3.5), prior to disclosure, a Party shall obtain, or shall have obtained prior to the date of this
Agreement, written agreement of such person to hold in confidence and not disclose, use or grant the use of the Confidential Information of the other Party except as expressly permitted under this Agreement. Each Party shall notify the other Party
promptly upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information. 
 11.2
Terms of Agreement. Neither Party shall disclose any terms or conditions of this Agreement to any Third Party without the prior written consent of the other Party; provided, that a Party may disclose the terms or conditions of this
Agreement, (a) on a need-to-know basis to its legal and financial advisors to the extent such disclosure is reasonably necessary in connection with such Party’s activities as expressly permitted by this Agreement, and (b) to a Third
Party in connection with: (i) an equity investment in or by, or underwriting by, such Third Party, (ii) a merger, consolidation or similar transaction involving such Third Party, or (iii) the sale of all or substantially all of the
assets of the Party to such Third Party; provided, further, that such Party shall make such disclosure only under appropriate conditions of confidentiality by the Third Party. Notwithstanding the foregoing, Sangamo may disclose the terms and
conditions of this Agreement to the extent that such disclosure is required pursuant to the terms of any Third Party License, provided that the licensor of such Third Party License is bound by a confidentiality obligation reasonably acceptable to
Shire. Shire acknowledges that the licensors of all Existing Third Party Licenses are bound by confidentiality obligations reasonably acceptable to Shire. 
 11.3 Permitted Disclosures. Notwithstanding Sections 11.1 and 11.2, each Party may disclose Confidential Information of the other Party to the extent required by applicable law, regulation
or order of a governmental agency or a court of competent jurisdiction, or in prosecuting or defending litigation; provided, that such Party shall provide advance written notice thereof (to the extent practicable) to the other Party, consult
with the other Party with respect to such disclosure, use reasonable efforts to minimize the amount of information necessary to be disclosed and provide the other Party sufficient opportunity to object to any such disclosure or to request
confidential treatment thereof. Notwithstanding Sections 11.1 and 11.2, Sangamo may disclose Confidential Information of Shire to the extent required by any Third Party License, provided that the licensor of such Third Party License is bound
by a confidentiality obligation reasonably acceptable to Shire. Shire acknowledges that the licensors of all Existing Third Party Licenses are bound by confidentiality obligations reasonably acceptable to Shire. The Parties acknowledge that either
or both Parties may be obligated to file a copy of this Agreement with the SEC or other government authorities. Each Party shall be entitled to make such a required filing subject to the provisions of this Section 11.3, provided that any
request by the other Party to redact information is consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. 

11.4 Confidentiality and Disclosure Agreement. The terms of the CDA, attached hereto as Schedule 11.4, are incorporated
herein by reference. To the extent there are any conflicts between this Agreement and the CDA, this Agreement shall control. 

  
 56 

 11.5 Press Release and Publications. On or after the Effective Date, the Parties
shall issue a joint press release relating to this Agreement in the mutually agreed upon form set forth in Schedule 11.5. Any other press release, public announcement, presentation or publication (including abstracts, posters, or other
scientific publications) that Sangamo proposes to present or issue specifically regarding this Agreement or any of the activities performed hereunder or data arising therefrom, must be agreed upon by Shire in advance of its release, with at least
[***] days notice by the disclosing Party prior to any submission for publication. Sangamo shall not be required to seek the permission of Shire to repeat any such information that has already been publicly disclosed by Sangamo in accordance with
this Section 11.5, provided such information remains accurate as of such time. Notwithstanding the foregoing, Sangamo shall have the right to issue press releases without the prior consent of Shire, that disclose any information required
by the rules and regulations of the United States Securities and Exchange Commission or similar federal, state or foreign authorities, as determined in good faith by independent legal counsel to the disclosing Party, subject to
Section 11.3 and provided that Sangamo shall use reasonable efforts to give Shire prior notice of the content and timing of such press release. Shire shall provide Sangamo with notice of any intent to terminate this Agreement, whether in
its entirety or with respect to a Shire Target, prior to issuing a press release about such intent. 
  

	 	12	INDEMNIFICATION 

 12.1
Sangamo. Sangamo shall indemnify, defend and hold harmless Shire and its Affiliates and Sublicensees, and each of its respective directors, officers, employees and agents (collectively “Shire Indemnified Party”), from and
against all losses, liabilities, damages and expenses, including reasonable attorneys’ fees and costs (collectively, “Liabilities”), to the extent resulting from any claims, demands, actions or other proceedings by any Third
Party arising out of (a) the material breach of any representation, warranty or covenant by Sangamo under this Agreement; (b) the practice by Sangamo of the licenses granted by Shire, (c) the development, clinical testing,
manufacture, use, handling, storage, distribution, marketing, promotion or sale of any ZF Compound or ZF Product by Sangamo, its Affiliates or licensees, as licensed and/or granted to Sangamo pursuant to Sections 3.10 and 14.5 (including any
such Liabilities arising out of or alleged to arise out of any ZF Compound or ZF Product manufactured, sold or distributed by or for Sangamo, its Affiliates or licensees or any violation of law by Sangamo, its Affiliates or licensees); (d) the
recklessness, negligence or intentional misconduct of any Sangamo Indemnified Party or licensees; (e) the practice by Sangamo, its Affiliates or licensees of the Sangamo Licensed Technology, and (f) the breach by Sangamo of any Third Party
license (other than such breach caused directly by the act or omission of Shire); except, in each case ((a), (b), (c) (d), (e) and (f)), to the extent (i) caused by the gross negligence or intentional misconduct of any Shire
Indemnified Party or a breach by Shire of any of its representations, warranties or covenants set forth in this Agreement or (ii) associated with any claim of patent infringement of Third Party intellectual property rights based on activity
conducted by Sangamo at the JSC’s direction, notwithstanding Sangamo’s objection to conducting such activity based on intellectual property concerns, as a result of Shire’s exercise of its final decision making authority. 

12.2 Shire. Shire shall indemnify, defend and hold harmless Sangamo and its Affiliates, and each of its respective directors,
officers, employees and agents (collectively “Sangamo Indemnified Party”), from and against all Liabilities to the extent resulting from any claims, demands, actions or other proceedings by any Third Party arising out of
(a) the material 

  
 57 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
breach of any representation, warranty or covenant by Shire under this Agreement; (b) the practice of the licenses granted by Sangamo or the development, clinical testing, manufacture, use,
handling, storage, distribution, marketing, promotion or sale of Shire ZF Compounds, Shire [***] or Shire ZF Products by Shire, its Affiliates or Sublicensees (including any such Liabilities arising out or alleged to arise out of any Shire ZF
Product manufactured, sold or distributed by or for Shire, its Affiliates or Sublicensees or any violation of law by Shire, its Affiliates or Sublicensees); (c) any claim of infringement or misappropriation of Third Party intellectual property
rights with respect to performance of the Research Program in accordance with a Research Plan that was approved as a result of Shire’s exercise of its final decision-making authority; or (d) the recklessness, negligence or intentional
misconduct of any Shire Indemnified Party; except, in each case ((a), (b), (c) and (d), to the extent caused by the gross negligence or intentional misconduct of any Sangamo Indemnified Party or a breach by Sangamo of any of its
representations, warranties or covenants set forth in this Agreement. 
 12.3 Procedure. If a Party (the
“Indemnitee”) intends to claim indemnification under this Article 12, it shall promptly notify the other Party (the “Indemnitor”) in writing of any claim, demand, action or other proceeding for which the
Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume the defense thereof with counsel of its choice, which counsel shall be reasonably
acceptable to the Indemnitee; provided that an Indemnitee shall have the right to retain its own counsel at its expense. Further, the obligations of this Article 12 shall not apply to amounts paid in settlement of any claim, demand,
action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent shall not be unreasonably withheld, conditioned, or delayed. The Indemnitor shall not settle any claim, demand, action or other proceeding
without the prior written consent of the Indemnified Party, not to be unreasonably withheld, conditioned or delayed, unless the settlement involves only the payment of money. The failure to deliver written notice to the Indemnitor within a
reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Article 12. The Indemnitee, its employees
and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Article 12. 

 

	 	13	INSURANCE 

 13.1
Insurance. 
 (a) Shire. During the Research Term (and for a tail period of five years thereafter) and for so long as
Shire develops or sells Shire ZF Products anywhere in the world (and for a tail period of five years thereafter), Shire shall, at its expense, maintain (i) comprehensive General Liability insurance covering death and bodily injury and property
damage, in a combined single limit of not less than [***], which policy shall include coverage for products liability and blanket contractual liability applicable to this Agreement; and (ii) Workers’ Compensation insurance including
Employers Liability limit of not less than $500,000 per accident or disease. All of the insurance policies required under this Subsection 13.1(a) shall be underwritten by insurers having a A.M. Best’s Rating of A-VII or higher.

  
 58 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (b) Sangamo. During the Research Term and for a tail period of five years thereafter,
Sangamo shall, at is expense, maintain commercial general liability insurance with reputable and financially secure insurance carriers to cover its indemnification obligations under Section 12.1 with limits of not less than [***] per
occurrence and in the aggregate. All of the insurance policies required under this Subsection 13.1(b) shall be underwritten by insurers having a A.M. Best’s Rating of A-VII or higher. 

13.2 Certificates of Insurance. At the request of a Party, the other Party shall furnish proof of all insurance coverages outlined
in this Article 13 in the form of insurance certificates reasonably acceptable to the other Party. Each Party shall provide the other Party with written notice at least thirty (30) days prior to the cancellation, non-renewal or material
change in such insurance or self-insurance which materially adversely affect the rights of the other Party hereunder. 
  

	 	14	TERM; TERMINATION; EFFECTS OF TERMINATION 

 14.1 Term. Unless earlier terminated as provided herein, the term of this Agreement shall commence on the Effective Date and shall continue until such time as all payment obligations with respect
to all Shire ZF Products expire (the “Term”). 
 14.2 Termination for Breach. Failure by a Party to
comply with any of its material obligations contained herein shall entitle the Party not in default to give to the Party in default notice specifying the nature of the default, requiring it to make good or otherwise cure such default, and stating
its intention to terminate if such default is not cured. If such default is not cured within 90 days after the receipt of such notice (or within thirty (30) days after the receipt of such notice in the event such default is solely based upon a
Party’s failure to pay any amounts due hereunder), the Party not in default shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in
equity, to terminate this Agreement in whole or in part as appropriate; provided, that any right to terminate under this Section 14.2 shall be stayed in the event that, during such cure period, the Party alleged to have been in
default shall have initiated dispute resolution in good faith in accordance with Section 15.2 with respect to the alleged default, which stay shall last so long as the initiating Party diligently and in good faith cooperates in the
prompt resolution of such dispute resolution proceedings. [***]. 
 14.3 Termination for Insolvency. This Agreement may
be terminated by either Party upon notice to the other should the other Party: (a) consent to the appointment of a receiver or a general assignment for the benefit of creditors or (b) file or consent to the filing of a petition under any
bankruptcy or insolvency law or have any such petition filed against it which has not been stayed within 60 days of such filing. 
 14.4 Termination by Shire. In addition to the termination provisions set forth in Section 3.10, beginning 24 months from the Effective Date, Shire may terminate this Agreement in whole
or in part on a Target-by-Target basis, effective upon at least ninety (90) days prior written notice, provided that any termination of a Shire Target (and not the entire Agreement) during Sangamo’s conduct of the Research Plan for such
Shire Target shall be deemed a Shire Unilateral Target Termination under Section 3.10 and shall be subject to the terms thereof. 

  
 59 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 14.5 Effect of Expiration or Termination. 

(a) By Sangamo under Sections 14.2 or 14.3 or by Shire under Section 14.4. If this Agreement is
terminated by Sangamo (in its entirety or with respect to one or more Shire Targets) under Sections 14.2 or 14.3, or if this Agreement is terminated by Shire in its entirety or with respect to one or more Shire Targets under
Section 14.4, in addition to any remedy available at law, then: 
 (i) Upon termination of this Agreement,
whether in its entirety or for one or more Shire Targets, all licenses and obligations with respect to the applicable Terminated Target(s), including all ZF Compounds and ZF Products directed to or developed with respect to such Terminated
Target(s), shall terminate; 
 (ii) All Terminated Targets shall be removed from the Shire Exclusive Target Pool and shall no
longer be Shire Targets; 
 (iii) Upon receipt of notice of termination, the provisions of Subsection 3.10(c) (including
without limitation Subsection 3.10(c)(iv)) shall apply as to all Terminated Target(s); 
 (iv) Shire shall assign to
Sangamo any IND/CTA previously assigned by Sangamo to Shire; 
 (v) To the extent requested by Sangamo, respecting any Shire ZF
Product related to each such Terminated Target for which Shire has obtained Marketing Approval and respecting all Shire ZF Products related to each such Terminated Target for which Shire has conducted clinical development but not obtained Marketing
Approval (other than Shire ZF Products whose clinical development Shire terminated for safety reasons) (“Terminated Products”), the Parties shall negotiate, in good faith, an agreement on commercially reasonable terms, which terms
shall include, [***]. 
 (A) Assignment by Shire to Sangamo of all Marketing Approvals and other regulatory filings in respect
of the Terminated Products; 
 (B) Grant by Shire to Sangamo of a worldwide right and license, with the right to sublicense
through multiple tiers in any country, such grant to sublicense only in conjunction with a sub-license or assignment of the applicable Terminated Product(s), under all intellectual property rights Controlled by Shire and its Affiliates at the time
of notice of termination that are necessary to develop, manufacture, sell, offer to sell, import and otherwise commercialize such Terminated Product(s) as they exist at the time of notice of termination (such intellectual property, the
“Shire Licensed IP”), provided that such agreement shall include, if the license is non-exclusive, a covenant by Shire not to practice or license such licensed intellectual property within the scope of the license granted to
Sangamo. Notwithstanding anything to the contrary in this Agreement, if Shire or its Affiliates is protecting any Know-How within such intellectual property rights as a trade secret, then Shire shall not be required to [***], provided that [***]
agrees, as part of the terms of such agreement, to conduct or have conducted those activities necessary [***] By way of example, if [***] the terms shall include [***] Such negotiation shall take into consideration,[***] or if Shire made [***] and
if 

  
 60 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
Sangamo has requested a [***] the amounts of such payments, to the extent applicable to the [***] that Shire was entitled to [***] In addition, for the avoidance of doubt, [***] shall not have
the right to any [***] after the notice of termination; provided, however, that the Shire Licensed IP will include [***]. 

(C) In the event that the Parties are unable to agree upon a commercially reasonable terms within [***] days of Sangamo’s election,
then the Parties shall submit the determination of [***] to an independent arbitrator agreed upon by Parties who has significant relevant experience in the [***] If the Parties do not agree on an arbitrator within [***] days after the termination of
the [***] day period immediately following Sangamo’s election, then either Party may request that JAMS appoint an arbitrator with such experience on behalf of the Parties in accordance with JAMS’ Comprehensive Arbitration Rules &
Procedures then in effect, except that the Parties expressly agree that any arbitration pursuant to this Subsection 14.5(a)(v)(C) shall be [***] The date on which such arbitrator is selected or appointed will be the “Section 14.5
Arbitration Commencement Date”. The arbitration shall be conducted under the JAMS Rules, to the extent consistent with this Subsection 14.5(a)(v)(C). Within [***] business days after the Section 14.5 Arbitration
Commencement Date, each Party will prepare and deliver to both the arbitrator and the other Party its proposed terms for the license or acquisition of the applicable data and/or intellectual property rights (the “Section 14.5
Proposal”), along with a memorandum (the “Section 14.5 Support Memorandum”) in support thereof; provided that unless the Parties agree otherwise in writing in advance, neither Section 14.5 Proposal may include an
upfront payment from Sangamo to Shire. The arbitrator will also be provided with a copy of this Agreement. Within [***] business days after receipt of the other Party’s Section 14.5 Support Memorandum, each Party may submit to the
arbitrator (with a copy to the other Party) a rebuttal to the other Party’s Section 14.5 Support Memorandum. Neither Party may have communications (either written or oral) with the arbitrator other than for the sole purpose of engaging the
arbitrator or as expressly permitted in this Subsection 14.5(a)(v)(C) or as directed by the arbitrator. Within [***] days after the Section 14.5 Arbitration Commencement Date, the arbitrator will select from the two Section 14.5
Proposals provided by the Parties the Section 14.5 Proposal that he or she believes most accurately reflects [***] provided that, for the avoidance of doubt, in no circumstance will [***] except for [***] The decision of the arbitrator shall be
final and unappealable. Within [***] days of receiving the arbitrator’s decision, Sangamo shall notify Shire of its acceptance or rejection of the selected Proposal, [***] Upon Sangamo’s acceptance of the selected Section 14.5
Proposal, the [***] Upon rejection of the selected Section 14.5 Proposal, [***] The arbitrator’s fees and expenses will be shared equally by the Parties. Each Party shall otherwise bear its own costs. 

(vi) At Sangamo’s request, Shire shall assign to Sangamo all right, title and interest in and to the trademarks then used by Shire
in connection with the commercialization of Terminated Products (excluding any such trademarks that include, in whole or part, any corporate name or logo of Shire or its Affiliate or Sublicensee), provided that Sangamo [***]. 

(vii) Shire shall, at Sangamo’s expense, provide reasonable consultation and assistance for a period of no more than one hundred
eighty (180) days for the purpose of transferring or transitioning to Sangamo all Know-How in the Shire Licensed IP not already in Sangamo’s possession and, at Sangamo’s request, all then-existing commercial arrangements

  
 61 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
relating specifically to Terminated Products that Shire is able, using reasonable commercial efforts, to transfer or transition to Sangamo, in each case, to the extent reasonably necessary or
useful for Sangamo to commence or continue developing, manufacturing, or commercializing Terminated Products. The foregoing shall include, without limitation, transferring, upon request of Sangamo, any agreements with Third Party suppliers or
vendors that specifically cover the supply or sale of Terminated Products. If any such contract between Shire and a Third Party is not assignable to Sangamo (whether by such contract’s terms or because such contract does not relate specifically
to Terminated Products) but is otherwise reasonably necessary or useful for Sangamo to commence or continue developing, manufacturing, or commercializing Terminated Products or if Shire manufactures the Terminated Product itself (and thus there is
no contract to assign), then Shire shall reasonably cooperate with Sangamo to negotiate for the continuation of such license and/or supply from such entity, and Shire shall supply such Terminated Product, as applicable, to Sangamo, for a reasonable
period (not to exceed twelve (12) months) until Sangamo establishes an alternative, validated source of supply for the Terminated Products. Sangamo shall pay Shire for such supply an amount equal to Shire’s cost of supplying, without
markup. 
 (viii) Sangamo shall have the right to purchase from Shire any or all of the inventory of Terminated Products held
by Shire as of the date of termination (that are not committed to be supplied to any Third Party or Sublicensee, in the ordinary course of business, as of the date of termination) at a price equal to Shire’s actual cost to acquire or
manufacture such inventory. Sangamo shall notify Shire within sixty (60) days after the date of termination whether Sangamo elects to exercise such right. 
 (ix) The rights and obligations of the Parties with respect to all Shire Targets (if any) other than any such Terminated Target shall remain in full force and effect. 

(b) Alternative to Termination by Shire under Section 14.2 or 14.3. 

(i) If Shire has the right to terminate this Agreement with respect to one or more Shire Targets pursuant to Section 14.2 or
14.3, on account of a Sangamo’s material breach, then in addition to any remedies available at law, Shire may by notice to Sangamo keep the Agreement in effect but (1) if such material breach was not a Fundamental Sangamo Breach,
reduce the Milestone Payments due to Sangamo in respect of such one or more Terminated Targets by [***] and reduce the future Earned Royalties with respect to such Terminated Target by [***] of the amount specified in Article 9 or (2) if
such material breach was a Fundamental Sangamo Breach, reduce the Milestone Payments due to Sangamo in respect of such one or more Terminated Targets by [***] and reduce the future Earned Royalties with respect to such Terminated Target by [***] of
the amount specified in Article 9. Such reductions shall be credited against any award obtained by Shire on account of such material breach, whether or not such material breach was a Fundamental Sangamo Breach. 

(ii) For the purpose of this Subsection 14.5(b), “Fundamental Sangamo Breach” means a material breach in
the performance of Sangamo’s obligations under Subsections 7.1(a), 7.3(a), 8.2, 10.1(b), and 10.3(b) of this Agreement that fundamentally frustrates the objectives or transactions contemplated by this Agreement. 

  
 62 

 

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (iii) The rights and obligations of the Parties with respect to all Shire Targets (if any)
other than any such Terminated Target shall remain in full force and effect. 
 (c) Survival of Certain Obligations.
Expiration or termination of this Agreement shall not relieve the Parties of any obligation that accrued before such expiration or termination. In addition to all other provisions contained in this Agreement that by their terms survive expiration or
termination of this Agreement, the following provisions also shall survive expiration or termination of this Agreement: Article 1, Sections 3.7(c), 3.8, 3.10(c), 8.3, 9.9-9.13, 10.1(a) (excluding the proviso in the first sentence),
11.1, 11.2 and 11.3, Article 12, Article 13, Section 14.5, and Article 15. 
  

	 	15	MISCELLANEOUS 

 15.1
Governing Law. This Agreement shall be governed by the laws of Delaware without regard to its choice of law principles, provided, that the United Nations Convention on Contracts for the International Sale of Goods shall not apply.

 15.2 Dispute Resolution. Matters within the authority of the JSC shall be resolved as provided in
Section 4.4. For matters outside the authority of the JSC: 
 (a) Notice of Dispute. The
Parties recognize that a bona fide dispute as to certain matters may from time to time arise during the term of this Agreement that relates to either Party’s rights and/or obligations hereunder. In the event of any dispute between the Parties
with respect to any matter relating to this Agreement, one Party may provide the other Party with a notice of dispute. 
 (b)
Upon a Party’s receipt of a notice of dispute, the Parties shall first use their good faith efforts to resolve such dispute among themselves without resorting to Executive Resolution. 

(c) Executive Resolution. In the event that such dispute is not resolved within thirty (30) days of providing a
notice of dispute, the dispute shall be taken to the Chief Executive Officer or an Executive Vice President of Sangamo and a Senior Vice President of Shire for resolution. If these individuals are unable to resolve the dispute within thirty
(30) days of the request for such meeting, then the Parties shall be free to pursue any avenue available to them under law or equity to resolve the dispute. 
 15.3 Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned or delegated, in whole or part, by either Party without the prior express written consent of the
other, which consent shall not be withheld unreasonably; provided, that either Party may assign or delegate any right or obligation hereunder, in whole or in part, to any of its Affiliates so long as such entity remains an Affiliate;
provided, however, that the assigning Party shall remain liable for its obligations hereunder to the extent not fulfilled by assignee. Either Party may assign this Agreement in its entirety to a successor in interest in connection with a Change of
Control of such Party. Sections 4.6 and 7.3 shall be applicable upon a Change of Control of Sangamo. Any permitted assignee shall assume all obligations of its assignor under this Agreement, and any permitted assignment shall be binding on
the successors of the assigning Party. Any purported assignment in violation of this Section 15.3 shall be void. 

  
 63 

 
Notwithstanding the foregoing, Sangamo shall not assign or delegate any right or obligation in full or in part to an Affiliate incorporated in Switzerland without Shire’s prior written
consent, which Shire shall not unreasonably withhold, other than in connection with a Change of Control. For the avoidance of doubt, a disadvantageous tax implication for Shire constitutes a reasonable reason to withhold consent. 

15.4 Independent Contractors. The relationship of the Parties hereto is that of independent contractors. Neither Party
hereto shall be deemed to be the agent, partner or joint venturer of the other for any purpose as a result of this Agreement or the transactions contemplated thereby. 
 15.5 Further Actions. Each Party agrees to execute, acknowledge and deliver such further documents and instruments and to perform all such other acts as may be necessary or appropriate in
order to carry out the purposes and intent of this Agreement. 
 15.6 Notices. All requests and notices required
or permitted to be given to the Parties hereto shall be given in writing, shall expressly reference the section(s) of this Agreement to which they pertain, and shall be delivered to the other Party by mail, any commercial delivery service or by
facsimile transmission, in all cases with confirmation of receipt and with delivery to be effective on receipt, at the appropriate address as set forth below or to such other addresses as may be designated in writing by the Parties from time-to-time
during the Term. 
 If to Shire: 
 Shire AG 
 Batiment 1 

Business Park Terre Bonne 
 Chemin de Terre Bonne 
 Eysins 1262 

Vaud 

Switzerland 

Att: Legal Department 
 Fax: 44 1256 894710 
 Copy to: 

Shire Human Genetic Therapies, Inc. 
 300 Shire Way 
 Lexington, MA 02421 

Att: Legal Department 
 Fax: 781-482-2918 
 If to Sangamo: 

Sangamo BioSciences, Inc. 
 Point Richmond Tech Center II 
 501 Canal Boulevard, Suite A100 

Richmond, California 94804 
 Att: Chief Executive Officer 
 Fax: 510-236-8951 

  
 64 

 Copy to: 
 Cooley LLP 
 3175 Hanover Street 

Palo Alto, CA 94304 
 Att: Marya A. Postner, Esq. 
 Fax: 650-849-7400 

15.7 Force Majeure. Nonperformance of a Party (other than for the payment of money) shall be excused to the extent that
performance is rendered impossible by strike, fire, earthquake, flood, governmental acts or orders or restrictions, terrorist acts, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by
the negligence, intentional conduct or misconduct of the nonperforming Party; provided, that the nonperforming Party shall use Commercially Reasonable Efforts to resume performance as soon as reasonably practicable. 

15.8 No Consequential Damages. IN NO EVENT SHALL A PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF
THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 15.8 IS INTENDED TO LIMIT OR RESTRICT
THE DAMAGES AVAILABLE FOR A BREACH OF ARTICLE 11 OR THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER ARTICLE 12 ABOVE. 
 15.9 Complete Agreement. This Agreement constitutes the entire agreement between the Parties regarding the subject matter hereof, and all prior representations, understandings and agreements
regarding the subject matter hereof, either written or oral, expressed or implied, are superseded and shall be of no effect. The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach,
prior to the Effective Date, by the other Party of its obligations pursuant to the CDA. 
 15.10 Counterparts. This
Agreement may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same agreement. 
 15.11 Headings. The captions to the several sections hereof are not a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or
interpretation. 
 15.12 Construction. This Agreement was negotiated and executed in English, and the original language
version shall be controlling; all communications and notices hereunder shall be in English. The Parties acknowledge that they have both had the opportunity to negotiate regarding any issues in connection with this Agreement that were of concern to
them and, 

  
 65 

 
therefore, expressly waive the benefit of any presumption that ambiguities should be construed in favor of or against either Party. Except where the context otherwise requires, the use of any
gender herein shall be deemed to be or include the other genders, the use of the singular shall be deemed to include the plural (and vice versa) and the word “or” is used in the inclusive sense. The words “include”,
“includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Unless the
context requires otherwise, (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or
otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (b) any reference herein to any Person shall be construed to include the Person’s successors and assigns, (c) the
words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof and (d) all references herein to
sections or Exhibits shall be construed to refer to sections or Exhibits of this Agreement. 
 15.13 Amendment. No
amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

15.14 Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of any provision hereof by the other Party shall not be
construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 
 15.15
Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this
Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement shall be construed as if such clause or portion thereof had never been
contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by applicable law. 

[The remainder of this page is left blank intentionally.] 

  
 66 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
respective duly authorized officers as of the day and year first above written. 
  

			
	SANGAMO BIOSCIENCES, INC.
		
	By:	 	 /s/ Edward O. Lanphier II

		
	Name:	 	 Edward O. Lanphier II

		
	Title:	 	 President and Chief Executive Officer

	
	SHIRE AG
		
	By:	 	 /s/ Ross Murdoch

		
	Name:	 	 Ross Murdoch

		
	Title:	 	 SAG DirectorForm of Senior Debt Indenture

 Exhibit 4.10 
 Sangamo BioSciences, Inc., 
 Issuer 

and 
 [Trustee],

 Trustee 
 INDENTURE 
 Dated as of
            ,          
 SENIOR DEBT SECURITIES 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 ARTICLE I
	  	DEFINITIONS	  	 	1	  
			
	 1.1
	  	Definitions of Terms	  	 	1	  
			
	 ARTICLE II
	  	ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES	  	 	5	  
			
	 2.1
	  	Designation and Terms of Securities	  	 	5	  
	 2.2
	  	Form of Securities and Trustee’s Certificate	  	 	7	  
	 2.3
	  	Denominations: Provisions for Payment	  	 	7	  
	 2.4
	  	Execution and Authentications	  	 	9	  
	 2.5
	  	Registration of Transfer and Exchange	  	 	10	  
	 2.6
	  	Temporary Securities	  	 	11	  
	 2.7
	  	Mutilated, Destroyed, Lost or Stolen Securities	  	 	11	  
	 2.8
	  	Cancellation	  	 	12	  
	 2.9
	  	Benefits of Indenture	  	 	12	  
	 2.10
	  	Authenticating Agent	  	 	12	  
	 2.11
	  	Global Securities	  	 	13	  
			
	 ARTICLE III
	  	REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS	  	 	14	  
			
	 3.1
	  	Redemption	  	 	14	  
	 3.2
	  	Notice of Redemption	  	 	14	  
	 3.3
	  	Payment Upon Redemption	  	 	15	  
	 3.4
	  	Sinking Fund	  	 	16	  
	 3.5
	  	Satisfaction of Sinking Fund Payments with Securities	  	 	16	  
	 3.6
	  	Redemption of Securities for Sinking Fund	  	 	16	  
			
	 ARTICLE IV
	  	COVENANTS	  	 	17	  
			
	 4.1
	  	Payment of Principal, Premium and Interest	  	 	17	  
	 4.2
	  	Maintenance of Office or Agency	  	 	17	  
	 4.3
	  	Paying Agents	  	 	18	  
	 4.4
	  	Appointment to Fill Vacancy in Office of Trustee	  	 	19	  
	 4.5
	  	Compliance with Consolidation Provisions	  	 	19	  
			
	 ARTICLE V
	  	SECURITYHOLDERS’ LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE	  	 	19	  
			
	 5.1
	  	Company to Furnish Trustee Names and Addresses of Securityholders	  	 	19	  
	 5.2
	  	Preservation Of Information; Communications With Securityholders	  	 	19	  
	 5.3
	  	Reports by the Company	  	 	20	  

  
 -i-

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
	 5.4
	  	Reports by the Trustee	  	 	20	  
			
	 ARTICLE VI
	  	REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT	  	 	20	  
			
	 6.1
	  	Events of Default	  	 	20	  
	 6.2
	  	Collection of Indebtedness and Suits for Enforcement by Trustee	  	 	22	  
	 6.3
	  	Application of Moneys Collected	  	 	23	  
	 6.4
	  	Limitation on Suits	  	 	24	  
	 6.5
	  	Rights and Remedies Cumulative; Delay or Omission Not Waiver	  	 	25	  
	 6.6
	  	Control by Securityholders	  	 	25	  
	 6.7
	  	Undertaking to Pay Costs	  	 	26	  
			
	 ARTICLE VII
	  	CONCERNING THE TRUSTEE	  	 	26	  
			
	 7.1
	  	Certain Duties and Responsibilities of Trustee	  	 	26	  
	 7.2
	  	Certain Rights of Trustee	  	 	27	  
	 7.3
	  	Trustee Not Responsible for Recitals or Issuance or Securities	  	 	28	  
	 7.4
	  	May Hold Securities	  	 	29	  
	 7.5
	  	Moneys Held in Trust	  	 	29	  
	 7.6
	  	Compensation and Reimbursement	  	 	29	  
	 7.7
	  	Reliance on Officer’s Certificate	  	 	30	  
	 7.8
	  	Disqualification; Conflicting Interests	  	 	30	  
	 7.9
	  	Corporate Trustee Required; Eligibility	  	 	30	  
	 7.10
	  	Resignation and Removal; Appointment of Successor	  	 	30	  
	 7.11
	  	Acceptance of Appointment By Successor	  	 	32	  
	 7.12
	  	Merger, Conversion, Consolidation or Succession to Business	  	 	33	  
	 7.13
	  	Preferential Collection of Claims Against the Company	  	 	33	  
	 7.14
	  	Notice of Default	  	 	33	  
			
	 ARTICLE VIII
	  	CONCERNING THE SECURITYHOLDERS	  	 	34	  
			
	 8.1
	  	Evidence of Action by Securityholders	  	 	34	  
	 8.2
	  	Proof of Execution by Securityholders	  	 	34	  
	 8.3
	  	Who May be Deemed Owners	  	 	35	  
	 8.4
	  	Certain Securities Owned by Company Disregarded	  	 	35	  
	 8.5
	  	Actions Binding on Future Securityholders	  	 	35	  
			
	 ARTICLE IX
	  	SUPPLEMENTAL INDENTURES	  	 	36	  
			
	 9.1
	  	Supplemental Indentures Without the Consent of Securityholders	  	 	36	  
	 9.2
	  	Supplemental Indentures With Consent of Securityholders	  	 	37	  
	 9.3
	  	Effect of Supplemental Indentures	  	 	37	  
	 9.4
	  	Securities Affected by Supplemental Indentures	  	 	37	  

  
 -ii-

 TABLE OF CONTENTS 

(continued) 
  

							
	  	  	 	  	Page	 
	 9.5
	  	Execution of Supplemental Indentures	  	 	38	  
			
	 ARTICLE X
	  	SUCCESSOR ENTITY	  	 	38	  
			
	 10.1
	  	Company May Consolidate, Etc.	  	 	38	  
	 10.2
	  	Successor Entity Substituted	  	 	39	  
	 10.3
	  	Evidence of Consolidation, Etc. to Trustee	  	 	39	  
			
	 ARTICLE XI
	  	SATISFACTION AND DISCHARGE	  	 	40	  
			
	 11.1
	  	Satisfaction and Discharge of Indenture	  	 	40	  
	 11.2
	  	Discharge of Obligations	  	 	40	  
	 11.3
	  	Deposited Moneys to be Held in Trust	  	 	41	  
	 11.4
	  	Payment of Moneys Held by Paying Agents	  	 	41	  
	 11.5
	  	Repayment to Company	  	 	41	  
			
	 ARTICLE XII
	  	IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS	  	 	41	  
			
	 12.1
	  	No Recourse	  	 	41	  
			
	 ARTICLE XIII
	  	MISCELLANEOUS PROVISIONS	  	 	42	  
			
	 13.1
	  	Effect on Successors and Assigns	  	 	42	  
	 13.2
	  	Actions by Successor	  	 	42	  
	 13.3
	  	Surrender of Company Powers	  	 	42	  
	 13.4
	  	Notices	  	 	42	  
	 13.5
	  	Governing Law	  	 	43	  
	 13.6
	  	Treatment of Securities as Debt	  	 	43	  
	 13.7
	  	Certificates and Opinions as to Conditions Precedent	  	 	43	  
	 13.8
	  	Payments on Business Days	  	 	43	  
	 13.9
	  	Conflict with Trust Indenture Act	  	 	44	  
	 13.10
	  	Counterparts	  	 	44	  
	 13.11
	  	Separability	  	 	44	  
	 13.12
	  	Compliance Certificates	  	 	44	  

  
 -iii-

 INDENTURE 
 INDENTURE, dated as of [*], 20[*], among Sangamo BioSciences, Inc., a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”): 

WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to
provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered
Securities without coupons, to be authenticated by the certificate of the Trustee; 
 WHEREAS, to provide the terms and
conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized the execution of this Indenture; and 
 WHEREAS, all things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done. 

NOW, THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually
covenanted and agreed as follows for the equal and ratable benefit of the holders of Securities: 
 ARTICLE I 

DEFINITIONS 
  

	 	1.1	Definitions of Terms. 

 The terms defined in this Section (except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires) for all purposes of this
Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this Indenture that are defined in the Trust Indenture Act
of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except as herein or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires), shall have the
meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this instrument. 
 “Authenticating Agent” means an authenticating agent with respect to all or any of the series of Securities appointed by the Trustee pursuant to Section 2.10. 

“Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of
debtors. 
 “Board of Directors” means the Board of Directors of the Company or any duly
authorized committee of such Board. 

  
 1 

 “Board Resolution” means a copy of a resolution certified
by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification. 

“Business Day” means, with respect to any series of Securities, any day other than a day on which federal
or state banking institutions in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated by law, executive order or regulation to close. 

“Certificate” means a certificate signed by any Officer. The Certificate need not comply with the
provisions of Section 13.07. 
 “Company” means Sangamo BioSciences, Inc., a corporation
duly organized and existing under the laws of the State of Delaware, and, subject to the provisions of Article Ten, shall also include its successors and assigns. 

“Corporate Trust Office” means the office of the Trustee at which, at any particular time, its corporate
trust business shall be principally administered, which office at the date hereof is located at 

“Custodian” means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy
Law. 
 “Default” means any event, act or condition that with notice or lapse of time, or both,
would constitute an Event of Default. 
 “Defaulted Interest” has the meaning set forth in
Section 2.03. 
 “Depositary” means, with respect to Securities of any series for which the
Company shall determine that such Securities will be issued as a Global Security, The Depository Trust Company, another clearing agency, or any successor registered as a clearing agency under the Exchange Act, or other applicable statute or
regulation, which, in each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11. 
 “Event of Default” means, with respect to Securities of a particular series, any event specified in Section 6.01, continued for the period of time, if any, therein designated.

 “Exchange Act” means the Securities and Exchange Act of 1934, as amended. 

“Global Security” means, with respect to any series of Securities, a Security executed by the Company and
delivered by the Trustee to the Depositary or pursuant to the Depositary’s instruction, all in accordance with the Indenture, which shall be registered in the name of the Depositary or its nominee. 

“Governmental Obligations” means securities that are (a) direct obligations of the United States of
America for the payment of which its full faith and credit is pledged or (b) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the payment of which is unconditionally
guaranteed as a full faith 

  
 2 

 
and credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof at any time prior to the stated maturity of the
Securities, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by
such custodian for the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from
any amount received by the custodian in respect of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt. 

“herein”, “hereof” and “hereunder”, and other words of similar import,
refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. 

“Indenture” means this instrument as originally executed or as it may from time to time be supplemented
or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof. 

“Interest Payment Date”, when used with respect to any installment of interest on a Security of a
particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date on which an installment of interest with respect to Securities of that series
is due and payable. 
 “Officer” means, with respect to the Company, the chairman of the Board
of Directors, a chief executive officer, a president, a chief financial officer, a chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any assistant treasurer, the controller or any
assistant controller or the secretary or any assistant secretary. 
 “Officer’s
Certificate” means a certificate signed by any Officer. Each such certificate shall include the statements provided for in Section 13.07, if and to the extent required by the provisions thereof. 

“Opinion of Counsel” means an opinion in writing subject to customary exceptions of legal counsel, who
may be an employee of or counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section 13.07, if and to the extent required by the
provisions thereof. 
 “Outstanding”, when used with reference to Securities of any series,
means, subject to the provisions of Section 8.04, as of any particular time, all Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore canceled by the
Trustee or any paying agent, or delivered to the Trustee or any paying agent for cancellation or that have previously been canceled; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in
the necessary amount shall have been deposited in trust with the Trustee or with any paying agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own paying agent);
provided, however, that if such Securities or 

  
 3 

 
portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as provided in Article Three, or provision satisfactory to the
Trustee shall have been made for giving such notice; and (c) Securities in lieu of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.07. 

“Person” means any individual, corporation, partnership, joint venture, joint-stock company, limited
liability company, association, trust, unincorporated organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof. 

“Predecessor Security” of any particular Security means every previous Security evidencing all or a
portion of the same debt as that evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section 2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to
evidence the same debt as the lost, destroyed or stolen Security. 
 “Responsible Officer” when
used with respect to the Trustee means the chairman of its board of directors, the chief executive officer, the president, any vice president, the secretary, the treasurer, any trust officer, any corporate trust officer or any other officer or
assistant officer of the Trustee customarily performing functions similar to those performed by the Persons who at the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of his or her knowledge of
and familiarity with the particular subject. 
 “Securities” means the debt Securities
authenticated and delivered under this Indenture. 
 “Securityholder”, “holder of
Securities”, “registered holder”, or other similar term, means the Person or Persons in whose name or names a particular Security shall be registered on the books of the Company kept for that purpose in accordance with the
terms of this Indenture. 
 “Security Register” and “Security Registrar” shall
have the meanings as set forth in Section 2.05. 
 “Subsidiary” means, with respect to any
Person, (i) any corporation at least a majority of whose outstanding Voting Stock shall at the time be owned, directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries,
(ii) any general partnership, joint venture or similar entity, at least a majority of whose outstanding partnership or similar interests shall at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one
or more of its Subsidiaries and (iii) any limited partnership of which such Person or any of its Subsidiaries is a general partner. 
 “Trustee” means
                                    , and, subject to the
provisions of Article Seven, shall also include its successors and assigns, and, if at any time there is more than one Person acting in such capacity hereunder, “Trustee” shall mean each such Person. The term
“Trustee” as used with respect to a particular series of the Securities shall mean the trustee with respect to that series. 

  
 4 

 “Trust Indenture Act” means the Trust Indenture Act of
1939, as amended. 
 “Voting Stock”, as applied to stock of any Person, means shares, interests,
participations or other equivalents in the equity interest (however designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such Person, other than shares, interests,
participations or other equivalents having such power only by reason of the occurrence of a contingency. 
 ARTICLE II

 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION 

AND EXCHANGE OF SECURITIES 
  

	 	2.1	Designation and Terms of Securities. 

 (a) The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate principal
amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or more indentures supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in
or pursuant to a Board Resolution, and set forth in an Officer’s Certificate, or established in one or more indentures supplemental hereto: 
 (i) the title of the Securities of the series (which shall distinguish the Securities of that series from all other Securities); 

(ii) any limit upon the aggregate principal amount of the Securities of that series that may be authenticated and
delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series); 

(iii) the date or dates on which the principal of the Securities of the series is payable, any original issue discount
that may apply to the Securities of that series upon their issuance, the principal amount due at maturity, and the place(s) of payment; 
 (iv) the rate or rates at which the Securities of the series shall bear interest or the manner of calculation of such rate or rates, if any; 

(v) the date or dates from which such interest shall accrue, the Interest Payment Dates on which such interest will be
payable or the manner of determination of such Interest Payment Dates, the place(s) of payment, and the record date for the determination of holders to whom interest is payable on any such Interest Payment Dates or the manner of determination of
such record dates; 
 (vi) the right, if any, to extend the interest payment periods and the duration of such
extension; 

  
 5 

 (vii) the period or periods within which, the price or prices at which and
the terms and conditions upon which Securities of the series may be redeemed, in whole or in part, at the option of the Company; 
 (viii) the obligation, if any, of the Company to redeem or purchase Securities of the series pursuant to any sinking fund, mandatory redemption, or analogous provisions (including payments made in cash in
satisfaction of future sinking fund obligations) or at the option of a holder thereof and the period or periods within which, the price or prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or
purchased, in whole or in part, pursuant to such obligation; 
 (ix) the form of the Securities of the series
including the form of the Certificate of Authentication for such series; 
 (x) if other than denominations of
one thousand U.S. dollars ($1,000) or any integral multiple thereof, the denominations in which the Securities of the series shall be issuable; 
 (xi) any and all other terms (including terms, to the extent applicable, relating to any auction or remarketing of the Securities of that series and any security for the obligations of the Company with
respect to such Securities) with respect to such series (which terms shall not be inconsistent with the terms of this Indenture, as amended by any supplemental indenture) including any terms which may be required by or advisable under United States
laws or regulations or advisable in connection with the marketing of Securities of that series; 
 (xii) whether
the Securities are issuable as a Global Security and, in such case, the terms and the identity of the Depositary for such series; 
 (xiii) whether the Securities will be convertible into or exchangeable for shares of common stock, preferred stock or other securities of the Company or any other Person and, if so, the terms and
conditions upon which such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at the Company’s option or the
holders’ option) conversion or exchange features, and the applicable conversion or exchange period; 
 (xiv)
if other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.01; 

any additional or different Events of Default or restrictive covenants (which may include, among other restrictions,
restrictions on the Company’s ability or the ability of the Company’s Subsidiaries to: incur additional indebtedness; issue additional securities; create liens; pay dividends or make distributions in respect of the capital stock of the
Company or the Company’s Subsidiaries; redeem capital stock; place restrictions on the Company’s Subsidiaries’ ability to pay dividends, make distributions or transfer assets; make investments or other restricted payments; sell or
otherwise dispose of assets; enter into sale- leaseback transactions; engage in transactions with stockholders or affiliates; issue or sell stock of the Company’s 

  
 6 

 
Subsidiaries; or effect a consolidation or merger) or financial covenants (which may include, among other financial covenants, financial covenants that require the Company and its Subsidiaries to
maintain specified interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios) provided for with respect to the Securities of the series; 

(xv) if other than dollars, the coin or currency in which the Securities of the series are denominated (including, but not
limited to, foreign currency); 
 (xvi) the terms and conditions, if any, upon which the Company shall pay
amounts in addition to the stated interest, premium, if any and principal amounts of the Securities of the series to any Securityholder that is not a “United States person” for federal tax purposes; and 

(xvii) any restrictions on transfer, sale or assignment of the Securities of the series. 

All Securities of any one series shall be substantially identical except as may otherwise be provided in or pursuant to
any such Board Resolution or in any indentures supplemental hereto. 
 If any of the terms of the series are
established by action taken pursuant to a Board Resolution of the Company, a copy of an appropriate record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or prior to the
delivery of the Officer’s Certificate of the Company setting forth the terms of the series. 
 Securities of
any particular series may be issued at various times, with different dates on which the principal or any installment of principal is payable, with different rates of interest, if any, or different methods by which rates of interest may be
determined, with different dates on which such interest may be payable and with different redemption dates. 
  

	 	2.2	Form of Securities and Trustee’s Certificate. 

 The Securities of any series and the Trustee’s certificate of authentication to be borne by such Securities shall be substantially of the tenor and purport as set forth in one or more indentures
supplemental hereto or as provided in a Board Resolution, and set forth in an Officer’s Certificate, and they may have such letters, numbers or other marks of identification or designation and such legends or endorsements printed, lithographed
or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or
regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage. 
  

	 	2.3	Denominations: Provisions for Payment. 

 The Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to Section 2.01(a)(10). 

  
 7 

 The Securities of a particular series shall bear interest payable on the
dates and at the rate specified with respect to that series. Subject to Section 2.01(a)(16), the principal of and the interest on the Securities of any series, as well as any premium thereon in case of redemption thereof prior to maturity,
shall be payable in the coin or currency of the United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company maintained for that purpose. Each Security shall be dated the date of its
authentication. Interest on the Securities shall be computed on the basis of a 360-day year composed of twelve 30-day months. 
 The interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities of that series shall be paid to the Person in whose name
said Security (or one or more Predecessor Securities) is registered at the close of business on the regular record date for such interest installment. In the event that any Security of a particular series or portion thereof is called for redemption
and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as provided in
Section 3.03. 
 Any interest on any Security that is payable, but is not punctually paid or duly provided
for, on any Interest Payment Date for Securities of the same series (herein called “Defaulted Interest”) shall forthwith cease to be payable to the registered holder on the relevant regular record date by virtue of having been such
holder; and such Defaulted Interest shall be paid by the Company, at its election, as provided in clause (1) or clause (2) below: 
 (i) The Company may make payment of any Defaulted Interest on Securities to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered at the close of business
on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner: the Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the
date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the
Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a
special record date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed
payment. The Trustee shall promptly notify the Company of such special record date and, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special record date therefor to be
mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security Register (as hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such
Defaulted Interest and the special record date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered on such special
record date. 

  
 8 

 The Company may make payment of any Defaulted Interest on any Securities in
any other lawful manner not inconsistent with the requirements of any securities exchange on which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the
proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee. 

Unless otherwise set forth in a Board Resolution or one or more indentures supplemental hereto establishing the terms of
any series of Securities pursuant to Section 2.01 hereof, the term “regular record date” as used in this Section with respect to a series of Securities and any Interest Payment Date for such series shall mean either the
fifteenth day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the first day of a month, or the first day of
the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a Business Day. 

Subject to the foregoing provisions of this Section, each Security of a series delivered under this Indenture upon
transfer of or in exchange for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other Security. 

 

	 	2.4	Execution and Authentications. 

 The Securities shall be signed on behalf of the Company by one of its Officers. Signatures may be in the form of a manual or facsimile signature. 

The Company may use the facsimile signature of any Person who shall have been an Officer, notwithstanding the fact that at
the time the Securities shall be authenticated and delivered or disposed of such Person shall have ceased to be such an officer of the Company. The Securities may contain such notations, legends or endorsements required by law, stock exchange rule
or usage. Each Security shall be dated the date of its authentication by the Trustee. 
 A Security shall not be
valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such signature shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that
the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for
authentication, together with a written order of the Company for the authentication and delivery of such Securities, signed by an Officer, and the Trustee in accordance with such written order shall authenticate and deliver such Securities.

 In authenticating such Securities and accepting the additional responsibilities under this Indenture in
relation to such Securities, the Trustee shall be entitled to receive, if requested, and (subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating that the form and terms thereof have been established in
conformity with the provisions of this Indenture. 

  
 9 

 The Trustee shall not be required to authenticate such Securities if the
issue of such Securities pursuant to this Indenture will affect the Trustee’s own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the Trustee. 

 

	 	2.5	Registration of Transfer and Exchange. 

 (a) Securities of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose, for other Securities of such series of authorized denominations,
and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, all as provided in this Section. In respect of any Securities so surrendered for exchange, the Company
shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of the same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not
contemporaneously outstanding. 
 (b) The Company shall keep, or cause to be kept, at its office or agency
designated for such purpose a register or registers (herein referred to as the “Security Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall register the Securities and the transfers of
Securities as in this Article provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein provided shall be appointed as
authorized by Board Resolution (the “Security Registrar”). 
 Upon surrender for transfer of any
Security at the office or agency of the Company designated for such purpose, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or Securities
of the same series as the Security presented for a like aggregate principal amount. 
 All Securities presented
or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the
Company or the Security Registrar, duly executed by the registered holder or by such holder’s duly authorized attorney in writing. 
 (c) Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer’s Certificate, or established in one or more indentures supplemental to this
Indenture, no service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in case of partial redemption of any series, but the Company may require payment of a sum sufficient to cover any tax
or other governmental charge in relation thereto, other than exchanges pursuant to Section 2.06, Section 3.03(b) and Section 9.04 not involving any transfer. 

(d) The Company shall not be required (i) to issue, exchange or register the transfer of any Securities during a
period beginning at the opening of business 15 days before the day of the mailing of a notice of redemption of less than all the Outstanding Securities of the same series and ending at the close of business on the day of such mailing, nor
(ii) to register the 

  
 10 

 
transfer of or exchange any Securities of any series or portions thereof called for redemption, other than the unredeemed portion of any such Securities being redeemed in part. The provisions of
this Section 2.05 are, with respect to any Global Security, subject to Section 2.11 hereof. 
  

	 	2.6	Temporary Securities. 

 Pending the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary Securities (printed, lithographed or typewritten) of any
authorized denomination. Such temporary Securities shall be substantially in the form of the definitive Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be appropriate for temporary Securities,
all as may be determined by the Company. Every temporary Security of any series shall be executed by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the
definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish definitive Securities of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange therefor
(without charge to the holders), at the office or agency of the Company designated for the purpose, and the Trustee shall authenticate and such office or agency shall deliver in exchange for such temporary Securities an equal aggregate principal
amount of definitive Securities of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and furnished until further notice from the Company. Until so exchanged, the temporary Securities of
such series shall be entitled to the same benefits under this Indenture as definitive Securities of such series authenticated and delivered hereunder. 
  

	 	2.7	Mutilated, Destroyed, Lost or Stolen Securities. 

 In case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding sentence) shall execute, and upon the Company’s
request the Trustee (subject as aforesaid) shall authenticate and deliver, a new Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the mutilated Security, or in lieu of and in
substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security shall furnish to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, and,
in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction of the destruction, loss or theft of the applicant’s Security and of the ownership thereof. The Trustee
may authenticate any such substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance of any substituted Security, the Company may require the payment of a sum sufficient to
cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith. 

In case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the
Company may, instead of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to the Company and the Trustee
such security or indemnity as they may require to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of such Security and of the ownership
thereof. 

  
 11 

 Every replacement Security issued pursuant to the provisions of this Section
shall constitute an additional contractual obligation of the Company whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to all the benefits of this
Indenture equally and proportionately with any and all other Securities of the same series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the
replacement or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect
to the replacement or payment of negotiable instruments or other securities without their surrender. 
  

	 	2.8	Cancellation. 

 All Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company or any paying agent, be delivered to the Trustee for
cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions of this Indenture. On request of the Company at the time
of such surrender, the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request the Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate
of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are
delivered to the Trustee for cancellation. 
  

	 	2.9	Benefits of Indenture. 

 Nothing in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties hereto and the holders of the Securities any legal or equitable
right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or provision herein contained; all such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the holders of the
Securities. 
  

	 	2.10	Authenticating Agent. 

 So long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities which the Trustee shall have the right to appoint. Said
Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled to the benefits of
this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an
Authenticating Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital and 

  
 12 

 
surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or in which it is doing business to conduct a trust business, and
that is otherwise authorized under such laws to conduct such business and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to be eligible in accordance with these
provisions, it shall resign immediately. 
 Any Authenticating Agent may at any time resign by giving written
notice of resignation to the Trustee and to the Company. The Trustee may at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating Agent and to
the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of
its appointment hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating Agent pursuant hereto. 

 

	 	2.11	Global Securities. 

 (a) If the Company shall establish pursuant to Section 2.01 that the Securities of a particular series are to be issued as a Global Security, then the Company shall execute and the Trustee shall, in
accordance with Section 2.04, authenticate and deliver, a Global Security that (i) shall represent, and shall be denominated in an amount equal to the aggregate principal amount of, all of the Outstanding Securities of such series,
(ii) shall be registered in the name of the Depositary or its nominee, (iii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositary’s instruction and (iv) shall bear a legend substantially to the
following effect: “Except as otherwise provided in Section 2.11 of the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor Depositary or to a nominee of such
successor Depositary.” 
 (b) Notwithstanding the provisions of Section 2.05, the Global Security of a
series may be transferred, in whole but not in part and in the manner provided in Section 2.05, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a
nominee of such successor Depositary. 
 (c) If at any time the Depositary for a series of the Securities
notifies the Company that it is unwilling or unable to continue as Depositary for such series or if at any time the Depositary for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or
regulation, and a successor Depositary for such series is not appointed by the Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, or if an Event of Default has occurred and is
continuing and the Company has received a request from the Depositary or from the Trustee, this Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute, and subject to Section 2.04, the
Trustee will authenticate and deliver the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series
in exchange for such Global Security. In addition, the Company may at any time determine that 

  
 13 

 
the Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of such series. In such
event the Company will execute and, subject to Section 2.04, the Trustee, upon receipt of an Officer’s Certificate evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive
registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. Upon the exchange of the Global Security for
such Securities in definitive registered form without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to
this Section 2.11(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver
such Securities to the Depositary for delivery to the Persons in whose names such Securities are so registered. 
 ARTICLE III

 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS 

 

	 	3.1	Redemption. 

 The Company may redeem the Securities of any series issued hereunder on and after the dates and in accordance with the terms established for such series pursuant to Section 2.01 hereof. 

 

	 	3.2	Notice of Redemption. 

 (a) In case the Company shall desire to exercise such right to redeem all or, as the case may be, a portion of the Securities of any series in accordance with any right the Company reserved for itself to
do so pursuant to Section 2.01 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption to holders of the Securities of such series to be redeemed by mailing, first class postage prepaid, a notice of such
redemption not less than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses as they shall appear upon the Security Register, unless a shorter period is specified in the
Securities to be redeemed. Any notice that is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered holder receives the notice. In any case, failure duly to give such notice to the
holder of any Security of any series designated for redemption in whole or in part, or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Securities of such series or any other series. In the
case of any redemption of Securities prior to the expiration of any restriction on such redemption provided in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an Officer’s Certificate
evidencing compliance with any such restriction. 
 Each such notice of redemption shall specify the date fixed
for redemption and the redemption price at which Securities of that series are to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made at the office or

  
 14 

 
agency of the Company, upon presentation and surrender of such Securities, that interest accrued to the date fixed for redemption will be paid as specified in said notice, that from and after
said date interest will cease to accrue and that the redemption is from a sinking fund, if such is the case. If less than all the Securities of a series are to be redeemed, the notice to the holders of Securities of that series to be redeemed in
part shall specify the particular Securities to be so redeemed. 
 In case any Security is to be redeemed in part
only, the notice that relates to such Security shall state the portion of the principal amount thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such
series in principal amount equal to the unredeemed portion thereof will be issued. 
 (b) If less than all the
Securities of a series are to be redeemed, the Company shall give the Trustee at least 45 days’ notice (unless a shorter notice shall be satisfactory to the Trustee) in advance of the date fixed for redemption as to the aggregate principal
amount of Securities of the series to be redeemed, and thereupon the Trustee shall select, by lot or in such other manner as it shall deem appropriate and fair in its discretion and that may provide for the selection of a portion or portions (equal
to one thousand U.S. dollars ($1,000) or any integral multiple thereof) of the principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly notify the Company in writing of the
numbers of the Securities to be redeemed, in whole or in part. The Company may, if and whenever it shall so elect, by delivery of instructions signed on its behalf by an Officer, instruct the Trustee or any paying agent to call all or any part of
the Securities of a particular series for redemption and to give notice of redemption in the manner set forth in this Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In
any case in which notice of redemption is to be given by the Trustee or any such paying agent, the Company shall deliver or cause to be delivered to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security
Register, transfer books or other records, or suitable copies or extracts therefrom, sufficient to enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section. 

 

	 	3.3	Payment Upon Redemption. 

 (a) If the giving of notice of redemption shall have been completed as above provided, the Securities or portions of Securities of the series to be redeemed specified in such notice shall become due and
payable on the date and at the place stated in such notice at the applicable redemption price, together with interest accrued to the date fixed for redemption and interest on such Securities or portions of Securities shall cease to accrue on and
after the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued interest with respect to any such Security or portion thereof. On presentation and surrender of such Securities on or after the
date fixed for redemption at the place of payment specified in the notice, said Securities shall be paid and redeemed at the applicable redemption price for such series, together with interest accrued thereon to the date fixed for redemption (but if
the date fixed for redemption is an interest payment date, the interest installment payable on such date shall be payable to the registered holder at the close of business on the applicable record date pursuant to Section 2.03). 

  
 15 

 Upon presentation of any Security of such series that is to be redeemed in
part only, the Company shall execute and the Trustee shall authenticate and the office or agency where the Security is presented shall deliver to the holder thereof, at the expense of the Company, a new Security of the same series of authorized
denominations in principal amount equal to the unredeemed portion of the Security so presented. 
  

	 	3.4	Sinking Fund. 

 The provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except as otherwise specified as contemplated by Section 2.01 for
Securities of such series. 
 The minimum amount of any sinking fund payment provided for by the terms of
Securities of any series is herein referred to as a “mandatory sinking fund payment,” and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to as an “optional sinking
fund payment”. If provided for by the terms of Securities of any series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 3.05. Each sinking fund payment shall be applied to the redemption of
Securities of any series as provided for by the terms of Securities of such series. 
  

	 	3.5	Satisfaction of Sinking Fund Payments with Securities. 

 The Company (i) may deliver Outstanding Securities of a series and (ii) may apply as a credit Securities of a series that have been redeemed either at the election of the Company pursuant to the
terms of such Securities or through the application of permitted optional sinking fund payments pursuant to the terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to the Securities of
such series required to be made pursuant to the terms of such Securities as provided for by the terms of such series, provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such purpose
by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly. 

 

	 	3.6	Redemption of Securities for Sinking Fund. 

 Not less than 45 days prior to each sinking fund payment date for any series of Securities (unless a shorter period shall be satisfactory to the Trustee), the Company will deliver to the Trustee an
Officer’s Certificate specifying the amount of the next ensuing sinking fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering and crediting Securities of that series
pursuant to Section 3.05 and the basis for such credit and will, together with such Officer’s Certificate, deliver to the Trustee any Securities to be so delivered. Not less than 30 days before each such sinking fund payment date the
Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.02 and cause notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner
provided in Section 3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Section 3.03. 

  
 16 

 ARTICLE IV 
 COVENANTS 
  

	 	4.1	Payment of Principal, Premium and Interest. 

 The Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that series at the time and place and in the manner provided herein
and established with respect to such Securities. Payments of principal on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check drawn on and mailed to the address of the
Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of
the applicable series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions to the Trustee no later than 15 days prior to the relevant payment date). Payments of interest on the Securities may be made at
the time provided herein and established with respect to such Securities by U.S. dollar check mailed to the address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S.
dollar account (such a wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions in
writing to the Security Registrar and the Trustee no later than 15 days prior to the relevant payment date. 
  

	 	4.2	Maintenance of Office or Agency. 

 So long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency with respect to each such series and at such other location or locations as may be designated
as provided in this Section 4.02, where (i) Securities of that series may be presented for payment, (ii) Securities of that series may be presented as herein above authorized for registration of transfer and exchange, and
(iii) notices and demands to or upon the Company in respect of the Securities of that series and this Indenture may be given or served, such designation to continue with respect to such office or agency until the Company shall, by written
notice signed by any officer authorized to sign an Officer’s Certificate and delivered to the Trustee, designate some other office or agency for such purposes or any of them. If at any time the Company shall fail to maintain any such required
office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to
receive all such presentations, notices and demands. The Company initially appoints the Corporate Trust Office of the Trustee as its paying agent with respect to the Securities. 

  
 17 

	 	4.3	Paying Agents. 

 (a) If the Company shall appoint one or more paying agents for all or any series of the Securities, other than the Trustee, the Company will cause each such paying agent to execute and deliver to the
Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section: 
 (i) that it will hold all sums held by it as such agent for the payment of the principal of (and premium, if any) or interest on the Securities of that series (whether such sums have been paid to it by
the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto; 
 (ii) that it will give the Trustee notice of any failure by the Company (or by any other obligor of such Securities) to make any payment of the principal of (and premium, if any) or interest on the
Securities of that series when the same shall be due and payable; 
 (iii) that it will, at any time during the
continuance of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee all sums so held in trust by such paying agent; and 

(iv) that it will perform all other duties of paying agent as set forth in this Indenture. 

(b) If the Company shall act as its own paying agent with respect to any series of the Securities, it will on or before
each due date of the principal of (and premium, if any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay such principal (and premium, if any) or
interest so becoming due on Securities of that series until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by it or any other obligor on such
Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any Securities of that series, deposit
with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or interest, and (unless such paying agent
is the Trustee) the Company will promptly notify the Trustee of this action or failure so to act. 
 (c)
Notwithstanding anything in this Section to the contrary, (i) the agreement to hold sums in trust as provided in this Section is subject to the provisions of Section 11.05, and (ii) the Company may at any time, for the purpose of
obtaining the satisfaction and discharge of this Indenture or for any other purpose, pay, or direct any paying agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by the Trustee upon the same
terms and conditions as those upon which such sums were held by the Company or such paying agent; and, upon such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability
with respect to such money. 

  
 18 

	 	4.4	Appointment to Fill Vacancy in Office of Trustee. 

 The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.10, a Trustee, so that there shall at all times be a Trustee
hereunder. 
  

	 	4.5	Compliance with Consolidation Provisions. 

 The Company will not, while any of the Securities remain Outstanding, consolidate with or merge into any other Person, in either case where the Company is not the survivor of such transaction, or sell or
convey all or substantially all of its property to any other Person unless the provisions of Article Ten hereof are complied with. 
 ARTICLE V 
 SECURITYHOLDERS’ LISTS AND REPORTS 

BY THE COMPANY AND THE TRUSTEE 
  

	 	5.1	Company to Furnish Trustee Names and Addresses of Securityholders. 

The Company will furnish or cause to be furnished to the Trustee (a) within 15 days after each regular record date
(as defined in Section 2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular record date, provided that the Company shall not be obligated to
furnish or cause to furnish such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b) at such other times as the Trustee may request in writing within 30 days
after the receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no such list need be furnished for any
series for which the Trustee shall be the Security Registrar. 
  

	 	5.2	Preservation Of Information; Communications With Securityholders. 

(a) The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and
addresses of the holders of Securities contained in the most recent list furnished to it as provided in Section 5.01 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as Security Registrar (if
acting in such capacity). 
 (b) The Trustee may destroy any list furnished to it as provided in
Section 5.01 upon receipt of a new list so furnished. 
 (c) Securityholders may communicate as provided in
Section 312(b) of the Trust Indenture Act with other Securityholders with respect to their rights under this Indenture or under the Securities, and, in connection with any such communications, the Trustee shall satisfy its obligations under
Section 312(b) of the Trust Indenture Act in accordance with the provisions of Section 312(b) of the Trust Indenture Act. 

  
 19 

	 	5.3	Reports by the Company. 

 The Company covenants and agrees to provide (which delivery may be via electronic mail) to the Trustee, after the Company files the same with the Securities and Exchange Commission, copies of the annual
reports and of the information, documents and other reports (or copies of such portions of any of the foregoing as the Securities and Exchange Commission may from time to time by rules and regulations prescribe) that the Company files with the
Securities and Exchange Commission pursuant to Section 13 or Section 15(d) of the Exchange Act; provided, however, the Company shall not be required to deliver to the Trustee any materials for which the Company has sought and received
confidential treatment by the Securities and Exchange Commission; and provided further, so long as such filings by the Company are available on the Securities and Exchange Commission’s Electronic Data Gathering, Analysis and Retrieval System
(EDGAR), such filings shall be deemed to have been filed with the Trustee for purposes of this Section 5.03 without any further action required by the Company. 
  

	 	5.4	Reports by the Trustee. 

 (a) If required by Section 313(a) of the Trust Indenture Act, the Trustee, within sixty (60) days after each May 1, shall transmit by mail, first class postage prepaid, to the
Securityholders, as their names and addresses appear upon the Security Register, a brief report dated as of such May 1, which complies with Section 313(a) of the Trust Indenture Act. 

(b) The Trustee shall comply with Section 313(b) and 313(c) of the Trust Indenture Act. 

(c) A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with
the Company, with each securities exchange upon which any Securities are listed (if so listed) and also with the Securities and Exchange Commission. The Company agrees to notify the Trustee when any Securities become listed on any securities
exchange. 
 ARTICLE VI 
 REMEDIES OF THE TRUSTEE AND 
 SECURITYHOLDERS ON EVENT OF DEFAULT

  

	 	6.1	Events of Default. 

 (a) Whenever used herein with respect to Securities of a particular series, “Event of Default” means any one or more of the following events that has occurred and is continuing: 

(i) the Company defaults in the payment of any installment of interest upon any of the Securities of that series, as and
when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms of any indenture supplemental hereto
shall not constitute a default in the payment of interest for this purpose; 

  
 20 

 (ii) the Company defaults in the payment of the principal of (or premium, if
any, on) any of the Securities of that series as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect
to that series; provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of principal or premium, if any; 

(iii) the Company fails to observe or perform any other of its covenants or agreements with respect to that series
contained in this Indenture or otherwise established with respect to that series of Securities pursuant to Section 2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture solely for the benefit of one
or more series of Securities other than such series) for a period of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a “Notice of Default” hereunder, shall
have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders of at least 51% in principal amount of the Securities of that series at the time Outstanding; 

(iv) the Company pursuant to or within the meaning of any Bankruptcy Law (i) commences a voluntary case,
(ii) consents to the entry of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment for the
benefit of its creditors; or 
 (v) a court of competent jurisdiction enters an order under any Bankruptcy Law
that (i) is for relief against the Company in an involuntary case, (ii) appoints a Custodian of the Company for all or substantially all of its property or (iii) orders the liquidation of the Company, and the order or decree remains
unstayed and in effect for 90 days. 
 (b) In each and every such case (other than an Event of Default specified
in clause (4) or clause (5) above), unless the principal of all the Securities of that series shall have already become due and payable, either the Trustee or the holders of not less than 51% in aggregate principal amount of the Securities
of that series then Outstanding hereunder, by notice in writing to the Company (and to the Trustee if given by such Securityholders), may declare the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of
that series to be due and payable immediately, and upon any such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified in clause (4) or clause (5) above occurs, the principal of and
accrued and unpaid interest on all the Securities of that series shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities. 

(c) At any time after the principal of (and premium, if any, on) and accrued and unpaid interest on the Securities of that
series shall have been so declared due and payable, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority in aggregate principal amount of the
Securities of that series then Outstanding hereunder, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if: (i) the Company has

  
 21 

 
paid or deposited with the Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the principal of (and premium, if any, on) any and all
Securities of that series that shall have become due otherwise than by acceleration (with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of
interest, at the rate per annum expressed in the Securities of that series to the date of such payment or deposit) and the amount payable to the Trustee under Section 7.06, and (ii) any and all Events of Default under the Indenture with
respect to such series, other than the nonpayment of principal on (and premium, if any, on) and accrued and unpaid interest on Securities of that series that shall not have become due by their terms, shall have been remedied or waived as provided in
Section 6.06. 
 No such rescission and annulment shall extend to or shall affect any subsequent default or
impair any right consequent thereon. 
 (d) In case the Trustee shall have proceeded to enforce any right with
respect to Securities of that series under this Indenture and such proceedings shall have been discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and
in every such case, subject to any determination in such proceedings, the Company and the Trustee shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall
continue as though no such proceedings had been taken. 
  

	 	6.2	Collection of Indebtedness and Suits for Enforcement by Trustee. 

(a) The Company covenants that (i) in case it shall default in the payment of any installment of interest on any of
the Securities of a series, or in any payment required by any sinking or analogous fund established with respect to that series as and when the same shall have become due and payable, and such default shall have continued for a period of 90 days, or
(ii) in case it shall default in the payment of the principal of (or premium, if any, on) any of the Securities of a series when the same shall have become due and payable, whether upon maturity of the Securities of a series or upon redemption
or upon declaration or otherwise then, upon demand of the Trustee, the Company will pay to the Trustee, for the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable on all such
Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal (and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon
overdue installments of interest at the rate per annum expressed in the Securities of that series; and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, and the amount payable to the
Trustee under Section 7.06. 
 (b) If the Company shall fail to pay such amounts forthwith upon such demand,
the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or
proceeding to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law
or equity out of the property of the Company or other obligor upon the Securities of that series, wherever situated. 

  
 22 

 (c) In case of any receivership, insolvency, liquidation, bankruptcy,
reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or property, the Trustee shall have power to intervene in such proceedings and take any action therein that may be permitted by
the court and shall (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the Trustee and of the holders of Securities of
such series allowed for the entire amount due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional amount that may become due and payable by the Company after such date, and to collect
and receive any moneys or other property payable or deliverable on any such claim, and to distribute the same after the deduction of the amount payable to the Trustee under Section 7.06; and any receiver, assignee or trustee in bankruptcy or
reorganization is hereby authorized by each of the holders of Securities of such series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Securityholders, to pay to
the Trustee any amount due it under Section 7.06. 
 (d) All rights of action and of asserting claims under
this Indenture, or under any of the terms established with respect to Securities of that series, may be enforced by the Trustee without the possession of any of such Securities, or the production thereof at any trial or other proceeding relative
thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for payment to the Trustee of any amounts due under
Section 7.06, be for the ratable benefit of the holders of the Securities of such series. 
 In case of an
Event of Default hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of
such rights, either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any
other legal or equitable right vested in the Trustee by this Indenture or by law. 
 Nothing contained herein
shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any
holder thereof or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceeding. 
  

	 	6.3	Application of Moneys Collected. 

 Any moneys collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied in the following order, at the date or dates fixed by the Trustee and, in
case of the distribution of such moneys on account of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon of the payment, if only partially paid, and upon surrender thereof if fully
paid: 
 FIRST: To the payment of reasonable costs and expenses of collection and of all amounts payable to the
Trustee under Section 7.06; 

  
 23 

 SECOND: To the payment of the amounts then due and unpaid upon Securities of
such series for principal (and premium, if any) and interest, in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such
Securities for principal (and premium, if any) and interest, respectively; and 
 THIRD: To the payment of the
remainder, if any, to the Company or any other Person lawfully entitled thereto. 
  

	 	6.4	Limitation on Suits. 

 No holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any suit, action or proceeding in equity or at law upon or under or
with respect to this Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless (i) such holder previously shall have given to the Trustee written notice of an Event of Default and of the continuance
thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided; (ii) the holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall have
made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; (iii) such holder or holders shall have offered to the Trustee such reasonable indemnity as it may require against the
costs, expenses and liabilities to be incurred therein or thereby; (iv) the Trustee for 90 days after its receipt of such notice, request and offer of indemnity, shall have failed to institute any such action, suit or proceeding and
(v) during such 90 day period, the holders of a majority in principal amount of the Securities of that series do not give the Trustee a direction inconsistent with the request. 

Notwithstanding anything contained herein to the contrary or any other provisions of this Indenture, the right of any
holder of any Security to receive payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due dates expressed in such Security (or in the case of redemption, on the redemption
date), or to institute suit for the enforcement of any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such holder and by accepting a Security hereunder it is expressly
understood, intended and covenanted by the taker and holder of every Security of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall have any right in any manner
whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder, or
to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all holders of Securities of such series. For the protection and enforcement of the provisions of this Section, each and
every Securityholder and the Trustee shall be entitled to such relief as can be given either at law or in equity. 

  
 24 

	 	6.5	Rights and Remedies Cumulative; Delay or Omission Not Waiver. 

(a) Except as otherwise provided in Section 2.07, all powers and remedies given by this Article to the Trustee or to
the Securityholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings or otherwise, to enforce the
performance or observance of the covenants and agreements contained in this Indenture or otherwise established with respect to such Securities. 
 (b) No delay or omission of the Trustee or of any holder of any of the Securities to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall impair any
such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein; and, subject to the provisions of Section 6.04, every power and remedy given by this Article or by law to the Trustee or the
Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders. 
  

	 	6.6	Control by Securityholders. 

 The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance with Section 8.04, shall have the right to direct the time,
method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series; provided, however, that such direction shall not be in conflict with any
rule of law or with this Indenture. Subject to the provisions of Section 7.01, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee,
determine that the proceeding so directed, subject to the Trustee’s duties under the Trust Indenture Act, would involve the Trustee in personal liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The
holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance with Section 8.04, may on behalf of the holders of all of the Securities of such series waive
any past default in the performance of any of the covenants contained herein or established pursuant to Section 2.01 with respect to such series and its consequences, except a default in the payment of the principal of, or premium, if any, or
interest on, any of the Securities of that series as and when the same shall become due by the terms of such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to pay all matured installments of
interest and principal and any premium has been deposited with the Trustee (in accordance with Section 6.01(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured for all purposes of this Indenture and the Company,
the Trustee and the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.

  
 25 

	 	6.7	Undertaking to Pay Costs. 

 All parties to this Indenture agree, and each holder of any Securities by such holder’s acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit
for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and
that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant;
but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of
any series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or interest on any Security of such series, on or after the respective due dates expressed in such Security or
established pursuant to this Indenture. 
 ARTICLE VII 

CONCERNING THE TRUSTEE 
  

	 	7.1	Certain Duties and Responsibilities of Trustee. 

 (a) The Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing of all Events of Default with respect to the Securities of that series that
may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such duties as are specifically set forth in this Indenture, and no implied covenants shall be read into this Indenture against the
Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the Trustee shall exercise with respect to Securities of that series such of the rights and powers vested in it by this
Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs. 

(b) No provision of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action,
its own negligent failure to act, or its own willful misconduct, except that: 
 (1) prior to the occurrence of
an Event of Default with respect to the Securities of a series and after the curing or waiving of all such Events of Default with respect to that series that may have occurred: (A) the duties and obligations of the Trustee shall with respect to
the Securities of such series be determined solely by the express provisions of this Indenture, and the Trustee shall not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are
specifically set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture against the Trustee; and (B) in the absence of bad faith on the part of the Trustee, the Trustee may with respect to the
Securities of such series conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and

  
 26 

 
conforming to the requirements of this Indenture; but in the case of any such certificates or opinions that by any provision hereof are specifically required to be furnished to the Trustee, the
Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture; 
 (2) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved that the Trustee was negligent
in ascertaining the pertinent facts; 
 (3) the Trustee shall not be liable with respect to any action taken or
omitted to be taken by it in good faith in accordance with the direction of the holders of not less than a majority in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture with respect to the Securities of that series; and 

(4) none of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or
otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers if there is reasonable ground for believing that the repayment of such funds or liability is not reasonably
assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably assured to it. 
  

	 	7.2	Certain Rights of Trustee. 

 Except as otherwise provided in Section 7.01: 
 (a) The
Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security or other paper or document believed by it
to be genuine and to have been signed or presented by the proper party or parties; 
 (b) Any request, direction,
order or demand of the Company mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed in the name of the Company by any authorized officer of the Company (unless other evidence in respect thereof is
specifically prescribed herein); 
 (c) The Trustee may consult with counsel and the written advice of such
counsel or, if requested, any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken or suffered or omitted hereunder in good faith and in reliance thereon; 

The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the
request, order or direction of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities that
may be incurred therein or thereby; nothing contained herein shall, however, relieve the Trustee of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities

  
 27 

 
(that has not been cured or waived), to exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and to use the same degree of care and
skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs; 
 (d) The Trustee shall not be liable for any action taken or omitted to be taken by it in good faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by
this Indenture; 
 (e) The Trustee shall not be bound to make any investigation into the facts or matters stated
in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security, or other papers or documents, unless requested in writing so to do by the holders of not less than a majority in
principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section 8.04); provided, however, that if the payment within a reasonable time to the Trustee of the costs, expenses or
liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture, the Trustee may require reasonable
indemnity against such costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid by the Trustee, shall be repaid by the Company upon demand; and

 (f) The Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either
directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder. 

In addition, the Trustee shall not be deemed to have knowledge of any Default or Event of Default except (1) any
Event of Default occurring pursuant to Sections 6.01(a)(1) and 6.01(a)(2) or (2) any Default or Event of Default of which the Trustee shall have received written notification in the manner set forth in this Indenture or a Responsible Officer of
the Trustee shall have obtained actual knowledge. Delivery of reports, information and documents to the Trustee under Section 5.03 is for informational purposes only and the information and the Trustee’s receipt of the foregoing shall not
constitute constructive notice of any information contained therein, or determinable from information contained therein including the Company’s compliance with any of their covenants thereunder (as to which the Trustee is entitled to rely
exclusively on an Officer’s Certificate). 
  

	 	7.3	Trustee Not Responsible for Recitals or Issuance or Securities. 

(a) The recitals contained herein and in the Securities shall be taken as the statements of the Company, and the Trustee
assumes no responsibility for the correctness of the same. 
 (b) The Trustee makes no representations as to the
validity or sufficiency of this Indenture or of the Securities. 

  
 28 

 (c) The Trustee shall not be accountable for the use or application by the
Company of any of the Securities or of the proceeds of such Securities, or for the use or application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.01, or for the
use or application of any moneys received by any paying agent other than the Trustee. 
  

	 	7.4	May Hold Securities. 

 The Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee,
paying agent or Security Registrar. 
  

	 	7.5	Moneys Held in Trust. 

 Subject to the provisions of Section 11.05, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received, but
need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any moneys received by it hereunder except such as it may agree with the Company to pay thereon. 

 

	 	7.6	Compensation and Reimbursement. 

 (a) The Company covenants and agrees to pay to the Trustee, and the Trustee shall be entitled to, such reasonable compensation (which shall not be limited by any provision of law in regard to the
compensation of a trustee of an express trust) as the Company and the Trustee may from time to time agree in writing, for all services rendered by it in the execution of the trusts hereby created and in the exercise and performance of any of the
powers and duties hereunder of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances incurred or made by the Trustee in
accordance with any of the provisions of this Indenture (including the reasonable compensation and the expenses and disbursements of its counsel and of all Persons not regularly in its employ), except any such expense, disbursement or advance as may
arise from its negligence or bad faith and except as the Company and Trustee may from time to time agree in writing. The Company also covenants to indemnify the Trustee (and its officers, agents, directors and employees) for, and to hold it harmless
against, any loss, liability or expense incurred without negligence or bad faith on the part of the Trustee and arising out of or in connection with the acceptance or administration of this trust, including the reasonable costs and expenses of
defending itself against any claim of liability in the premises. 
 (b) The obligations of the Company under this
Section to compensate and indemnify the Trustee and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances shall constitute additional indebtedness hereunder. Such additional indebtedness shall be secured by a lien prior
to that of the Securities upon all property and funds held or collected by the Trustee as such, except funds held in trust for the benefit of the holders of particular Securities. 

  
 29 

	 	7.7	Reliance on Officer’s Certificate. 

 Except as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it reasonably necessary or desirable that a matter be proved or
established prior to taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be
deemed to be conclusively proved and established by an Officer’s Certificate delivered to the Trustee and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any
action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof. 
  

	 	7.8	Disqualification; Conflicting Interests. 

 If the Trustee has or shall acquire any “conflicting interest” within the meaning of Section 310(b) of the Trust Indenture Act, the Trustee and the Company shall in all respects comply with
the provisions of Section 310(b) of the Trust Indenture Act. 
  

	 	7.9	Corporate Trustee Required; Eligibility. 

 There shall at all times be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and doing business under the laws of the United States of America
or any state or territory thereof or of the District of Columbia, or a corporation or other Person permitted to act as trustee by the Securities and Exchange Commission, authorized under such laws to exercise corporate trust powers, having a
combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision or examination by federal, state, territorial, or District of Columbia authority. 

If such corporation or other Person publishes reports of condition at least annually, pursuant to law or to the
requirements of the aforesaid supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other Person shall be deemed to be its combined capital and surplus as set forth in its
most recent report of condition so published. The Company may not, nor may any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee. In case at any time the Trustee shall cease to be
eligible in accordance with the provisions of this Section, the Trustee shall resign immediately in the manner and with the effect specified in Section 7.10. 
  

	 	7.10	Resignation and Removal; Appointment of Successor. 

 (a) The Trustee or any successor hereafter appointed may at any time resign with respect to the Securities of one or more series by giving written notice thereof to the Company and by transmitting notice
of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear upon the Security Register. Upon receiving such notice of resignation, the Company shall promptly appoint a successor
trustee with respect to Securities of such series by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no
successor trustee shall have been so 

  
 30 

 
appointed and have accepted appointment within 30 days after the mailing of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment
of a successor trustee with respect to Securities of such series, or any Securityholder of that series who has been a bona fide holder of a Security or Securities for at least six months may on behalf of himself and all others similarly situated,
petition any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee. 

(b) In case at any time any one of the following shall occur: 

(1) the Trustee shall fail to comply with the provisions of Section 7.08 after written request therefor by the
Company or by any Securityholder who has been a bona fide holder of a Security or Securities for at least six months; or 
 (2) the Trustee shall cease to be eligible in accordance with the provisions of Section 7.09 and shall fail to resign after written request therefor by the Company or by any such Securityholder; or

 (3) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or commence a
voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation,
conservation or liquidation; then, in any such case, the Company may remove the Trustee with respect to all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of
which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or any Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder and all
others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the
Trustee and appoint a successor trustee. 
 (c) The holders of a majority in aggregate principal amount of the
Securities of any series at the time Outstanding may at any time remove the Trustee with respect to such series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company.

 (d) Any resignation or removal of the Trustee and appointment of a successor trustee with respect to the
Securities of a series pursuant to any of the provisions of this Section shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.11. 

(e) Any successor trustee appointed pursuant to this Section may be appointed with respect to the Securities of one or
more series or all of such series, and at any time there shall be only one Trustee with respect to the Securities of any particular series. 

  
 31 

	 	7.11	Acceptance of Appointment By Successor. 

 (a) In case of the appointment hereunder of a successor trustee with respect to all Securities, every such successor trustee so appointed shall execute, acknowledge and deliver to the Company and to the
retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all
the rights, powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor
trustee all the rights, powers, and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such successor trustee all property and money held by such retiring Trustee hereunder. 

(b) In case of the appointment hereunder of a successor trustee with respect to the Securities of one or more (but not
all) series, the Company, the retiring Trustee and each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor trustee shall accept such appointment
and which (i) shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities
of that or those series to which the appointment of such successor trustee relates, (ii) shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring Trustee
with respect to the Securities of that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and (iii) shall add to or change any of the provisions of this Indenture as shall be
necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of the same trust, that
each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible for any act or failure to act on the part of any
other Trustee hereunder; and upon the execution and delivery of such supplemental indenture the resignation or removal of the retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall with respect to the
Securities of that or those series to which the appointment of such successor trustee relates have no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this
Indenture, and each such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which the
appointment of such successor trustee relates; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by such supplemental
indenture, the property and money held by such retiring Trustee hereunder with respect to the Securities of that or those series to which the appointment of such successor trustee relates. 

(c) Upon request of any such successor trustee, the Company shall execute any and all instruments for more fully and
certainly vesting in and confirming to such successor trustee all such rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case may be. 

  
 32 

 (d) No successor trustee shall accept its appointment unless at the time of
such acceptance such successor trustee shall be qualified and eligible under this Article. 
 (e) Upon acceptance
of appointment by a successor trustee as provided in this Section, the Company shall transmit notice of the succession of such trustee hereunder by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon
the Security Register. If the Company fails to transmit such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be transmitted at the expense of the Company. 

 

	 	7.12	Merger, Conversion, Consolidation or Succession to Business. 

Any corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation
resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to the corporate trust business of the Trustee, including the administration of the trust created by this Indenture, shall be
the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions of Section 7.08 and eligible under the provisions of Section 7.09, without the execution or filing of any paper or any further
act on the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion or
consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities. 

 

	 	7.13	Preferential Collection of Claims Against the Company. 

 The Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship described in Section 311(b) of the Trust Indenture Act. A Trustee who has resigned or
been removed shall be subject to Section 311(a) of the Trust Indenture Act to the extent included therein. 
  

	 	7.14	Notice of Default 

 If any Default or any Event of Default occurs and is continuing and if such Default or Event of Default is known to a Responsible Officer of the Trustee, the Trustee shall mail to each Securityholder in
the manner and to the extent provided in Section 313(c) of the Trust Indenture Act notice of the Default or Event of Default within the earlier of 90 days after it occurs and 30 days after it is known to a Responsible Officer of the Trustee or
written notice of it is received by the Trustee, unless such Default or Event of Default has been cured; provided, however, that, except in the case of a default in the payment of the principal of (or premium, if any) or interest on any Security,
the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee or a trust committee of directors and/or Responsible Officers of the Trustee in good faith determine that the withholding of
such notice is in the interest of the Securityholders. 

  
 33 

 ARTICLE VIII 
 CONCERNING THE SECURITYHOLDERS 
  

	 	8.1	Evidence of Action by Securityholders. 

 Whenever in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities of a particular series may take any action (including the
making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action the holders of such majority or specified percentage of that series have joined
therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of that series in person or by agent or proxy appointed in writing. 

If the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice,
consent, waiver or other action, the Company may, at its option, as evidenced by an Officer’s Certificate, fix in advance a record date for such series for the determination of Securityholders entitled to give such request, demand,
authorization, direction, notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver or other action may be
given before or after the record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders of the requisite proportion of
Outstanding Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall be computed
as of the record date; provided, however, that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later
than six months after the record date. 
  

	 	8.2	Proof of Execution by Securityholders. 

 Subject to the provisions of Section 7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization) or his agent or proxy and proof of the holding by
any Person of any of the Securities shall be sufficient if made in the following manner: 
 (a) The fact and date
of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee. 
 (b) The ownership of Securities shall be proved by the Security Register of such Securities or by a certificate of the Security Registrar thereof. 

The Trustee may require such additional proof of any matter referred to in this Section as it shall deem necessary.

  
 34 

	 	8.3	Who May be Deemed Owners. 

 Prior to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar may deem and treat the Person in whose name such Security
shall be registered upon the books of the Company as the absolute owner of such Security (whether or not such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone other than the Security Registrar)
for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to Section 2.03) interest on such Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor any
Security Registrar shall be affected by any notice to the contrary. 
  

	 	8.4	Certain Securities Owned by Company Disregarded. 

 In determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any direction, consent or waiver under this Indenture, the Securities
of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly controlling or controlled by or under common control with the Company or any other obligor on the Securities
of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that for the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent or waiver,
only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been pledged in good faith may be regarded as Outstanding for the purposes of this Section, if the pledgee shall
establish to the satisfaction of the Trustee the pledgee’s right so to act with respect to such Securities and that the pledgee is not a Person directly or indirectly controlling or controlled by or under direct or indirect common control with
the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee. 

 

	 	8.5	Actions Binding on Future Securityholders. 

 At any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the holders of the majority or percentage in aggregate principal amount
of the Securities of a particular series specified in this Indenture in connection with such action, any holder of a Security of that series that is shown by the evidence to be included in the Securities the holders of which have consented to such
action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section 8.02, revoke such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall be
conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange therefor, on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in
regard thereto is made upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action shall be
conclusively binding upon the Company, the Trustee and the holders of all the Securities of that series. 

  
 35 

 ARTICLE IX 
 SUPPLEMENTAL INDENTURES 
  

	 	9.1	Supplemental Indentures Without the Consent of Securityholders. 

In addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from
time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent of the Securityholders, for one or more of the following
purposes: 
 (a) to cure any ambiguity, defect, or inconsistency herein or in the Securities of any series;

 (b) to comply with Article Ten; 

(c) to provide for uncertificated Securities in addition to or in place of certificated Securities; 

(d) to add to the covenants, restrictions, conditions or provisions relating to the Company for the benefit of the holders
of all or any series of Securities (and if such covenants, restrictions, conditions or provisions are to be for the benefit of less than all series of Securities, stating that such covenants, restrictions, conditions or provisions are expressly
being included solely for the benefit of such series), to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default, or to surrender any
right or power herein conferred upon the Company; 
 (e) to add to, delete from, or revise the conditions,
limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein set forth; 
 (f) to make any change that does not adversely affect the rights of any Securityholder in any material respect; 
 (g) to provide for the issuance of and establish the form and terms and conditions of the Securities of any series as provided in Section 2.01, to establish the form of any certifications required to
be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders of any series of Securities; 
 (h) to evidence and provide for the acceptance of appointment hereunder by a successor trustee; or 
 (i) to comply with any requirements of the Securities and Exchange Commission or any successor in connection with the qualification of this Indenture under the Trust Indenture Act. 

  
 36 

 The Trustee is hereby authorized to join with the Company in the execution
of any such supplemental indenture, and to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee’s
own rights, duties or immunities under this Indenture or otherwise. 
 Any supplemental indenture authorized by
the provisions of this Section may be executed by the Company and the Trustee without the consent of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section 9.02. 

 

	 	9.2	Supplemental Indentures With Consent of Securityholders. 

 With the consent (evidenced as provided in Section 8.01) of the holders of not less than a majority in aggregate principal amount of the Securities of each series affected by such supplemental
indenture or indentures at the time Outstanding, the Company, when authorized by a Board Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the
provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not
covered by Section 9.01 the rights of the holders of the Securities of such series under this Indenture; provided, however, that no such supplemental indenture shall, without the consent of the holders of each Security then Outstanding and
affected thereby, (a) extend the fixed maturity of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon, or reduce any premium payable upon the redemption
thereof or (b) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture. 
 It shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular form of any proposed supplemental indenture, but it shall be
sufficient if such consent shall approve the substance thereof. 
  

	 	9.3	Effect of Supplemental Indentures. 

 Upon the execution of any supplemental indenture pursuant to the provisions of this Article or of Section 10.01, this Indenture shall, with respect to such series, be and be deemed to be modified and
amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the holders of Securities of the series affected thereby shall thereafter be
determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this
Indenture for any and all purposes. 
  

	 	9.4	Securities Affected by Supplemental Indentures. 

 Securities of any series affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant to the provisions of this Article or of
Section 10.01, may bear a notation in form approved by the Company, provided such form meets the requirements of any securities exchange upon which such series may be 

  
 37 

 
listed, as to any matter provided for in such supplemental indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of
Directors, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated by the Trustee and delivered in exchange for the Securities of that series then Outstanding. 

 

	 	9.5	Execution of Supplemental Indentures. 

 Upon the request of the Company, accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon the filing with the Trustee of evidence of the consent of
Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee’s own rights, duties or immunities under
this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of Section 7.01, may receive an Officer’s Certificate
or, if requested, an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article is authorized or permitted by, and conforms to, the terms of this Article and that it is proper for the Trustee under
the provisions of this Article to join in the execution thereof; provided, however, that such Officer’s Certificate or Opinion of Counsel need not be provided in connection with the execution of a supplemental indenture that establishes the
terms of a series of Securities pursuant to Section 2.01 hereof. 
 Promptly after the execution by the
Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee shall transmit by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture,
to the Securityholders of all series affected thereby as their names and addresses appear upon the Security Register. Any failure of the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity
of any such supplemental indenture. 
 ARTICLE X 
 SUCCESSOR ENTITY 
  

	 	10.1	Company May Consolidate, Etc. 

 Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer’s Certificate, or established in one or more indentures supplemental to this Indenture,
nothing contained in this Indenture shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated with the Company) or successive consolidations or mergers in which the Company or its successor or
successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or other disposition of the property of the Company or its successor or successors as an entirety, or substantially as an entirety, to any other corporation
(whether or not affiliated with the Company or its successor or successors) authorized to acquire and operate the same; provided, however, (a) the Company hereby covenants and agrees that, upon any such consolidation or merger (in each case, if
the 

  
 38 

 
Company is not the survivor of such transaction), sale, conveyance, transfer or other disposition, the due and punctual payment of the principal of (premium, if any) and interest on all of the
Securities of all series in accordance with the terms of each series, according to their tenor, and the due and punctual performance and observance of all the covenants and conditions of this Indenture with respect to each series or established with
respect to such series pursuant to Section 2.01 to be kept or performed by the Company shall be expressly assumed, by supplemental indenture (which shall conform to the provisions of the Trust Indenture Act, as then in effect) reasonably
satisfactory in form to the Trustee executed and delivered to the Trustee by the entity formed by such consolidation, or into which the Company shall have been merged, or by the entity which shall have acquired such property and (b) in the
event that the Securities of any series then Outstanding are convertible into or exchangeable for shares of common stock or other securities of the Company, such entity shall, by such supplemental indenture, make provision so that the
Securityholders of Securities of that series shall thereafter be entitled to receive upon conversion or exchange of such Securities the number of securities or property to which a holder of the number of shares of common stock or other securities of
the Company deliverable upon conversion or exchange of those Securities would have been entitled had such conversion or exchange occurred immediately prior to such consolidation, merger, sale, conveyance, transfer or other disposition. 

 

	 	10.2	Successor Entity Substituted. 

 (a) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental indenture, executed and delivered to the
Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section 10.01 on all of the Securities of all series Outstanding, such successor entity shall succeed to and be substituted for the Company with the same effect
as if it had been named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this Indenture and the Securities. 

(b) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition, such changes in
phraseology and form (but not in substance) may be made in the Securities thereafter to be issued as may be appropriate. 
 (c) Nothing contained in this Article shall require any action by the Company in the case of a consolidation or merger of any Person into the Company where the Company is the survivor of such transaction,
or the acquisition by the Company, by purchase or otherwise, of all or any part of the property of any other Person (whether or not affiliated with the Company). 
  

	 	10.3	Evidence of Consolidation, Etc. to Trustee. 

 The Trustee, subject to the provisions of Section 7.01, may receive an Officer’s Certificate and, if requested, an Opinion of Counsel as conclusive evidence that any such consolidation, merger,
sale, conveyance, transfer or other disposition, and any such assumption, comply with the provisions of this Article. 

  
 39 

 ARTICLE XI 
 SATISFACTION AND DISCHARGE 
  

	 	11.1	Satisfaction and Discharge of Indenture. 

 If at any time: (a) the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated and not delivered to the Trustee for cancellation (other than
any Securities that shall have been destroyed, lost or stolen and that shall have been replaced or paid as provided in Section 2.07 and Securities for whose payment money or Governmental Obligations have theretofore been deposited in trust or
segregated and held in trust by the Company and thereupon repaid to the Company or discharged from such trust, as provided in Section 11.05); or (b) all such Securities of a particular series not theretofore delivered to the Trustee for
cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption,
and the Company shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination thereof, sufficient in the opinion of a nationally recognized firm of independent public
accountants expressed in a written certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if
any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder with respect to such series by the Company then
this Indenture shall thereupon cease to be of further effect with respect to such series except for the provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03 and 7.10, that shall survive until the date of maturity or redemption date, as the case
may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of the Company and at the cost and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging
this Indenture with respect to such series. 
  

	 	11.2	Discharge of Obligations. 

 If at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that have not become due and payable as described in Section 11.01 shall have
been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon redemption all such Securities of that series not theretofore delivered to the
Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums
payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental Obligations, as the case may be, are deposited with the Trustee the obligations of the Company under this Indenture with respect to such
series shall cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10 and 11.05 hereof that shall survive until such Securities shall mature and be paid. Thereafter, Sections 7.06 and 11.05
shall survive. 

  
 40 

	 	11.3	Deposited Moneys to be Held in Trust. 

 All moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be available for payment as due, either directly or through any
paying agent (including the Company acting as its own paying agent), to the holders of the particular series of Securities for the payment or redemption of which such moneys or Governmental Obligations have been deposited with the Trustee.

  

	 	11.4	Payment of Moneys Held by Paying Agents. 

 In connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent under the provisions of this Indenture shall, upon demand of the
Company, be paid to the Trustee and thereupon such paying agent shall be released from all further liability with respect to such moneys or Governmental Obligations. 
  

	 	11.5	Repayment to Company. 

 Any moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of principal of or premium, if any, or interest on the Securities
of a particular series that are not applied but remain unclaimed by the holders of such Securities for at least two years after the date upon which the principal of (and premium, if any) or interest on such Securities shall have respectively become
due and payable, or such other shorter period set forth in applicable escheat or abandoned or unclaimed property law, shall be repaid to the Company on May 31 of each year or upon the Company’s request or (if then held by the Company)
shall be discharged from such trust; and thereupon the paying agent and the Trustee shall be released from all further liability with respect to such moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive
such payment shall thereafter, as a general creditor, look only to the Company for the payment thereof. 
 ARTICLE XII

 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS 

 

	 	12.1	No Recourse. 

 No recourse under or upon any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or otherwise in respect thereof, shall be had against any
incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or successor corporation, either directly or through the Company or any such predecessor or successor corporation, whether by
virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that this Indenture and the obligations issued hereunder are solely corporate obligations, and that no
such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation

  
 41 

 
of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom; and that any
and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because
of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and released as a
condition of, and as a consideration for, the execution of this Indenture and the issuance of such Securities. 
 ARTICLE XIII

 MISCELLANEOUS PROVISIONS 
  

	 	13.1	Effect on Successors and Assigns. 

 All the covenants, stipulations, promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors and assigns, whether so expressed or not. 

 

	 	13.2	Actions by Successor. 

 Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of the Company shall and may be done and performed with like
force and effect by the corresponding board, committee or officer of any corporation that shall at the time be the lawful successor of the Company. 
  

	 	13.3	Surrender of Company Powers. 

 The Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the powers reserved to the Company, and thereupon such power so
surrendered shall terminate both as to the Company and as to any successor corporation. 
  

	 	13.4	Notices. 

Except as otherwise expressly provided herein, any notice, request or demand that by any provision of this Indenture is
required or permitted to be given, made or served by the Trustee or by the holders of Securities or by any other Person pursuant to this Indenture to or on the Company may be given or served by being deposited in first class mail, postage prepaid,
addressed (until another address is filed in writing by the Company with the Trustee), as follows: 

__________________________________________ 

__________________________________________ 

__________________________________________ 

Any notice, election, request or demand by the Company or any Securityholder or by any other Person pursuant to this
Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee. 

  
 42 

	 	13.5	Governing Law. 

 This Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of Delaware, and for all purposes shall be construed in accordance with the laws of said State,
except to the extent that the Trust Indenture Act is applicable. 
  

	 	13.6	Treatment of Securities as Debt. 

 It is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of this Indenture shall be interpreted to further this intention.

  

	 	13.7	Certificates and Opinions as to Conditions Precedent. 

 (a) Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officer’s Certificate
stating that all conditions precedent provided for in this Indenture (other than the certificate to be delivered pursuant to Section 13.12) relating to the proposed action have been complied with and, if requested, an Opinion of Counsel stating
that in the opinion of such counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the furnishing of such documents is specifically required by any provision of this
Indenture relating to such particular application or demand, no additional certificate or opinion need be furnished. 
 (b) Each certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture shall include (i) a statement
that the Person making such certificate or opinion has read such covenant or condition; (ii) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or
opinion are based; (iii) a statement that, in the opinion of such Person, he has made such examination or investigation as is reasonably necessary to enable him to express an informed opinion as to whether or not such covenant or condition has
been complied with; and (iv) a statement as to whether or not, in the opinion of such Person, such condition or covenant has been complied with. 
  

	 	13.8	Payments on Business Days. 

 Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer’s Certificate, or established in one or more indentures supplemental to this Indenture, in
any case where the date of maturity of interest or principal of any Security or the date of redemption of any Security shall not be a Business Day, then payment of interest or principal (and premium, if any) may be made on the next succeeding
Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for the period after such nominal date. 

  
 43 

	 	13.9	Conflict with Trust Indenture Act. 

 If and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317, inclusive, of the Trust Indenture Act, such imposed duties shall
control. 
  

	 	13.10	Counterparts. 

 This Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. 

 

	 	13.11	Separability. 

 In case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other provisions of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable provision had never
been contained herein or therein. 
  

	 	13.12	Compliance Certificates. 

 The Company shall deliver to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series were outstanding, an officer’s certificate stating whether or not
the signers know of any Default or Event of Default that occurred during such fiscal year. Such certificate shall contain a certification from the principal executive officer, principal financial officer or principal accounting officer of the
Company that a review has been conducted of the activities of the Company and the Company’s performance under this Indenture and that the Company has complied with all conditions and covenants under this Indenture. For purposes of this
Section 13.12, such compliance shall be determined without regard to any period of grace or requirement of notice provided under this Indenture. If the officer of the Company signing such certificate has knowledge of such a Default or Event of
Default, the certificate shall describe any such Default or Event of Default and its status. 
 IN WITNESS
WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day and year first above written. 
  

			
	SANGAMO BIOSCIENCES, INC.
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 44 

			
	[TRUSTEE], as Trustee
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]